

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Endoscopic sphincterotomy for delaying cholecystectomy in mild acute biliary pancreatitis (EMILY study): protocol of a multicenter randomized clinical trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025551
Article Type:	Protocol
Date Submitted by the Author:	01-Aug-2018
Complete List of Authors:	<p>Kucserik, Levente; Universitatea de Medicina si Farmacie din Targu Mures, Division of Surgery  Márta, Katalin; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine; János Szentágothai Research Center, University of Pécs  Kelemen, Dezső; Pecs Tudományegyetem, Surgery Clinic  Vincze, Áron; Pecs Tudományegyetem Általános Orvostudományi Kar, Division of Gastroenterology, First Department of Internal Medicine; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine  Lázár, György; University of Szeged, Department of Surgery  Czakó, László; University of Szeged, First Department of Medicine  Szentkereszty, Zsolt; University of Debrecen, Department for Surgery  Papp, Maria; Debreceni Egyetem, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine  Palatka, Károly; Debreceni Egyetem, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine  Izbéki, Ferenc; Fejer County Saint George Teaching Hospital of University of Pécs, Division of Gastroenterology  Altorjay, Áron; Fejer County Saint George Teaching Hospital of University of Pécs, Division of Surgery  Török, Imola; Universitatea de Medicina si Farmacie din Targu Mures, Division of Gastroenterology  Barbu, Sorin; Universitatea de Medicina si Farmacie din Cluj Napoca, Division of Gastroenterology  Tantau, Marcel; Universitatea de Medicina si Farmacie din Cluj Napoca, Division of Gastroenterology  Vereczkei, András; Pecs Tudományegyetem Általános Orvostudományi Kar, Department for Surgery  Bogár, Lajos; Pecs Tudományegyetem Általános Orvostudományi Kar, Department of Anaesthesiology and Intensive Therapy  Dénes, Márton; County Hospital Targu Mures  Szentesi, Andrea; Pecs Tudományegyetem, Institute for Translational Medicine; Szegedi Tudományegyetem, MTA-SZTE Translational Gastroenterology Research Group  Lerch, Markus; Universitätsmedizin Greifswald, Department of Medicine A  Neoptolemos, John; University of Heidelberg  Sahin-Toth, Miklos; Boston University  Petersen, Ole; Cardiff University, Medical Research Council Group  Hegyi, Péter; Pecs Tudományegyetem Általános Orvostudományi Kar,</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Institute for Translational Medicine; MTA-SZTE Translational Gastroenterology Research Group
Keywords:	acute biliary pancreatitis, cholecystectomy, endoscopic sphincterotomy

SCHOLARONE™  
Manuscripts

For peer review only

**Endoscopic sphincterotomy for delay in cholecystectomy in mild acute biliary pancreatitis (EMILY study): protocol of a multicenter randomized clinical trial**

Levente-Pál Kucserik MD<sup>1</sup>, Katalin Márta MD<sup>2,3</sup>, Áron Vincze MD PhD<sup>2,4</sup>, György Lázár MD PhD DSc<sup>5</sup>, László Czako MD PhD DSc<sup>6</sup>, Zsolt Szentkereszty MD PhD<sup>7</sup>, Mária Papp MD PhD<sup>8</sup>, Károly Palatka MD PhD<sup>8</sup>, Ferenc Izbéki MD PhD DSc<sup>9</sup>, Áron Altorjay MD PhD DSc<sup>10</sup>, Imola Török MD<sup>11</sup>, Sorin Barbu MD PhD<sup>12</sup>, Marcel Tantau MD PhD<sup>12</sup>, András Vereczkei MD PhD DSc<sup>13</sup>, Lajos Bogár MD PhD DSc<sup>14</sup>, Márton Dénes MD<sup>15</sup>, Andrea Szentesi PhD<sup>2</sup>, Markus Lerch MD PhD DSc<sup>16</sup>, John Neoptolemos MD PhD DSc<sup>17</sup>, Miklos Sahin-Tóth MD PhD DSc<sup>18</sup>, Ole Petersen MD PhD DSc<sup>19</sup>, Dezső Kelemen\* MD PhD<sup>13</sup>, Péter Hegyi\* MD PhD DSc<sup>2,20</sup>.

1 Division of Surgery, Universitatea de Medicina si Farmacie din Targu Mures, Targu Mures, RO  
 2 Institute for Translational Medicine, University of Pécs Medical School, Pécs, HU  
 3 János Szentágotthai Research Center, University of Pécs, Pécs, HU  
 4 Division of Gastroenterology, First Department of Internal Medicine, University of Pécs Medical School, Pécs, HU  
 5 Department of Surgery, University of Szeged, Szeged, HU  
 6 First Department of Medicine, University of Szeged, Szeged, HU  
 7 Department for Surgery, University of Debrecen, Debrecen, HU  
 8 Division of Gastroenterology, University of Debrecen, Debrecen, HU  
 9 Division of Gastroenterology, Fejér County Saint George Teaching Hospital of University of Pécs, Székesfehérvár, HU  
 10 Division of Surgery, Fejér County Saint George Teaching Hospital of University of Pécs, Székesfehérvár, HU  
 11 Division of Gastroenterology, Universitatea de Medicina si Farmacie din Targu Mures, Targu Mures, RO  
 12 Division of Gastroenterology, Universitatea de Medicina si Farmacie din Cluj Napoca, Cluj Napoca, RO  
 Tantau, Marcel; Universitatea de Medicina si Farmacie din Cluj Napoca  
 13 Surgery Clinic, University of Pécs, Pécs, HU  
 14 Department of Anaesthesiology and Intensive Therapy, University of Pécs Medical School, Pécs, HU  
 15 County Hospital Targu Mures, Targu Mures, RO  
 16 Department of Medicine A, University Medicine Greifswald, Germany  
 17 Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK  
 18 Center for Exocrine Disorders, Department of Molecular and Cell Biology, Boston, USA; University Henry M. Goldman School of Dental Medicine, Boston, Massachusetts, USA  
 19 Medical Research Council Group, Cardiff School of Biosciences, Cardiff University, Cardiff, CF10 3AX, Wales, UK  
 20 Hungarian Academy of Sciences - University of Szeged, Translational Multidisciplinary Research Group, Szeged, Hungary

\*: equally contributed

E-mail addresses of the authors:

LK [k.levente.p@gmail.com](mailto:k.levente.p@gmail.com), DK [kelemende@gmail.com](mailto:kelemende@gmail.com), AV [vereczkei.andras@pte.hu](mailto:vereczkei.andras@pte.hu), IT [torokimola@gmail.com](mailto:torokimola@gmail.com), ÁV [vincze.aron@pte.hu](mailto:vincze.aron@pte.hu), GyL [lazar.gyorgy@med.u-szeged.hu](mailto:lazar.gyorgy@med.u-szeged.hu), LC [czako.laszlo@med.u-szeged.hu](mailto:czako.laszlo@med.u-szeged.hu), ZsSz [szentkerzs@freemail.hu](mailto:szentkerzs@freemail.hu), MP [papp.maria@med.unideb.hu](mailto:papp.maria@med.unideb.hu), KP [palatka@med.unideb.hu](mailto:palatka@med.unideb.hu), FI [fizbeki@gmail.com](mailto:fizbeki@gmail.com), ÁA [altorjay@mail.fmkorhaz.hu](mailto:altorjay@mail.fmkorhaz.hu), SB [barbu@pancreasclub.ro](mailto:barbu@pancreasclub.ro), MD [denesmatyi@yahoo.com](mailto:denesmatyi@yahoo.com), LB [bogar.lajos@pte.hu](mailto:bogar.lajos@pte.hu), MT [matantau@gmail.com](mailto:matantau@gmail.com), KM [katalin.martak@gmail.com](mailto:katalin.martak@gmail.com), ASz [szentesiai@gmail.com](mailto:szentesiai@gmail.com), JN [jneoptolemos1@gmail.com](mailto:jneoptolemos1@gmail.com), MM [lerch@uni-greifswald.de](mailto:lerch@uni-greifswald.de), MST [miklos@bu.edu](mailto:miklos@bu.edu), OP [PetersenOH@cardiff.ac.uk](mailto:PetersenOH@cardiff.ac.uk), PH [hegyi2009@gmail.com](mailto:hegyi2009@gmail.com)

**Corresponding Investigator:** Péter Hegyi MD, PhD, DSc

Phone: +(36-70) 375-1031

e-mail: [hegyi.peter@pte.hu](mailto:hegyi.peter@pte.hu), [p.hegyi@tm-pte.org](mailto:p.hegyi@tm-pte.org)

**Coordinating institution:**

University of Pecs – Medical School

Institute for Translational Medicine

12 Szigeti Street, PÉCS, H-7624, HUNGARY

FAX: +(36-72) 536-247

Phone: +(36-72) 536-246

web: [www.tm-pte.org](http://www.tm-pte.org)

**ABSTRACT**

**Introduction.** According to the literature, early cholecystectomy is necessary to avoid complications related to gallstones after an initial episode of acute biliary pancreatitis (ABP). A randomized, controlled multicenter trial (the PONCHO trial) revealed that in the case of gallstone-induced pancreatitis, early cholecystectomy was safe in patients with mild gallstone pancreatitis and reduced the risk of recurrent gallstone-related complications, as compared with interval cholecystectomy. We hypothesize that carrying out a sphincterotomy (ES) early after ABP allows us to delay cholecystectomy, thus making it logistically easier to perform and potentially increasing the efficacy and safety of the procedure.

**Methods/Design.** EMILY is a prospective, randomized, controlled multicenter trial. The patients are randomized to two groups: (1) early cholecystectomy (within 6 days after ES) and (2) patients with delayed (interval) cholecystectomy (between 45 and 60 days after ES). During a 12-month period, 89 patients will be enrolled from participating clinics. The primary endpoint is a composite endpoint of mortality and recurrent acute biliary events (that is, recurrent ABP, acute cholecystitis, uncomplicated biliary colic, and cholangitis). The secondary endpoints are organ failure, biliary leakage, technical difficulty of the cholecystectomy, surgical and other complications.

**Discussion.** In the EMILY trial, the planned target is to show that the risk of biliary events will not be increased in case of endoscopic sphincterotomy combined with delayed cholecystectomy, compared to early cholecystectomy.

**Ethics and dissemination.** The trial has been registered at the ISRCTN (ref no. 35066) and approved by the relevant organisation, the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (EKU/2018/12176-5).

**Keywords:** acute biliary pancreatitis, cholecystectomy, endoscopic sphincterotomy

## ARTICLE SUMMARY

EMILY is a prospective, randomized-controlled, multicenter trial aiming to show that the risk of biliary events will not be increased in case of ES combined with delayed cholecystectomy, compared to early cholecystectomy. This trial provides the first evidence concerning the possible benefits of ES on timing cholecystectomy. All patients with mild ABP will have the possibility to take part in the trial.

### Strengths and limitation

**Strength 1:** The study is designed to achieve conclusion on the highest evidence level including (i) multinational (ii) multicentric approach, (iii) international trial registration and (iv) publication of the pre-study protocol

**Strength 2:** Only high volume, expert centers can join to the study. They have to provide (i) laparoscopically trained surgeons with >100 laparoscopic procedures performed and (ii) ERCP/ES trained gastroenterologist with >50 ES completed within a year.

**Strength 3:** The study enjoys continuous support from (i) an International Translational Advisory Board (ITAB) including top, well-established experts from different areas of research field (ii) an Independent Data Management Board (IDMB).

**Strength 4:** The final conclusion can be achieved with low number of patients within a relatively short period.

**Limitation 1:** The study will provide no evidence concerning the usefulness of ES in moderate and severe ABP.

## INTRODUCTION

Acute pancreatitis is one of the leading gastrointestinal causes of acute hospital admissions [1, 2]. In most cases, it is caused by gallstones, sludge or edema [3]. Gallstone-induced pancreatitis involves a pathophysiologic factor, namely a distal common channel of the biliary and pancreatic ducts, which can be found in 80% of acute biliary pancreatitis (ABP) [4]. Acute biliary pancreatitis is a clinical entity with high rates of morbidity (15–50%) and mortality (20–35%) [5]. After ABP, several complications may occur; recurrent acute pancreatitis, cholestasis and fistula affecting the hepatobiliary system or other biliary events, such as acute cholecystitis, obstruction of the common biliary duct, cholangitis or biliary colic [6, 7]. Interval cholecystectomy after mild ABP is associated with a high risk of readmission for recurrent biliary events, especially after recurrent ABP [8]. The international practice guidelines recommend that in case of cholangitis or choledocholithiasis an ERCP should be performed to clear the bile duct with endoscopic sphincterotomy (ES). In addition, cholecystectomy should also be performed to avoid complications related to recurrent biliary events [9, 10]. In patients with clinically severe pancreatitis, with local complications, such as pancreatic necrosis or organ failure, the intervention namely the laparoscopic cholecystectomy (LC) is delayed 6 months until complications are resolved [11]. In cases of mild ABP, cholecystectomy is recommended between days 7 and 21 [4]. The latest studies show that after discharge of patients with ABP, cholecystectomy could reduce the risk of a recurrent ABP and other gallstone-induced complications [12]. In this setting, surgeons still prefer delayed cholecystectomy for efficacy and safety and for logistical reasons [13]. Some publications draw attention to ERCP/ES, which could reduce mortality and the formation of severe biliary complications [3, 14]. The aim of the EMILY trial is to combine a surgical treatment and a

gastroenterological procedure to investigate if ES with delayed cholecystectomy (within 45 to 60 days after ES) compared with ES with early cholecystectomy (within 5 to 6 days after ES) could reduce recurrent biliary events.

## METHODS

**Design:** EMILY is a prospective, randomized-controlled, multicenter trial. The patients are randomized to two groups: (1) Patients who undergo early cholecystectomy (within 6 days after ES) and (2) patients who undergo delayed (interval) cholecystectomy (between 45 and 60 days after ES). During a 12-month period, 89 patients will be enrolled from participating clinics. The primary endpoint is a composite endpoint of mortality and recurrent acute biliary events (which are recurrent ABP, acute cholecystitis, uncomplicated biliary colic and cholangitis). The secondary endpoints are: organ failure, biliary leakage, technical difficulty of cholecystectomy, and surgical and other complications.

This study was structured following the SPIRIT 2013 [15] guideline defining standard protocol items for clinical trials and got the relevant ethical approval EKU/2018/12176-5 (Scientific and Research Ethical Committee, Medical Research Council, Hungary).

**Trial organization, committees and boards:** The coordinator and designer of the EMILY study is the Centre for Translational Medicine at the University of Pécs Medical School (coordinating institution and sponsor, [www.tm-centre.org](http://www.tm-centre.org)) and the Hungarian Pancreatic Study Group (HPSG-coordinating society, [www.pancreas.hu](http://www.pancreas.hu)). The HPSG was established in 2011 to stimulate research in pancreatic diseases.

Until now, it has launched three international observational clinical studies in 2014 [16-18] (EASY, APPLE and PINEAPPLE) and two interventional studies (PREPAST [19] – 2014 and GOULASH [20] – 2017) and has published the relevant guidelines for pancreatic diseases to improve patient care in pancreatology [21-24].

The following committees and boards will be involved: Steering Committee (SC): The committee will be led by PH (corresponding investigator, gastroenterologist and internal medicine specialist).

The members in Szeged (HU) will be: LC (gastroenterologist), GL (surgeon); Debrecen (HU): MP (gastroenterologist), KP (gastroenterologist), ZS (surgeon); Pécs (HU): ÁV (gastroenterologist), DK (surgeon); Székesfehérvár (HU): FI (gastroenterologist), ÁA (surgeon); Targu Mures (RO): IT (gastroenterologist), LK (surgeon); Cluj Napoca (RO): BS (gastroenterologist), TM (surgeon). KM is a trial management specialist, whereas AS leads the multidisciplinary core facility which will assist the scientists to run the study successfully. The SC will make decisions concerning all relevant questions including drop outs during the study.

International Translational Advisory Board (ITAB): The board will consist of a gastroenterologist (MML), a surgeon and two basic scientists (JN, MST, OHP). The ITAB will continuously monitor the progress of the study and will advise the SC.

The study was designed by the SC and ITAB. It was funded by the University of Pécs, Medical School. The sponsor was not involved in the design of the study, and will have no access to database or the randomization code.

The study also contains an independent physician and safety manager as required by the ethical regulation.

1 **Study population:** All patients with mild ABP will be informed of the possibility to take part in the EMILY trial. After the  
2 consent form is signed participants will be randomized to 2 groups if they meet all the inclusion and no exclusion criteria (*Figure*  
3 *1*).  
4  
5

6 **Inclusion criteria:** The criteria for inclusion in the study: (1) patients older than 18 years of age; (2) diagnosis of acute  
7 pancreatitis (at least 2 of the following 3 symptoms: upper abdominal pain, serum lipase or amylase is three times higher than the  
8 upper limit of normal and characteristic findings for acute pancreatitis on imaging); (3) the presence of ABP (any of the following  
9 3 definitions): diagnosis of gallstones or sludge on imaging, a dilated common bile duct on ultrasound (>8 mm in patients ≤75  
10 years old or >10 mm in patients >75 years old) in the absence of gallstones or sludge in the gallbladder; and alanine  
11 aminotransferase level >2 times higher than normal values with ALT > AST; (4) mild ABP (meaning no pancreatic necrosis, no  
12 transient or persistent organ failure (>48 hours)) is present; (5) ERCP/ES during the present ABP without complication; and (6)  
13 signed written informed consent (all included patient will sign the consent which contains the information about the trial and  
14 procedures) (*Figure 1*).  
15  
16

17 **Exclusion criteria:** A patient's bad physical status can be an exclusion criterion. American Society of Anesthesiologists (ASA)  
18 III patients >75 years old; ASA IV or V patients, will be excluded. Patients with continuous alcohol abuse, acute or chronic  
19 cholecystitis during hospitalization, chronic pancreatitis, pregnancy, previous ES or cholecystectomy will also be excluded  
20 (*Figure 1*).  
21  
22

23 **Time of randomization:** 5 criteria are described by the PONCHO trial [25]. If these 5 criteria are met, the informed consent will  
24 be signed by the patient and a control abdominal CT will be carried out before discharge. The patient can then be randomized.  
25 These criteria are the following: (1) Anticipation on the part of the treating physician that the patient can be discharged; (2) no  
26 need for opioid analgesics; (3) declining C-reactive protein levels and <100 mg/l; (4) no evidence of local or systemic  
27 complications (for example, no fever); (5) resumed oral intake on the part of the patient.  
28  
29

30 **Randomization:** Randomization should be done as described above. The patient can be randomized by the study coordinator  
31 using a randomization module with sealed envelope. Patient data will be uploaded with the help of the administrator to the data  
32 base, which will be followed by the randomization. This randomization module will allocate the participants to the 2 different  
33 groups. This method makes it impossible for researchers to predict the allocation of the patients involved in the study. It is  
34 impossible to conceal the distribution of the patients in this study because the patients need to be scheduled for either an early  
35 cholecystectomy or a delayed cholecystectomy (*Figure 1*).  
36  
37

38 Allocation will be carried out based on predefined randomisation lists created separately for each recruiting centre. The allocation  
39 sequence will be prepared with a block size of 4 and with an allocation ratio 1:1 by the Independent Data Management Board  
40 (IDMB).  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Blinding:** In prevention of patient's selection to group A and B trial participants, care providers and outcome assessors will be blinded until the allocation, as no access to randomization sequence. From assignment to intervention blinding cannot be provided considering the study characteristics (exact date of cholecystectomy). The allocation sequence is unblinded only to data analysts who are completely independent from medical team (decision making) and data collection.

## Endpoints

**Primary endpoint.** The primary endpoint is a composite endpoint, which is based on mortality and on recurrent biliary events (which are recurrent ABP, acute cholecystitis, uncomplicated biliary colic, and cholangitis). The observation period is three months. We decide based on criteria in *Figure 2* if a complication is present or not.

**Secondary endpoints.** We hypothesize that cholecystectomy for ABP between days 45-60 after discharge in patients with ES is as effective and safe as early cholecystectomy (within 6 day after ES). In order to evaluate this, we will observe the following parameters: the number of biliary colic registered for the patient, difficulty of cholecystectomy (on a scale of 0-10, 0=easy, 5=moderately difficult, 10=hard, rate of conversion to open cholecystectomy, total length of hospital stay, need for ICU admission and total length of ICU stay, organ failure and biliary leakage (*Figure 2*).

## Treatment protocol

Randomization: Group A. Early cholecystectomy

Group B. Delayed cholecystectomy

We randomize patients into two groups after ES (*Figure 3*):

Group A: The patient is randomized to the early cholecystectomy group, and cholecystectomy will be performed within 6 days after ES.

Group B: The patient is randomized to the delayed cholecystectomy group, and the cholecystectomy will be carried out between 45 to 60 days.

Discontinuing or the modification of the allocated interventions for a trial participant is based on surgical causes like contraindicated opus, need for conversion to open cholecystectomy, or when the patient does not present to the hospital for cholecystectomy. Switching over the two interventions is not possible considering the trial characteristics, however in case of acute cholecystitis acute cholecystectomy can be performed independently from this trial. The case must be presented to SC.

**Surgical details and quality control:** ERCP/ES will be performed according to the European Society of Gastrointestinal Endoscopy (ESGE) guidelines [26] and the laparoscopic cholecystectomy will follow the European Association Guidelines for Endoscopic Surgery [27]. The patients will be operated on by laparoscopically trained surgeons with >100 laparoscopic procedures performed and by an ERCP/ES trained gastroenterologist with >50 endoscopic sphincterotomies completed within a year. Centers which intend to randomize at least 15 patients and are able to perform an early cholecystectomy and ERCP/ES are

1 eligible to participate in the study. ES data will then be collected on the incidence of choledocholithiasis, percentage bile duct  
2 injury, duration, and perceived difficulty (on a scale of 0-10).  
3  
4

5 **Diagnosing and treating ABP:** In the first 24 hours of admission, all patients will undergo either an ultrasonography or a  
6 contrast-enhanced computed tomography (CECT) to detect if the gallbladder contains gallstones or sludge and to determinate the  
7 diameter of the common bile duct.  
8  
9

10  
11  
12 **Data collection and follow-up:** Data will be collected in a personalized database, and follow-up will consist of questionnaires  
13 (*supplementary figure 1*). The patient will be asked to note every biliary event during the follow-up period and will be contacted  
14 in person within 90 days after ES to collect information. After data collection, we can draw conclusions about the treatment  
15 strategy. Improperly completed datasheets and incorrect data upload will be avoided and controlled by the administrator.  
16  
17 The personal information about enrolled participants will only be shared with IDMB as uploaded data for randomization, after  
18 data analysis only randomization code will be used for identification to protect confidentiality during, and after the trial. Only the  
19 principal investigator and the IDMB will have access to the final trial dataset. However only identification code is used, we can  
20 aside from duplicated patient's data as cholecystectomy can not be performed twice.  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Sample size estimation method**

30 **Primary endpoint:** a composite of gallstone-related complications or mortality occurring within 6 months after randomization

31  
32 **Hypothesis:** With regard to our hypothesis, based on an equivalence (non-inferiority) trial, we found no difference between the  
33 two groups (5%) in mortality or readmission for gallstone-related complications within 3 months after randomization.  
34  
35

36 **Starting point:** Considering the results of the PONCHO trial involving 264 patients, where a subgroup of 77 patients underwent  
37 endoscopic sphincterotomy: the primary endpoint occurred for 1 subject in the same-admission cholecystectomy group (3%) and 7  
38 subjects in the interval admission group (17%). The difference between the two groups was not significant at the 5% level  
39 ( $p=0.07$ ). The results for the current sample size estimation were reached using the difference between the two proportions above  
40 (14%) calculated with a 5% drop-out rate. They are listed in the table below (*Figure 4*):  
41  
42  
43  
44  
45  
46

47 **Data management and statistical analyses:** Data will be handled by an independent Clinical Research Organizer. Electronic  
48 CRF (eCRF) will be used. The Investigator will ensure that the data in the eCRF are accurate, complete and legible. Detailed data  
49 flow will be described in a Data Management Plan (DMP). Data from completed eCRFs will be validated under the direction of  
50 the Data Manager according to a Data Cleaning Plan (DCP). Adverse events will be coded using MedDRA according to GCP,  
51 GLP, FDA 21CFR PART11 and other relevant regulatory requirements.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Safety Analysis Set (SAS, all patients enrolled in the study), Per Protocol Set (PPS, all enrolled patients who finished the study  
2 conforming to the requirements of the study protocol) and Intention to Treat (ITT, all randomised participants who start on a  
3 treatment, excluding consent withdrawals) will be performed.  
4

5 Baseline patient and disease characteristics will be analysed using descriptive analysis. Demographic and baseline characteristics  
6 will be summarised for the overall study population. Descriptive statistics for both the primary and secondary parameters will be  
7 analysed similarly.  
8

9 Subgroup analyses will be performed concerning the imaging alterations (1: no gallstones or sludge on imaging, 2) sludge or 3)  
10 gallstone).  
11

12 In case of important protocol modifications IDMB will report to the SC. SC will discuss and if the adverse effect is confirmed it  
13 will be reported to the relevant institutional and national ethical committee <http://www.ett.hu/tukeb.htm>  
14

15 **Premature termination of the study:** In the interests of patient safety, an interim analysis will be conducted after 15 patients and  
16 after half of the presumed number of patients (45) have completed the study. IDMB will perform an independent assessment of  
17 the trial related documents and activities, with the aim of ensuring the respect of subjects' right, safety and well-being and to  
18 guarantee the plausibility of clinical data. Similarity of groups at baseline will be also checked. The study will also be stopped if  
19 the two groups' results differ significantly ( $p < 0.001$ ). The study will be discontinued if the difference between the planned number  
20 of patients and the actual number is higher than 60% within one year. IDMB will report to SC.  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 **Centers:** The trial will be launched in four Hungarian (Szeged, Debrecen, Pécs and Székesfehérvár) and two Romanian centres  
31 (Targu Mures and Cluj Napoca), after which the study will be open to other centres. In all cases, the IDMB will conduct an audit  
32 of the center and will report to the SC. The SC maintains the right to decide whether a center meets the required quality to join the  
33 study.  
34  
35  
36

37 The full protocol will be available for public in an open access journal.  
38

39 **Publication policy:** We would like to publish the results in one of the internationally highly recognized decent journals. Centers  
40 providing more than 25 patients can provide 4 authors to the authorship list: 2 surgeons and 2 gastroenterologists.  
41  
42  
43  
44

45 **Patient and Public Involvement:** This pre-study protocol contains no results and data, therefore patients and or public were not  
46 involved.  
47  
48  
49

## 50 DISCUSSION

51 In the case of early laparoscopic cholecystectomy, while dissection and logistics are more difficult [6, 7] compared with delayed  
52 (interval) cholecystectomy, it is still more effective. Delayed cholecystectomy in a mild form of ABP is preferred by many  
53 surgeons, but a number of complications can occur: recurrent ABP, acute cholecystitis, obstruction of ductus choledochus, and  
54 uncomplicated biliary colic [6, 7]. After ERCP/ES is performed, the common bile duct is cleared, the complications caused by  
55  
56  
57  
58  
59

gallstones or sludge are significantly reduced [28]. The EMILY study is designed to determine if ERCP/ES for mild ABP aids in delaying the cholecystectomy to day 45-60 after discharge among patients with ABP.

If an ES aids in delaying a cholecystectomy, then we can reduce early cholecystectomy-related complications and the surgeons can proceed with a safer, easier cholecystectomy using this method of treatment.

## ACKNOWLEDGEMENTS

**Funding:** Center costs (IT, biostatistics, trial organization, etc) are covered by the University of Pécs Medical School, Momentum Grant of the Hungarian Academy of Sciences (LP2014-10/2014); and Economic Development and Innovation Operative Programme Grant and Highly Cited Publication Grant of the National Research, Development and Innovation Office (GINOP-2.3.2-15-2016-00048 Stay Alive, KH-125678 and EFOP 3.6.2-16-2017-00006 Live Longer), and Translational Medicine Foundation.

Since no additional treatment is necessary for the study, the general healthcare costs are covered by the National Healthcare System (University of Pécs-Medical School).

This study was designed with help of the Centre for Translational Medicine at the University of Pécs. This center is committed to improve patients life with research activities like registries, observational and interventional trial organizations (<https://tm-centre.org>).

There are no financial and other competing interests for principal investigators (LK, DK), included patients or any member of the trial.

## ETHICS AND DISSEMINATION

**Trial registration:** The trial has been registered at the ISRCTN (reference number 35066).

**Ethical approval:** Scientific and Research Ethics Committee of the Hungarian Medical Research Council (EKU/2018/12176-5).

**Protocol Version:** V1.0 10.07.2018.

**Start of the patient recruitment:** In September, 2018.

**Additional information and future plan:** Blood samples (serum and plasma) will be stored from all patients in order to study laboratory parameters later if required (e.g. the laboratory could not measure it), and in order to build up a biobank for later clinical studies to which all participants will give informed consent. The samples will be stored at -80°C.

The post-trial care will follow the routine treatment protocols. In case if patient suffer a harm during hospitalization all of the responsibility is taken by the hospital where the patient is treated.

## AUTHORS' CONTRIBUTION

LK, KM, DK, ÁV, LC, MP, FI, ÁA, MT and PH designed the study. As a member of the ITAB MML, JN, MST and OHP gave advices and will continuously monitor the progress of the study. LK, KM, PH, ZsSz, KP and IM drafted the manuscript, GyL, SB,

AV, LB, MD and Asz edited the manuscript. ZsSz, KP, IT, ASz edited the figures and tables.

All authors read and approved the final manuscript.

During the study IT, ÁV, LC, MP and MT are going to manage the endoscopic treatments. LP, DK, GyL, ZssZ, MD and SB are responsible for cholecystectomies. ITAB and SC members are listed ahead.

## LIST OF ABBREVIATIONS

ABP – acute biliary pancreatitis

ASA – American Society of Anesthesiologists

CECT – contrast enhanced computed tomography

DCP – Data Cleaning Plan

DMP – Data Management Plan

ES – endoscopic shicterotomy

eCRF – electronic case report form

ESGE – European Society of Gastrointestinal Endoscopy

HPSG – Hungarian Pancreatic Study Group

IDMB – Independent Data Management Board

ITAB – International Translational Advisory Board

ITT – Intent to Treat

LC – Laparoscopic cholecystectomy

PPS – Per Protocol Set

SAS – Safety Analysis Set

SC – Steering Committee

## References

1. Peery AF, Dellon ES, Lund J, Crockett SD, et al. Burden of gastrointestinal disease in the United States: 2012 update. *Gastroenterology* 2012;143:1179–87. doi: 10.1053/j.gastro.2012.08.002
2. Dhiraj Y, Albert BL. The epidemiology of pancreatitis and pancreatic cancer gastroenterology. *Gastroenterology* 2013;144(6):1252–1261. doi: 10.1053/j.gastro.2013.01.068
3. Schepers NJ, Bakker OJ, Besselink MG, et al. Early biliary decompression versus conservative treatment in acute biliary pancreatitis (APEC trial): study protocol for a randomized controlled trial. Schepers et al. *Trials* 2016;17:5. doi: 10.1186/s13063-015-1132-0

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
4. Uhl W, Müller CA, Krähenbühl L et al. Acute gallstone pancreatitis, Timing of laparoscopic cholecystectomy in mild and severe disease. *SurgEndosc* 1999;13:1070–1076
5. Schietroma M, Carlei F, Lezoche E, et al. Acute biliary pancreatitis: staging and management. *Hepato-gastroenterology* 2001;48(40):988–993
6. UK Working Party on Acute Pancreatitis. UK guidelines for the management of acute pancreatitis. *Gut* 2005;54(Suppl 3):iii1–iii9. doi: 10.1136/gut.2004.057026
7. Forsmark CE, Baillie J. AGA institute technical review on acute pancreatitis. *Gastroenterology* 2007;132:2022–2044. doi: 10.1053/j.gastro.2007.03.065.
8. van Baal MC, Besselink MG, Bakker OJ, et al. for the Dutch Pancreatitis Study Group: Interval cholecystectomy after mild biliary pancreatitis is associated with a high risk of readmission for recurrent biliary events, especially recurrent biliary pancreatitis. *Annals of Surgery* 2012;255(5):860–866. doi: 10.1097/sla.0b013e3182507646
9. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. *Am J Gastroenterol* 2006;101:2379–2400. doi: 10.1111/j.1572-0241.2006.00856.x.
10. Uhl W, Warshaw A, Imrie C, et al. IAP Guidelines for the Surgical Management of Acute Pancreatitis. *Pancreatology* 2002;2:565–573. doi: 10.1159/000067684
11. Nealon WH, Bawduniak J, Walser EM. Appropriate timing of cholecystectomy in patients who present with moderate to severe gallstone-associated acute pancreatitis with peripancreatic fluid collections. *Ann Surg* 2004;239:741–749. doi:10.1097/01.sla.0000128688.97556.94
12. da Costa DW, Bouwense SA, Schepers NJ, et al. Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicenter randomized controlled trial. *Lancet* 2015;386:1261–68. doi: 10.1016/s0140-6736(15)00274-3
13. Paul GL, Bettina WD, Markus ML. Clinical perspectives in pancreatology: Compliance with Acute Pancreatitis Guidelines in Germany. *Pancreatology* 2005;5:591–593. doi: 10.1159/000087501
14. Uomo G, Manes G, Laccetti M, et al. Endoscopic sphincterotomy and recurrence of acute pancreatitis in gallstone patients considered unfit for surgery. *Pancreas* 1997;14:28–31.
15. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* 2013;158:200–7. doi: 10.7326/0003-4819-158-3-201302050-00583
16. Hritz I, Hegyi P. Early Achievable Severity (EASY) index for simple and accurate expedite risk stratification in acute pancreatitis. *J Gastrointestin Liver Dis* 2015;24(2):177–82. doi: 10.15403/jgld.2014.1121.242.easy
17. Párniczky A, Mosztbacher D, Zsoldos F et al. Analysis of Pediatric Pancreatitis (APPLE Trial): Pre-study protocol of a multinational prospective clinical trial. *Digestion* 2016;93(2):105–10. doi: 10.1159/000441353
18. Zsoldos F, Párniczky A, Mosztbacher D, et al. Pain in the Early Phase of Pediatric Pancreatitis (PINEAPPLE Trial): Pre-study protocol of a multinational prospective clinical trial. *Digestion* 2016;93(2):121–6. doi: 10.1159/000441352

19. Dubravcsik Z, Madácsy L, Gyökeres T, et al. Preventive pancreatic stents in the management of acute biliary pancreatitis (PREPAST trial): pre-study protocol for a multicenter, prospective, randomized, interventional, controlled trial. *Pancreatology* 2015;15(2):115–23. doi: 10.1016/j.pan.2015.02.007
20. Márta K, Szabó AN, Pécsi D, et al. High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial. *BMJ Open* 2017;7(9):e015874. doi: 10.1136/bmjopen-2017-015874
21. Dubravcsik Z, Farkas G, Hegyi P, et al. [Autoimmune pancreatitis. Evidence-based management guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(8):292–307. doi: 10.1556/OH.2015.30061
22. Hritz I, Czakó L, Dubravcsik Z, et al. [Acute pancreatitis. Evidence-based practice guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):244–61. doi: 10.1556/OH.2015.30059
23. Parniczky A, Czakó L, Dubravcsik Zs, et al. [Pediatric pancreatitis. Evidence-based management guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(8):308–25. doi: 10.1556/OH.2015.30062
24. Takacs T, Czakó L, Dubravcsik Z, et al. [Chronic pancreatitis. Evidence-based management guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):262–88. doi: 10.1556/OH.2015.30060
25. Bouwense SA, Besselink MG, van Brunshot S, et al. Pancreatitis of biliary origin, optimal timing of cholecystectomy (PONCHO trial): study protocol for a randomized controlled trial. Published online 26 Nov 2012. doi: 10.1186/1745-6215-13-225
26. Pier AT, Alberto M, Lars A, et al. Papillary cannulation and sphincterotomy techniques at ERCP: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Endoscopy* 2016 Jul;48(7):657-83. doi: 10.1055/s-0042-108641
27. Edmund AMN, Hans T, CK Kum, et al. EAES Clinical Practice Guidelines on Laparoscopic Cholecystectomy, Appendectomy, and Hernia Repair (1994). In: EAES guidelines for endoscopic surgery: Twelve years evidence-based surgery in Europe. E. Neugebauer, S. Sauerland, A.B. Fingerhut, B. Millat, G.F. Buess (Eds.). Springer Berlin Heidelberg, 2006:265-289
28. Testoni PA. Acute recurrent pancreatitis: Etiopathogenesis, diagnosis and treatment. *World J Gastroenterol* 2014;20(45):16891. doi: 10.3748/wjg.v20.i45.16891
29. Banks PA, Bollen TL, Dervenis C, et al. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 2012;62(1):102-11. doi: 10.1136/gutjnl-2012-302779
30. van Santvoort HC, Besselink MG, de Vries AC, et al. Early endoscopic retrograde cholangiopancreatography in predicted severe acute biliary pancreatitis: a prospective multicenter study. *Ann Surg* 2009;250:68–75. doi: 10.1097/SLA.0b013e3181a77bb4
31. Keus F, de Jong JA, Gooszen HG, van Laarhoven CJ: Laparoscopic versus open cholecystectomy for patients with symptomatic cholecystolithiasis. *Cochrane Database Syst Rev* 2006;4:CD006231. doi: 10.1002/14651858.cd006231
32. Mayumi T, Takada T, Kawarada Y, et al. Results of the Tokyo Consensus Meeting Tokyo Guidelines. *J Hepatobiliary Pancreat Surg* 2007;14:114–121. doi: 10.1007/s00534-006-1163-8

33. Max JS, Douglas AD. What Is New in Rome IV. Journal of Neurogastroenterology and Motility 2017; 23(2): 151-163. doi:  
10.5056/jnm16214

For peer review only

Figure 1 Shows the flow chart of participants according to SPIRIT 2013 guideline (34).

\* no pancreatic necrosis, no transient or persistent organ failure (>48 hours) is present with any of the following 3 definitions:

1) diagnosis of gallstones or sludge on imaging, 2) a dilated common bile duct on ultrasound (>8 mm in patients  $\leq 75$  years old or >10 mm in patients >75 years old) in the absence of gallstones or sludge in the gallbladder, 3) and alanine aminotransferase level >2 times higher than normal values with ALT > AST

\*\* American Society of Anesthesiologists (ASA) IV or V patients and ASA III >75 years old

Figure 2 Shows the evaluation of primary and secondary endpoints.




Figure 3 Schedule of enrolment, interventions and assessments according to the SPIRIT 2013 statement [15]

1  
2 \*In the first 24 hours of admission, all patients will undergo either an ultrasonography or a contrast-enhanced computed  
3 tomography (CECT) to detect if the gallbladder contains gallstones or sludge and to determinate the diameter of the common bile  
4 duct.  
5

6  
7 \*\*These criteria are the following: (1) Anticipation on the part of the treating physician that the patient can be discharged within  
8 1 or 2 days; (2) no need for opioid analgesics; (3) declining C-reactive protein levels and <100 mg/l; (4) no evidence of local or  
9 systemic complications (for example, no fever); (5) resumed oral intake on the part of the patient; and (6) ERCP/ES without  
10 complications. Befor discharge or transfer to surgery department.  
11  
12

13  
14 \*\*\* Data will be collected in a personalized database, and follow-up will consist of questionnaires. The patient will be asked to  
15 note every biliary event during the follow-up period and will be contacted in person within the 90 days after cholecystectomy to  
16 collect information. After data collection, we can draw conclusions about the treatment strategy. Improperly completed datasheets  
17 and incorrect data upload will be avoided and controlled by the administrator. (Q=question)  
18  
19  
20  
21  
22

23 Figure 4 The listed parameters were used to estimate results for the current sample size.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



25 Figure 1 Shows the flow chart of participants according to SPIRIT 2013 guideline (34).

26 \* no pancreatic necrosis, no transient or persistent organ failure (>48 hours) is present with any of the  
 27 following 3 definitions: 1) diagnosis of gallstones or sludge on imaging, 2) a dilated common bile duct on  
 28 ultrasound (>8 mm in patients ≤75 years old or >10 mm in patients >75 years old) in the absence of  
 29 gallstones or sludge in the gallbladder, 3) and alanine aminotransferase level >2 times higher than normal  
 30 values with ALT > AST

31 \*\* American Society of Anesthesiologists (ASA) IV or V patients and ASA III >75 years old

32  
33 265x151mm (300 x 300 DPI)

ENDPOINTS		
PRIMARY	SECONDARY	
Mortality	Biliary colic Difficulty of cholecystectomy	ICU admission Length of ICU stay
Recurrent biliary events (recurrent biliary pancreatitis, acute cholecystitis, uncomplicated biliary colic and cholangitis)	Conversion to open cholecystectomy	Organ failure
	Total length of hospital stay	Biliary leakage
<p><b>Diagnosis of acute pancreatitis</b> at least two of the three following features are present<sup>[30]</sup></p> <ol style="list-style-type: none"> <li>Upper abdominal pain;</li> <li>Serum lipase or amylase levels above three times the upper level of normal;</li> <li>Characteristic findings of acute pancreatitis on cross-sectional abdominal imaging.</li> </ol>		
<p><b>Biliary pancreatitis</b> one of the following presents<sup>[31]</sup></p> <ol style="list-style-type: none"> <li>Gallstones and/or sludge diagnosed on imaging (transabdominal or endoscopic ultrasound or computed tomography);</li> <li>In the absence of gallstones and/or sludge, a dilated common bile duct on ultrasound (&gt;8 mm in patients ≤75 years old or &gt;10 mm in patients &gt;75 years old);</li> <li>The following laboratory abnormality: alanine aminotransferase (ALAT) level &gt;2 times higher than normal values, with ALAT &gt;aspartate aminotransferase.</li> </ol>	<p><b>Cholecystitis</b> 2007 Tokyo classification grade I to III<sup>[32,33]</sup></p> <p>A. Local signs of inflammation: 1) Murphy's sign; 2) RUQ mass/pain/tenderness.</p> <p>B. Systemic signs of inflammation: 1) Fever; 2) Elevated C-reactive protein; 3) Elevated white blood cell count.</p> <p>C. Imaging findings characteristic of acute cholecystitis.</p> <p style="text-align: center;"><b>Definite diagnosis</b></p> <p>1) One item in A and one item in B are positive; 2) C confirms the diagnosis when acute cholecystitis is suspected clinically.</p>	
<p><b>Cholangitis</b> All of the following features as previously defined<sup>[31]</sup></p> <ol style="list-style-type: none"> <li>Serum total bilirubin level &gt;40 μmol/l (&gt;2.3 mg/dl) and/or dilated common bile duct (&gt;6 mm) on transabdominal or endoscopic ultrasound or computed tomography;</li> <li>Temperature &gt;38.5°C.</li> </ol>	<p><b>Biliary colic</b> Rome criteria<sup>[33]</sup></p> <p>Upper abdominal pain (either right upper quadrant or epigastric pain) lasting at least 30 minutes, according to the</p>	

Figure 2 Shows the evaluation of primary and secondary endpoints.

198x154mm (300 x 300 DPI)

STUDY PERIOD						
DIVISION	Gastroenterology management			Department of Surgery		Control visit
SERVING	DOCTOR no.1 and no.2			DOCTOR no.3		DOCTOR no.4
	1	1	2	1		
OBJECT	MBP management and randomization			Cholecystectomy after ES		Follow up
TIMEPOINT	- several days	0	+ several days	Within 5-6 days	Between day 45-60	Day 90±7 after ES
<b>ENROLMENT:</b>						
Diagnosis of acute biliary pancreatitis*	X					
Endoscopic sphincterotomy		X				
Eligibility screen			X Q2-4			
TEST 1**				X Q5		
Sign of Informed consent form				X Q6		
Allocation***				X Q6		
Randomization***				X Q6		
Discharge**** to home or to surg.				X		
<b>INTERVENTIONS:</b>						
Group A Early cholecystectomy				X		
Group B Delayed cholecystectomy					X	
TEST 2**				X Q7	X Q7	
<b>ASSESSMENTS:</b>						
Follow up (with the help of an administrator)*****						X

Figure 3 Schedule of enrolment, interventions and assessments according to the SPIRIT 2013 statement [15]

\*In the first 24 hours of admission, all patients will undergo either an ultrasonography or a contrast-enhanced computed tomography (CECT) to detect if the gallbladder contains gallstones or sludge and to determinate the diameter of the common bile duct.

\*\*These criteria are the following: (1) Anticipation on the part of the treating physician that the patient can be discharged within 1 or 2 days; (2) no need for opioid analgesics; (3) declining C-reactive protein levels and <100 mg/l; (4) no evidence of local or systemic complications (for example, no fever); (5) resumed oral intake on the part of the patient; and (6) ERCP/ES without complications. Befor discharge or transfer to surgery department.

\*\*\* Data will be collected in a personalized database, and follow-up will consist of questionnaires. The patient will be asked to note every biliary event during the follow-up period and will be contacted in person within the 90 days after cholecystectomy to collect information. After data collection, we can draw conclusions about the treatment strategy. Improperly completed datasheets and incorrect data upload will be avoided and controlled by the administrator. (Q=question)

269x154mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Hypothesised proportion in each group	Significance level	Power	Acceptable max. difference for equivalency	Sample size needed for analysis (per group)	Sample size for screening (with 5% drop-out rate)
5%	95%	90%	14%	42	89

Figure 4 The listed parameters were used to estimate results for the current sample size.

271x39mm (300 x 300 DPI)

Endoscopic sphincterotomy for delay in  
cholecystectomy in mild acute biliary pancreatitis



## QUESTIONNAIRE

### 1. Personal data

#### 1.1 Patient's data

Name: \_\_\_\_\_

Sex: Male / Female

Date of Birth: \_\_\_\_\_

Age: \_\_\_\_\_

Insurance number: \_\_\_\_\_

Phone number: \_\_\_\_\_

The patient's study number:

#### 1.2 Doctors' data

##### DOCTOR No. 1:

Name of the doctor **responsible for the treatment of ABP**: \_\_\_\_\_

The phone number of the doctor: \_\_\_\_\_

Institute: \_\_\_\_\_

##### DOCTOR No. 2:

Name of the doctor **responsible for the randomization**: \_\_\_\_\_

The phone number of the doctor: \_\_\_\_\_

Institute: \_\_\_\_\_

##### DOCTOR No. 3:

Name of the doctor **responsible for the operation**: \_\_\_\_\_

The phone number of the doctor: \_\_\_\_\_

Institute: \_\_\_\_\_

##### DOCTOR No. 4:

Name of the doctor **responsible for the 90 days' visit**: \_\_\_\_\_

The phone number of the doctor: \_\_\_\_\_

Institute: \_\_\_\_\_

**E**ndoscopic sphincterotomy **M**y for delay **I**ng  
cholecystectomy in mild acute biliary **Y** pancreatitis

**2. Inclusion criteria** /DOCTOR No. 2/

Patients older than 18 age	<b>YES</b>	<b>NO</b>
Diagnosis of acute pancreatitis (two of them have to be positive) <ul style="list-style-type: none"> <li>- upper abdominal pain</li> <li>- serum lipase or amylase is three times higher of upper limit of normal</li> <li>- characteristic findings of acute pancreatitis on abdominal imaging</li> </ul>	<b>YES</b>	<b>NO</b>
Presence of biliary pancreatitis (one of them has to be true) <ul style="list-style-type: none"> <li>- diagnosis of gallstone or sludge on imaging</li> <li>- the absence of gallstone or sludge with a dilated common bile duct on ultrasound (&gt;8 mm in patients ≤75 years of age or &gt;10 mm in patients &gt;75 years old)</li> <li>- alanine aminotransferase level &gt;2 times higher than normal values</li> </ul>	<b>YES</b>	<b>NO</b>
Mild acute biliary pancreatitis (all of them have to be true) /HAS TO BE DETERMINED AT DISCHARGE OF THE PATIENT/ <ul style="list-style-type: none"> <li>- no peripancreatic fluid collections</li> <li>- no pancreatic necrosis</li> <li>- no <b>transient or</b> persistent organ failure</li> </ul>	<b>YES</b>	<b>NO</b>
ERCP/ES without complications	<b>YES</b>	<b>NO</b>
Written informed consent	<b>YES</b>	<b>NO</b>
<b>One „NO” is present = DO NOT INCLUDE!</b>		

**3. Exclusion criteria** /DOCTOR No. 2/

American Society of Anesthesiologists (ASA) classification <ul style="list-style-type: none"> <li>- III patients &gt;75 years old</li> <li>- IV, V, VI. Groups</li> </ul>	<b>YES</b>	<b>NO</b>
Acute or chronic cholecystitis during hospitalization	<b>YES</b>	<b>NO</b>
Previous sphincterotomy or cholecystectomy	<b>YES</b>	<b>NO</b>
Continuous alcohol abuse or chronic pancreatitis	<b>YES</b>	<b>NO</b>
Pregnancy	<b>YES</b>	<b>NO</b>
<b>One „YES” is present = EXCLUDE!</b>		

**4. If all inclusions and no exclusion criteria are met, than the physician may indicate the patient to participate in the study.** / DOCTOR No. 2/

The treating physician (DOCTOR No. 2) anticipates that the patient can be discharged	<b>YES</b>	<b>NO</b>
No need for opioid analgesics	<b>YES</b>	<b>NO</b>
Declining C-reactive protein levels and <100 mg/l	<b>YES</b>	<b>NO</b>
No evidence of local or systemic complications	<b>YES</b>	<b>NO</b>
The patient has resumed solid oral nutrient	<b>YES</b>	<b>NO</b>
<b>If all YES = RANDOMIZATION /see point 6/</b>		



Endoscopic sphincterotomy for delay in cholecystectomy in mild acute biliary pancreatitis  
**5. Medical History and characteristics of ABP / DOCTOR No. 1/**

Date of admission (diagnosis of AP):.....

Date of discharge: .....

**5.1 Anamnesis**

History of upper abdominal surgery: Yes / No  
 If yes, interventions:.....  
 .....  
 History of biliary colics Yes / No  
 History of cholecystitis Yes / No  
 Fever Yes / No .....°C  
 Diabetes Yes / No  
 Antibiotic therapy during the ABP Yes / No

BMI Weight:\_\_\_ kg, Height:\_\_\_ cm, BMI:\_\_\_ kg/m<sup>2</sup>

ASA classification (ASA PHYSICAL STATUS CLASSIFICATION SYSTEM)

I. group(Normal healthy patient)	YES	NO
II. group(Patient with mild systemic disease with no functional limitations)	YES	NO
III. group(Patient with moderate systemic disease with functional limitations)	YES	NO

**5.2. Laboratory measurements**

At discharge after AP:

Amylase(U/l)		Hematocrit(%)	
Lipase(U/l)		Hemoglobin(g/l)	
Gamma GT(U/l)		Kreatinine(umol/l)	
White blood cell(G/l)		eGFR	
ASAT/GOT(U/l)		CRP(mg/l)	
INR(U/l)		Alkaline phosphatase(U/l)	



Endoscopic sphincterotomy for delay  
cholecystectomy in mild acute biliary pancreatitis

### 5.3. Pancreatic imaging /At discharge after AP/

#### 5.3.1 Abdominal Computed Tomography: yes/no

Modified CTSI Score (0-10): .....

Please NOTE! Abdominal CT is compulsory when the patient is discharged

- **CTSI:**

**CTSI Score: (I)** Normal pancreas 0 point, intrinsic pancreatic abnormalities with or without inflammatory changes in peripancreatic fat 2 points, Pancreatic or peripancreatic fluid collection or peripancreatic fat necrosis 4 points **(II)** Necrosis absent 0 Points, < 30% necrosis 2 Points, > 30% necrosis 4 points **(III)** presence of extrapancreatic findings 2 points.

MAXIMUM OF: 10 points

- **Pancreas Size:**

- Normal
- Partially enlarged (body AP diameter is over 2 cm and/or head AP diameter is over 2,5 cm, none exceeds 3 cm)
- Definitely enlarged (any part over 3 cm AP diameter)

- Largest diameter of peripancreatic **fat infiltration:** ..... cm

- **Peripancreatic fluid:**

- none
- present
- Large pseudocyst(s)

- Size of peripancreatic fluid or pseudocyst: ..... cm

- **Necrotizing area** (nonenhancement):

- Largest diameter of necrosis area: ..... cm
- Location of necrosis: .....
- Type: patchy / full width
- Estimated necrosis: 0%, < 30% , 30% - 60%, > 60%

- **Wirsung** dilatation: YES / NO (yes, diameter: ..... mm)

- Distant **abdominal fluid:**

- Small amount (hard to see, less than 2 cm in lesser pelvis, less than 1 cm around liver/spleen)



**E**ndoscopic sphincterotomy for delay **I**ng  
cholecystectomy in mild acute biliar **Y** pancreatitis

- Moderate amount (easy to see, but without pelvic or abdominal distension)
- Large amount with abdominal/pelvic distension

**- Pleural effusion:**

- none
- one sided:..... (AP diameter: ..... cm)
- Both sides, L - ..... cm, R - ..... cm

**- Extrapancreatic findings:**

- Inflammation (Cholecystitis, Duodenitis, etc.) location: .....
- Cholecystolithiasis
- Choledocholithiasis
- Signs of bowel ischaemia
- Bowel distension, ileus
- Venous thrombosis
- Pseudoaneurysm
- Parenchymal organ involvement, define: .....
- none

Other Description:

.....  
 .....  
 .....  
 .....

**5.4. Characteristics of AP**

Date of diagnosis (admission).....

Date of EST: .....

Date of discharge: .....



1 **E**ndoscopic sphincterotomy for delay **I**ng  
 2  
 3 cho**L**ecystectomy in mild acute biliar **Y** pancreatitis  
 4  
 5

6 **6. Randomization** / DOCTOR No. 2/  
 7

8 The patient will be randomized by an internet randomization module in the following 2  
 9 groups:  
 10

- 11 Randomization:           **A.** Early cholecystectomy (within 6 days after  
 12 ERCP/ES)  
 13                               **B.** Delayed cholecystectomy (between 45 and 60 days  
 14 after ERCP/ES)  
 15  
 16  
 17

18 Please circle the relevant group after randomization:  
 19  
 20



21 Please inform the patient concerning the **1)** Date for imaging examination and blood  
 22 measurements before the operation, **2)** Date for the operation, **3)** Date for the 90 days  
 23 visit  
 24  
 25

26 **7. Operation** /responsibility of DOCTOR No. 3/  
 27  
 28

29 Date of operation: .....

30 Length of days between ES and operation: .....

31 If the operation is not in the time period described in point 6 please provide the  
 32 reason: .....

For peer review only



**E**ndoscopic sphincterotomy **M**y for delay **I**ng  
cho**L**ecystectomy in mild acute biliar **Y** pancreatitis

**7.1 Anamnesis (between discharge after ABP and operation)**

<p><b>Acute pancreatitis</b>                  - Upper abdominal pain                  - Serum lipase or amylase is three times higher of upper limit of normal                  - Characteristic findings of acute pancreatitis on cross-sectional abdominal imaging</p>	<p><b>YES</b></p>	<p><b>NO</b></p>
<p><b>Biliary pancreatitis</b>                  - Diagnosis of gallstone or sludge on imaging                  - Dilated common bile duct on ultrasound (&gt;8 mm in patients ≤75 years old or &gt;10 mm in patients &gt;75 years old                  - Alanine aminotransferase level &gt;2 times higher than normal values</p>	<p><b>YES</b></p>	<p><b>NO</b></p>
<p><b>Cholecystitis</b>                  A. Local signs of inflammation:                  1) Murphy's sign;                  2) RUQ mass/pain/tenderness.                  B. Systemic signs of inflammation:                  1) Fever;                  2) Elevated C-reactive protein;                  3) Elevated white blood cell count.                  C. Imaging findings characteristic of acute cholecystitis  <b>Final diagnosis</b>                  1) One item in A and one item in B are positive;                  2) C confirms the diagnosis when acute cholecystitis is suspected clinically</p>	<p><b>YES</b></p>	<p><b>NO</b></p>
<p><b>Biliary colics</b>                  Upper abdominal pain (either right upper quadrant or epigastric pain) lasting at least 30 minutes, according to the Rome criteria</p>	<p><b>YES</b></p>	<p><b>NO</b></p>
<p><b>Cholangitis</b>                  1) Serum total bilirubin level &gt;40 µmol/l (&gt;2.3 mg/dl) and/or dilated common bile duct (&gt;6 mm) on transabdominal or endoscopic ultrasound or computed tomography;                  2) Temperature &gt;38.5°C.</p>	<p><b>YES</b></p>	<p><b>NO</b></p>
<p><b>Organ failure</b>                  1) Respiratory: PaO<sub>2</sub> ≤60 mmHg (SaO<sub>2</sub> ≤ 90%) or need for mechanical ventilation;                  2) Cardiovascular: systolic blood pressure &lt;90 mmHg or need for catecholamine support;                  3) Renal: creatinine level &gt;177 µmol/l after rehydration or need for hemofiltration or hemodialysis (not including pre-existent renal failure).</p>	<p><b>YES</b></p>	<p><b>NO</b></p>
<p>Mortality</p>	<p><b>YES</b></p>	<p><b>NO</b></p>

If any of the answers is **YES** please provide the dates: .....

Except mortality, all of the above mentioned diseases can occur multiple times. Please provide details for all events separately.

Other reasons for hospitalization: .....

**E**ndoscopic sphincterotomy for delay **I**ng  
cho**L**ecystectomy in mild acute biliar **Y** pancreatitis

## 7.2 Laboratory measurements (no more than 24h before the operation)

Amylase(U/l)		Hematocrit(%)	
Lipase(U/l)		Hemoglobin(g/l)	
Gamma GT(U/l)		Kreatinine(umol/l)	
White blood cell(G/l)		eGFR	
ASAT/GOT(U/l)		CRP(mg/l)	
INR(U/l)		Alcaline phosphatase(U/l)	

If the patient is in group A, and the operation is performed within 24h after the blood samples are taken during the discharge of the patients, NO ADDITIONAL BLOOD SAMPLE HAS TO BE TAKEN. Please copy the values from 5.2.

## 7.3 Pancreatic imaging

### 7.3.1 Abdominal ultrasonography:

- **Visualization:**
  - Good, complete (head at least partially visualized, body and neck well visualized, tail: partially visualized)
  - Partially, incomplete (only body or only head visualized)
  - Poor, non-diagnostic
- **Size:**
  - Normal
  - Partially enlarged (body AP diameter is over 2 cm and/or head AP diameter is over 2,5 cm, none exceeds 3 cm)
  - Definitely enlarged (any part over 3 cm AP diameter)
- **Peripancreatic fluid:**
  - none
  - present
  - Large pseudocyst(s)
- Size of peripancreatic fluid or pseudocyst: ..... cm
- **Pancreas homogeneity:**
  - Homogenous
  - Inhomogeneous, includes area(s) of low echogenicity
  - Inhomogeneous, includes calcifications
- In case of circumscribed low echogenicity area, it's size: ..... cm
- **Wirsung dilatation:** YES / NO (yes, diameter: ..... mm)

Other Description:

.....  
 .....  
 .....



Endoscopic sphincterotomy for delay in  
cholecystectomy in mild acute biliary pancreatitis

7.3.2 Abdominal Computed Tomography: yes/no  
Modified CTSI Score (0-10): .....

- **CTSI:**

**CTSI Score: (I)** Normal pancreas 0 point, intrinsic pancreatic abnormalities with or without inflammatory changes in peripancreatic fat 2 points, Pancreatic or peripancreatic fluid collection or peripancreatic fat necrosis 4 points **(II)** Necrosis absent 0 Points, < 30% necrosis 2 Points, > 30% necrosis 4 points **(III)** presence of extrapancreatic findings 2 points.  
MAXIMUM OF: 10 points

- **Pancreas Size:**
  - o Normal
  - o Partially enlarged (body AP diameter is over 2 cm and/or head AP diameter is over 2,5 cm, none exceeds 3 cm)
  - o Definitely enlarged (any part over 3 cm AP diameter)
- Largest diameter of peripancreatic **fat infiltration:** ..... cm
- **Peripancreatic fluid:**
  - o none
  - o present
  - o Large pseudocyst(s)
- Size of peripancreatic fluid or pseudocyst: ..... cm
- **Necrotizing area** (nonenhancement):
  - o Largest diameter of necrosis area: ..... cm
  - o Location of necrosis: .....
  - o Type: patchy / full width
  - o Estimated necrosis: 0%, < 30% , 30% - 60%, > 60%
- **Wirsung** dilatation: YES / NO (yes, diameter: ..... mm)
- Distant **abdominal fluid:**
  - o Small amount (hard to see, less than 2 cm in lesser pelvis, less than 1 cm around liver/spleen)



**E**ndoscopic sphincterotomy for delay **I**ng  
 cho**L**ecystectomy in mild acute biliar **Y** pancreatitis

- Moderate amount (easy to see, but without pelvic or abdominal distension)
- Large amount with abdominal/pelvic distension

- **Pleural effusion:**

- none
- one sided:..... (AP diameter: ..... cm)
- Both sides, L - ..... cm, R - ..... cm

- **Extrapancreatic findings:**

- Inflammation (Cholecystitis, Duodenitis, etc.) location: .....
- Cholecystolithiasis
- Choledocholithiasis
- Signs of bowel ischaemia
- Bowel distension, ileus
- Venous thrombosis
- Pseudoaneurysm
- Parenchymal organ involvement, define: .....
- none

Other Description:

.....  
 .....  
 .....  
 .....

If the patient is in group A, and the operation is performed within 24h after the imaging is performed during the discharge of the patients, NO ADDITIONAL IMAGING EXAMINATION HAS TO BE ORDERED. Please copy the details from 5.3.



**E**ndoscopic sphincterotomy for delay **I**ng  
cho**L**ecystectomy in mild acute biliar **Y** pancreatitis

**7.4. Characteristics of the Operation**

The difficulty of cholecystectomy(10 – hard, 5 – average difficulty):

1	2	3	4	5	6	7	8	9	10

- Conversion to open cholecystectomy: Yes / No
- The length of the operation (min): \_\_\_\_\_
- Days spent in hospital after cholecystectomy: \_\_\_\_\_
- Intenziv unit care: Yes / No
- Mortality: Yes / No
- Haemorrhage, reintervention needed: Yes / No
- No iatrogenic perforation of the gallbladder Yes / No
- Common bile duct (CBD) injuries Yes / No
- Bile leakage Yes / No
- Sub-hepatic abscess Yes / No

**8. Visit 90 days after ES / DOCTOR No. 4/**

The visit has to be completed +/- 7 days (between 83 and 97 days after ES)

Date of the visit: .....

Length of days between ES and visit: .....

**8.1 Anamnesis (between the operation and visit)**

<b>Acut pancreatitis</b> - Upper abdominal pain - Serum lipase or amylase is three times higher of upper limit of normal - Characteristic findings of acute pancreatitis on cross-sectional abdominal imaging	<b>YES</b>	<b>NO</b>
<b>Biliary pancreatitis</b> - Diagnosis of gallstone or sludge on imaging - Dilated common bile duct on ultrasound (>8 mm in patients ≤75 years old or >10 mm in patients >75 years old - Alanine aminotransferase level >2 times higher than normal values	<b>YES</b>	<b>NO</b>
<b>Cholecystitis</b> A. Local signs of inflammation: 1) Murphy’s sign; 2) RUQ mass/pain/tenderness. B. Systemic signs of inflammation: 1) Fever; 2) Elevated C-reactive protein; 3) Elevated white blood cell count. C. Imaging findings characteristic of acute cholecystitis <b>Final diagnosis</b>	<b>YES</b>	<b>NO</b>



## Endoscopic sphincterotomy for delay

1) On EUS and/or one item in B is positive 2) C confirms the diagnosis when acute cholecystitis is suspected clinically		
<b>Biliary colics</b> Upper abdominal pain (either right upper quadrant or epigastric pain) lasting at least 30 minutes, according to the Rome criteria	<b>YES</b>	<b>NO</b>
<b>Cholangitis</b> 1) Serum total bilirubin level >40 µmol/l (>2.3 mg/dl) and/or dilated common bile duct (>6 mm) on transabdominal or endoscopic ultrasound or computed tomography; 2) Temperature >38.5°C.	<b>YES</b>	<b>NO</b>
<b>Organ failure</b> 1) Respiratory: PaO <sub>2</sub> ≤60 mmHg (SaO <sub>2</sub> ≤ 90%) or need for mechanical ventilation; 2) Cardiovascular: systolic blood pressure <90 mmHg or need for catecholamine support; 3) Renal: creatinine level >177 µmol/l after rehydration or need for hemofiltration or hemodialysis (not including pre-existent renal failure).	<b>YES</b>	<b>NO</b>
Mortality	<b>YES</b>	<b>NO</b>

If any of the answers **YES** please provide the dates: .....

Except mortality, all of the above mentioned diseases can occur multiple times.  
Please provide details for all events separately.

Other reason for hospitalization: .....

### SIGNATURES:

Doctor No.1..... Date:.....

Doctor No.2..... Date:.....

Doctor No.3..... Date:.....

Doctor No.4..... Date:.....



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	–
Protocol version	3	Date and version identifier	8
Funding	4	Sources and types of financial, material, and other support	8
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 9
	5b	Name and contact information for the trial sponsor	3, 8
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	4
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	3, 4, 6-7

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

## Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3
	6b	Explanation for choice of comparators	3, 8
Objectives	7	Specific objectives or hypotheses	4, 8
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	3

## Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	4, 7-8,
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	4
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	5-6
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	6
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	6
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	–
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	6
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Fig.3

1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	6-7
4				
5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7-8
6				
7				

## 8 **Methods: Assignment of interventions (for controlled trials)**

### 9 Allocation:

10				
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	5
13				
14				
15				
16				
17	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	5
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	5
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	5
25				
26				
27				
28				
29		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	–
30				
31				

## 32 **Methods: Data collection, management, and analysis**

33				
34				
35	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	6
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	6
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	7
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	7
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	7
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	6
<b>Methods: Monitoring</b>			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	7
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	7
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	7
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	7

40 **Ethics and dissemination**

41  
42  
43  
44  
45  
46  
47

1				
2				
3	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	3, 8
4				
5				
6	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	6
7				
8				
9				
10				
11	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	6
12				
13				
14		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	9
15				
16				
17				
18	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	6
19				
20				
21				
22	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	8
23				
24				
25	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	8
26				
27				
28				
29	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	9
30				
31				
32				
33				
34	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	8
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

31b	Authorship eligibility guidelines and any intended use of professional writers	8
31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	8

**Appendices**

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Attached
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	9

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

# BMJ Open

## Endoscopic sphincterotomy for delaying cholecystectomy in mild acute biliary pancreatitis (EMILY study): protocol of a multicenter randomized clinical trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025551.R1
Article Type:	Protocol
Date Submitted by the Author:	21-Jan-2019
Complete List of Authors:	<p>Kucserik, Levente; Universitatea de Medicina si Farmacie din Targu Mures, Division of Surgery</p> <p>Márta, Katalin; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine; János Szentágothai Research Center, University of Pécs</p> <p>Vincze, Áron; Pecs Tudományegyetem Általános Orvostudományi Kar, Division of Gastroenterology, First Department of Internal Medicine; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine</p> <p>Lázár, György; University of Szeged, Department of Surgery</p> <p>Czakó, László; University of Szeged, First Department of Medicine</p> <p>Szentkereszty, Zsolt; University of Debrecen, Department for Surgery</p> <p>Papp, Maria; Debreceni Egyetem, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine</p> <p>Palatka, Károly; Debreceni Egyetem, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine</p> <p>Izbéki, Ferenc; Fejér County Saint George Teaching Hospital of University of Pécs, Division of Gastroenterology</p> <p>Altörjay, Áron; Fejér County Saint George Teaching Hospital of University of Pécs, Division of Surgery</p> <p>Török, Imola; Universitatea de Medicina si Farmacie din Targu Mures, Division of Gastroenterology</p> <p>Barbu, Sorin; Universitatea de Medicina si Farmacie din Cluj Napoca, Division of Gastroenterology</p> <p>Tantau, Marcel; Universitatea de Medicina si Farmacie din Cluj Napoca, Division of Gastroenterology</p> <p>Vereczkei, András; Pecs Tudományegyetem Általános Orvostudományi Kar, Department for Surgery</p> <p>Bogár, Lajos; Pecs Tudományegyetem Általános Orvostudományi Kar, Department of Anaesthesiology and Intensive Therapy</p> <p>Dénes, Márton; County Hospital Targu Mures</p> <p>Németh, Imola; Adware Research Developing and Consulting Ltd</p> <p>Szentesi, Andrea; Pecs Tudományegyetem, Institute for Translational Medicine; Szegedi Tudományegyetem, MTA-SZTE Translational Gastroenterology Research Group</p> <p>Zádori, Noémi; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine</p> <p>Antal, Judit; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine</p>



	Lerch, Markus; Universitätsmedizin Greifswald, Department of Medicine A Neoptolemos, John; University of Liverpool Department of Molecular and Clinical Cancer Medicine Sahin-Toth, Miklos; Boston University Petersen, Ole; Cardiff University, Medical Research Council Group Kelemen, Dezső; Pecs Tudományegyetem, Surgery Clinic Hegy, Péter; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine; MTA-SZTE Translational Gastroenterology Research Group
<b>Primary Subject Heading</b> :	Gastroenterology and hepatology
Secondary Subject Heading:	Surgery
Keywords:	acute biliary pancreatitis, cholecystectomy, endoscopic sphincterotomy

SCHOLARONE™  
Manuscripts

**Endoscopic sphincterotomy for delayIng choLecystectomy in mild acute biliarY pancreatitis (EMILY study): protocol of a multicenter randomized clinical trial**

Levente-Pál Kucserik MD<sup>1</sup>, Katalin Márta MD<sup>2,3</sup>, Áron Vincze MD PhD<sup>2,4</sup>, György Lázár MD PhD DSc<sup>5</sup>, László Czako MD PhD DSc<sup>6</sup>, Zsolt Szentkereszty MD PhD<sup>7</sup>, Mária Papp MD PhD<sup>8</sup>, Károly Palatka MD PhD<sup>8</sup>, Ferenc Izbéki MD PhD DSc<sup>9</sup>, Áron Altorjay MD PhD DSc<sup>10</sup>, Imola Török MD<sup>11</sup>, Sorin Barbu MD PhD<sup>12</sup>, Marcel Tantau MD PhD<sup>12</sup>, András Vereczkei MD PhD DSc<sup>13</sup>, Lajos Bogár MD PhD DSc<sup>14</sup>, Márton Dénes MD<sup>15</sup>, Imola Németh PhD<sup>16</sup>, Andrea Szentesi PhD<sup>2,21</sup>, Noémi Zádori MD<sup>2</sup>, Judit Antal PhD<sup>2</sup>, Markus M. Lerch MD PhD DSc<sup>17</sup>, John Neoptolemos MD PhD DSc<sup>18</sup>, Miklos Sahin-Tóth MD PhD DSc<sup>19</sup>, Ole H. Petersen MD PhD DSc<sup>20</sup>, Dezső Kelemen\* MD PhD<sup>13</sup>, Péter Hegyi\* MD PhD DSc<sup>2,21</sup>.

1 Division of Surgery, Universitatea de Medicina si Farmacie din Targu Mures, Targu Mures, RO

2 Institute for Translational Medicine, University of Pécs Medical School, Pécs, HU

3 János Szentágotthai Research Center, University of Pécs, Pécs, HU

4 Division of Gastroenterology, First Department of Internal Medicine, University of Pécs Medical School, Pécs, HU

5 Department of Surgery, University of Szeged, Szeged, HU

6 First Department of Medicine, University of Szeged, Szeged, HU

7 Department for Surgery, University of Debrecen, Debrecen, HU

8 Division of Gastroenterology, University of Debrecen, Debrecen, HU

9 Division of Gastroenterology, Fejér County Saint George Teaching Hospital of University of Pécs, Székesfehérvár, HU

10 Division of Surgery, Fejér County Saint George Teaching Hospital of University of Pécs, Székesfehérvár, HU

11 Division of Gastroenterology, Universitatea de Medicina si Farmacie din Targu Mures, Targu Mures, RO

12 4th Department of Surgery, University of Medicine & Pharmacy "Iuliu Hatieganu" Cluj, RO

13 Surgery Clinic, University of Pécs, Pécs, HU

14 Department of Anaesthesiology and Intensive Therapy, University of Pécs Medical School, Pécs, HU

15 County Hospital Targu Mures, Targu Mures, RO

16 Adware Research Developing and Consulting Ltd., Balatonfüred, HU

17 Department of Medicine A, University Medicine Greifswald, Germany

18 Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK

19 Center for Exocrine Disorders, Department of Molecular and Cell Biology, Boston, USA; University Henry M. Goldman School of Dental Medicine, Boston, Massachusetts, USA

20 Medical Research Council Group, Cardiff School of Biosciences, Cardiff University, Cardiff, CF10 3AX, Wales, UK

21 Hungarian Academy of Sciences - University of Szeged, Translational Multidisciplinary Research Group, Szeged, Hungary

\*: equally contributed

E-mail addresses of the authors:

LPK [k.levente.p@gmail.com](mailto:k.levente.p@gmail.com), KM [katalin.marta@aok.pte.hu](mailto:katalin.marta@aok.pte.hu), ÁV [vincze.aron@pte.hu](mailto:vincze.aron@pte.hu), GyL [lazar.gyorgy@med.u-szeged.hu](mailto:lazar.gyorgy@med.u-szeged.hu), LC [czako.laszlo@med.u-szeged.hu](mailto:czako.laszlo@med.u-szeged.hu), ZsSz [szentkerzs@freemail.hu](mailto:szentkerzs@freemail.hu), MP [papp.maria@med.unideb.hu](mailto:papp.maria@med.unideb.hu), KP [palatka@med.unideb.hu](mailto:palatka@med.unideb.hu), FI [fizbeki@gmail.com](mailto:fizbeki@gmail.com), ÁA [altorjay@mail.fmkorhaz.hu](mailto:altorjay@mail.fmkorhaz.hu), IT [torokimola@gmail.com](mailto:torokimola@gmail.com), SB [barbu@pancreasclub.ro](mailto:barbu@pancreasclub.ro), MT [matantau@gmail.com](mailto:matantau@gmail.com), AV [vereczkei.andras@pte.hu](mailto:vereczkei.andras@pte.hu), LB [bogar.lajos@pte.hu](mailto:bogar.lajos@pte.hu), MD [denesmatyi@yahoo.com](mailto:denesmatyi@yahoo.com), IN [imola.nemeth@adwareresearch.com](mailto:imola.nemeth@adwareresearch.com), ASz [szentesiai@gmail.com](mailto:szentesiai@gmail.com), NZ [znoemi@gmail.com](mailto:znoemi@gmail.com), JA [juditaltal2014@gmail.com](mailto:juditaltal2014@gmail.com), MML [lerch@uni-greifswald.de](mailto:lerch@uni-greifswald.de), JN [jneoptolemos1@gmail.com](mailto:jneoptolemos1@gmail.com), MST [miklos@bu.edu](mailto:miklos@bu.edu), OHP [PetersenOH@cardiff.ac.uk](mailto:PetersenOH@cardiff.ac.uk), DK [kelemende@gmail.com](mailto:kelemende@gmail.com), PH [p.hegyi@tm-centre.org](mailto:p.hegyi@tm-centre.org)

**Corresponding Investigator:**

Péter Hegyi MD, PhD, DSc

Phone: +(36-70) 375-1031

e-mail: [p.hegyi@tm-centre.org](mailto:p.hegyi@tm-centre.org)**Coordinating institution:**

University of Pecs – Medical School

Institute for Translational Medicine

12 Szigeti Street, PÉCS, H-7624, HUNGARY

FAX: +(36-72) 536-247

Phone: +(36-72) 536-246

web: [www.tm-centre.org](http://www.tm-centre.org)

For peer review only

**ABSTRACT**

**Introduction.** According to the literature, early cholecystectomy is necessary to avoid complications related to gallstones after an initial episode of acute biliary pancreatitis (ABP). A randomized, controlled multicenter trial (the PONCHO trial) revealed that in the case of gallstone-induced pancreatitis, early cholecystectomy was safe in patients with mild gallstone pancreatitis and reduced the risk of recurrent gallstone-related complications, as compared with interval cholecystectomy. We hypothesize that carrying out a sphincterotomy (ES) allows us to delay cholecystectomy, thus making it logistically easier to perform and potentially increasing the efficacy and safety of the procedure.

**Methods/Design.** EMILY is a prospective, randomized, controlled multicenter trial. The patients are randomized to two groups: (1) early cholecystectomy (within 6 days after discharge) and (2) patients with delayed (interval) cholecystectomy (between 45 and 60 days after discharge). During a 12-month period, 89 patients will be enrolled from participating clinics. The primary endpoint is a composite endpoint of mortality and recurrent acute biliary events (that is, recurrent ABP, acute cholecystitis, uncomplicated biliary colic, and cholangitis). The secondary endpoints are organ failure, biliary leakage, technical difficulty of the cholecystectomy, surgical and other complications.

**Ethics and dissemination.** The trial has been registered at the ISRCTN (ref no. 10667869) and approved by the relevant organisation, the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (EKU/2018/12176-5).

**Keywords:** acute biliary pancreatitis, cholecystectomy, endoscopic sphincterotomy

## Strengths and limitation

**Strength 1:** The study is designed as a prospective, randomized-controlled trial to achieve conclusion on the highest evidence level to provide the first evidence concerning the possible benefits of ES on timing cholecystectomy, it is (i) multinational (ii) multicentric, (iii) internationally registered and (iv) the pre-study protocol is published.

**Strength 2:** Only high volume, expert centers can join to the study. They have to provide (i) laparoscopically trained surgeons with >100 laparoscopic procedures performed and (ii) if ERCP/ES is provided during the index admission, trained gastroenterologist with >50 ES completed within a year must be on duty.

**Strength 3:** The study enjoys continuous support from (i) an International Translational Advisory Board (ITAB) including top, well-established experts from different area of research field (ii) an Independent Data Management Board (IDMB).

**Strength 4:** The final conclusion can be achieved with low number of patients within a relatively short period.

**Limitation 1:** The study will provide evidence in a selected population (mild ABP who underwent ERCP+ES) and no evidence concerning the usefulness of ES in moderate and severe ABP.

## INTRODUCTION

Acute pancreatitis is one of the leading gastrointestinal causes of acute hospital admissions [1, 2]. In most cases, it is caused by gallstones, sludge or edema [3]. Gallstone-induced pancreatitis involves a pathophysiologic factor, namely a distal common channel of the biliary and pancreatic ducts, which can be found in 80% of acute biliary pancreatitis (ABP) [4]. Acute biliary pancreatitis is a clinical entity with high rates of morbidity (15–50%) and mortality (20–35%) [5]. After ABP, several complications may occur; recurrent acute pancreatitis, cholestasis and fistula affecting the hepatobiliary system or other biliary events, such as acute cholecystitis, obstruction of the common biliary duct, cholangitis or biliary colic [6, 7]. Interval cholecystectomy after mild ABP is associated with a high risk of readmission for recurrent biliary events, especially after recurrent ABP [8]. The international practice guidelines recommend that in case of cholangitis or choledocholithiasis an ERCP should be performed to clear the bile duct with endoscopic sphincterotomy (ES). In addition, cholecystectomy should also be performed to avoid complications related to recurrent biliary events [9, 10]. In patients with clinically severe pancreatitis, with local complications, such as pancreatic necrosis or organ failure, the intervention namely the laparoscopic cholecystectomy (LC) is delayed 6 months until complications are resolved [11]. In cases of mild ABP, cholecystectomy is recommended between days 7 and 21 [4]. The latest studies show that after discharge of patients with ABP, cholecystectomy could reduce the risk of a recurrent ABP and other gallstone-induced complications [12]. In this setting, surgeons still prefer delayed cholecystectomy for efficacy and safety and for logistical reasons [13]. Some publications draw attention to ERCP/ES, which could reduce mortality and the formation of severe biliary complications [3, 14]. The aim of the EMILY trial is to combine a surgical treatment and a gastroenterological procedure to investigate if ES with delayed cholecystectomy (within 45 to 60 days after discharge) compared with ES with early cholecystectomy (within 6 days after discharge) could reduce recurrent biliary events.

## METHODS

**Design:** EMILY is a prospective, randomized-controlled, multicenter trial. The patients are randomized to two groups: (1) Patients who undergo early cholecystectomy (within 6 days after discharge) and (2) patients who undergo delayed (interval) cholecystectomy (between 45 and 60 days after discharge). During a 12-month period, 89 patients will be enrolled from participating clinics. The primary endpoint is a composite endpoint of mortality and recurrent acute biliary events (which are recurrent ABP, acute cholecystitis, uncomplicated biliary colic and cholangitis). The secondary endpoints are: organ failure, biliary leakage, technical difficulty of cholecystectomy, and surgical and other complications.

This study was structured following the SPIRIT 2013 [15] guideline defining standard protocol items for clinical trials and got the relevant ethical approval EKV/2018/12176-5 (Scientific and Research Ethical Committee, Medical Research Council, Hungary).

**Trial organization, committees and boards:** The coordinator and designer of the EMILY study is the Centre for Translational Medicine at the University of Pécs Medical School (coordinating institution and sponsor, [www.tm-centre.org](http://www.tm-centre.org)) and the Hungarian Pancreatic Study Group (HPSG-coordinating society, [www.pancreas.hu](http://www.pancreas.hu)). The HPSG was established in 2011 to stimulate research in pancreatic diseases.

Until now, it has launched three international observational clinical studies in 2014 [16, 17, 18] (EASY, APPLE and PINEAPPLE) and two interventional studies (PREPAST [19] – 2014 and GOULASH [20] – 2017) and has published the relevant guidelines for pancreatic diseases to improve patient care in pancreatology [21, 22, 23, 24].

The following committees and boards will be involved: Steering Committee (SC): The committee will be led by PH (corresponding investigator, gastroenterologist and internal medicine specialist).

The members in Szeged (HU) will be: LC (gastroenterologist), GL (surgeon); Debrecen (HU): MP (gastroenterologist), KP (gastroenterologist), ZS (surgeon); Pécs (HU): ÁV (gastroenterologist), DK (surgeon); Székesfehérvár (HU): FI (gastroenterologist), ÁA (surgeon); Targu Mures (RO): IT (gastroenterologist), LPK (surgeon); Cluj Napoca (RO): BS (surgeon), TM (gastroenterologist). KM is a trial management specialist, whereas AS leads the multidisciplinary core facility which will assist the scientists to run the study successfully. The SC will make decisions concerning all relevant questions including drop outs during the study.

International Translational Advisory Board (ITAB): The board will consist of a gastroenterologist (MML), a surgeon and two basic scientists (JN, MST, OHP). The ITAB will continuously monitor the progress of the study and will advise the SC.

The study was designed by the SC and ITAB. It was funded by the University of Pécs, Medical School. The sponsor was not involved in the design of the study, and will have no access to database or the randomization code.

The study also contains an independent physician and safety manager as required by the ethical regulation.

**Study population:** All patients with mild ABP will be informed of the possibility to take part in the EMILY trial. After the consent form is signed participants will be randomized to 2 groups if they meet all the inclusion and no exclusion criteria (*Figure 1*).

**Inclusion criteria:** The criteria for inclusion in the study: (1) patients older than 18 years of age; (2) diagnosis of acute pancreatitis (at least 2 of the following 3 symptoms: upper abdominal pain, serum lipase or amylase is three times higher than the upper limit of normal and characteristic findings for acute pancreatitis on imaging); (3) the presence of ABP (any of the following 3 definitions): diagnosis of gallstones or sludge on imaging, a dilated common bile duct on ultrasound (>8 mm in patients  $\leq 75$  years old or >10 mm in patients >75 years old) in the absence of gallstones or sludge in the gallbladder; and alanine aminotransferase level >2 times higher than normal values with ALT > AST; (4) mild ABP (meaning no pancreatic necrosis, no transient or persistent organ failure (>48 hours) is present; (5) ERCP/ES either during the index admission or in the medical history without complication (6) signed written informed consent (all included patient will sign the consent which contains the information about the trial and procedures) (*Figure 1*).

**Exclusion criteria:** A patient's bad physical status can be an exclusion criterion. American Society of Anesthesiologists (ASA) III patients >75 years old; ASA IV or V patients, will be excluded. Patients with continuous alcohol abuse, acute or chronic cholecystitis during hospitalization, chronic pancreatitis, pregnancy, previous cholecystectomy will also be excluded (*Figure 1*).

**Time of randomization:** 5 criteria are described by the PONCHO trial [25]. If these 5 criteria are met, the informed consent will be signed by the patient and a control abdominal CT will be carried out before discharge. These criteria are the following: (1) anticipation on the part of the treating physician that the patient can be discharged; (2) the patient has no abdominal pain and there is no need for analgesics; (3) declining C-reactive protein levels and <150 mg/l; (4) no evidence of local or systemic complications (for example, no fever); (5) oral feeding is tolerated for 24 hrs. The patient must be randomized on the day of the discharge.

**Randomization:** The method of randomization is the following: The patient can be randomized by the study coordinator using a randomization module with sealed envelope. Patient data will be uploaded with the help of the administrator to the data base, which will be followed by the randomization. This randomization module will allocate the participants to the 2 different groups. This method makes it impossible for researchers to predict the allocation of the patients involved in the study. It is impossible to conceal the distribution of the patients in this study because the patients need to be scheduled for either an early cholecystectomy or a delayed cholecystectomy (*Figure 1*).

Allocation will be carried out based on predefined randomisation lists created separately for each recruiting centre. The allocation sequence will be prepared with a block size of 4 and with an allocation ratio 1:1 by the Independent Data Management Board (IDMB).

**Blinding:** In prevention of patient's selection to group A and B trial participants, care providers and outcome assessors will be blinded until the allocation, as no access to randomization sequence. From assignment to intervention blinding cannot be provided considering the study characteristics (exact date of cholecystectomy). The allocation sequence is unblinded only to data analysts who are completely independent from medical team (decision making) and data collection.

## Endpoints

**Primary endpoint.** The primary endpoint is a composite endpoint, which is based on mortality and on recurrent biliary events (which are recurrent ABP, acute cholecystitis, uncomplicated biliary colic, and cholangitis). The observation period is three months. We decide based on criteria in *Figure 2* if a complication is present or not.

**Secondary endpoints.** We hypothesize that cholecystectomy for ABP between days 45-60 after discharge in patients with ES is as effective and safe as early cholecystectomy (within 6 day after discharge). In order to evaluate this, we will observe the following parameters: the number of biliary colic registered for the patient, difficulty of cholecystectomy (on a scale of 0-10, 0=easy, 5=moderately difficult, 10=hard, rate of conversion to open cholecystectomy, total length of hospital stay, need for ICU admission and total length of ICU stay, organ failure and biliary leakage (*Figure 2*).

## Treatment protocol

Randomization: Group A. Early cholecystectomy

Group B. Delayed cholecystectomy

We randomize patients into two groups after discharge (*Figure 3*):

Group A: The patient is randomized to the early cholecystectomy group, and cholecystectomy will be performed within 6 days after discharge.

Group B: The patient is randomized to the delayed cholecystectomy group, and the cholecystectomy will be carried out between 45 to 60 days.

Discontinuing or the modification of the allocated interventions for a trial participant is based on surgical causes like contraindicated opus, need for conversion to open cholecystectomy, or when the patient does not present to the hospital for cholecystectomy.

Switching over the two interventions is not possible considering the trial characteristics, however in case of acute cholecystitis acute cholecystectomy can be performed independently from this trial. The case must be presented to SC.

**Surgical details and quality control:** If it will be the first ERCP/ES performed in the patient's medical history it will be performed according to the European Society of Gastrointestinal Endoscopy (ESGE) guidelines. [26] The laparoscopic cholecystectomy will follow the European Association Guidelines for Endoscopic Surgery [27]. The patients will be operated on by laparoscopically trained surgeons with >100 laparoscopic procedures performed and by a trained gastroenterologist with >50 ES completed within a year must be on duty if ERCP/ES is provided during the index admission. Centers which intend to randomize at least 15 patients and are able to perform an early cholecystectomy and ERCP/ES are eligible to participate in the study. In those centers which ES data will then be collected on the incidence of choledocholithiasis, percentage bile duct injury, duration, and perceived difficulty (on a scale of 0-10).



**Diagnosing and treating ABP:** In the first 24 hours of admission, all patients will undergo either an ultrasonography or a contrast-enhanced computed tomography (CECT) to detect if the gallbladder contains gallstones or sludge and to determinate the diameter of the common bile duct. ERCP should be performed only in the case of cholangitis or choledocholithiasis, to clear the bile duct with endoscopic sphincterotomy (ES) as described in the IAP/APA guideline. When only the laboratory parameters suggest common bile duct obstruction or choledocholithiasis, MRCP/EUS should be carried out [10].

**Data collection and follow-up:** Data will be collected in a personalized database, and follow-up will consist of questionnaires (*Supplementary File*). The patient will be asked to note every biliary event during the follow-up period and will be contacted in person within 90 days after discharge to collect information. After data collection, we can draw conclusions about the treatment strategy. Improperly completed datasheets and incorrect data upload will be avoided and controlled by the administrator. The personal information about enrolled participants will only be shared with IDMB as uploaded data for randomization, after data analysis only randomization code will be used for identification to protect confidentiality during, and after the trial. Only the principal investigator and the IDMB will have access to the final trial dataset. However only identification code is used, we can aside from duplicated patient's data as cholecystectomy can not be performed twice.

### Sample size estimation method

**Primary endpoint:** a composite of gallstone-related complications or mortality occurring within 6 months after discharge.

**Hypothesis:** With regard to our hypothesis, based on a non-inferiority design, there is no difference between the two groups (5% in mortality or readmission for gallstone-related complications within 3 months after discharge).

**Starting point:** Sample size estimation was based on the results obtained by the PONCHO trial carried out on 264 patients, where a non-significant difference of 14% was obtained between the two study groups (3% in the same-admission cholecystectomy group compared to 17% in the interval admission group). Thus, using the hypothesized 5% for the occurrence of the primary endpoint in the same-admission cholecystectomy group and a max difference of 14% given by the results of the PONCHO trial a total sample size of 89 was obtained using a 5% drop-out rate. The sample size estimation results are listed in the table below (*Figure 4*).

**Data management and statistical analyses:** Data will be handled by an independent Clinical Research Organizer. Electronic CRF (eCRF) will be used. The Investigator will ensure that the data in the eCRF are accurate, complete and legible. Detailed data flow will be described in a Data Management Plan (DMP). Data from completed eCRFs will be validated under the direction of the Data Manager according to a Data Cleaning Plan (DCP). Adverse events will be coded using MedDRA according to GCP, GLP, FDA 21CFR PART11 and other relevant regulatory requirements.

Safety Analysis Set (SAS, all patients enrolled in the study), Per Protocol Set (PPS, all enrolled patients who finished the study conforming to the requirements of the study protocol) and Intention to Treat (ITT, all randomized participants who start on a treatment, excluding consent withdrawals) will be performed.

1 Baseline patient and disease characteristics will be analyzed using descriptive analysis. Demographic and baseline characteristics  
2 will be summarized for the overall study population. Descriptive statistics for both the primary and secondary parameters will be  
3 analyzed similarly.  
4

5 Subgroup analyses will be performed concerning the imaging alterations (1: no gallstones or sludge on imaging, 2) sludge or 3)  
6 gallstone).  
7

8 In case of important protocol modifications IDMB will report to the SC. SC will discuss and if the adverse effect is confirmed it  
9 will be reported to the relevant institutional and national ethical committee <http://www.ett.hu/tukeb.htm>  
10

11 **Premature termination of the study:** In the interests of patient safety, an interim analysis will be conducted after 15 patients and  
12 after half of the presumed number of patients (45) have completed the study. IDMB will perform an independent assessment of the  
13 trial related documents and activities, with the aim of ensuring the respect of subjects' right, safety and well-being and to guarantee  
14 the plausibility of clinical data. Similarity of groups at baseline will be also checked. The study will also be stopped if the two  
15 groups' results differ significantly ( $p < 0.001$ ). The study will be discontinued if the difference between the planned number of  
16 patients and the actual number is higher than 60% within one year. IDMB will report to SC.  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 **Centers:** The trial will be launched in four Hungarian (Szeged, Debrecen, Pécs and Székesfehérvár) and two Romanian centres  
27 (Targu Mures and Cluj Napoca), after which the study will be open to other centres. In all cases, the IDMB will conduct an audit of  
28 the center and will report to the SC. The SC maintains the right to decide whether a center meets the required quality to join the  
29 study.  
30  
31  
32  
33

34 The full protocol will be available for public in an open access journal.

35 **Publication policy:** We would like to publish the results in one of the internationally highly recognized decent journals. Centers  
36 providing more than 25 patients can provide 4 authors to the authorship list: 2 surgeons and 2 gastroenterologists.  
37  
38  
39  
40  
41

42 **Patient and Public Involvement:** This pre-study protocol contains no results and data, therefore patients and or public were not  
43 involved.  
44  
45  
46  
47

## 48 DISCUSSION

49 In the case of early laparoscopic cholecystectomy, while dissection and logistics are more difficult [6, 7] compared with delayed  
50 (interval) cholecystectomy, it is still more effective. Delayed cholecystectomy in a mild form of ABP is preferred by many surgeons,  
51 but a number of complications can occur: recurrent ABP, acute cholecystitis, obstruction of ductus choledochus, and uncomplicated  
52 biliary colic [6, 7]. After ERCP/ES is performed, the common bile duct is cleared, the complications caused by gallstones or sludge  
53 are significantly reduced [28]. The EMILY study is designed to determine if ERCP/ES for mild ABP aids in delaying the  
54 cholecystectomy to day 45-60 after discharge among patients with ABP.  
55  
56  
57  
58  
59  
60

If an ES aids in delaying a cholecystectomy, then we can reduce early cholecystectomy-related complications and the surgeons can proceed with a safer, easier cholecystectomy using this method of treatment.

## ACKNOWLEDGEMENTS

**Funding:** Center costs (IT, biostatistics, trial organization, etc) are covered by the University of Pécs Medical School, Momentum Grant of the Hungarian Academy of Sciences (LP2014-10/2014); and Economic Development and Innovation Operative Programme Grant and Highly Cited Publication Grant of the National Research, Development and Innovation Office (GINOP-2.3.2-15-2016-00048 Stay Alive, KH-125678 and EFOP 3.6.2-16-2017-00006 Live Longer), and Translational Medicine Foundation.

Since no additional treatment is necessary for the study, the general healthcare costs are covered by the National Healthcare System (University of Pécs-Medical School).

This study was designed with help of the Centre for Translational Medicine at the University of Pécs. This center is committed to improve patient's life with research activities like registries, observational and interventional trial organizations (<https://tm-centre.org>).

There are no financial and other competing interests for principal investigators (LPK, DK), included patients or any member of the trial.

## AUTHORS' CONTRIBUTION

LPK, KM, DK, ÁV, LC, MP, FI, ÁA, MT and PH designed the study. As a member of the ITAB MML, JN, MST and OHP gave advices and will continuously monitor the progress of the study. LPK, KM, PH, ZsSz, KP drafted the manuscript, GyL, SB, AV, LB, MD, NZ, JA and ASz edited the manuscript. IN carried out the sample size calculation. ZsSz, KP, IT, NZ, JA, ASz edited the figures and tables. All authors read and approved the final manuscript.

During the study IT, ÁV, LC, MP and MT are going to manage the endoscopic treatments. DK, GyL, ZsSz, MD and SB are responsible for cholecystectomies. ITAB and SC members are listed ahead.

## ETHICS AND DISSEMINATION

**Trial registration:** The trial has been registered at the ISRCTN10667869.

**Ethical approval:** Scientific and Research Ethics Committee of the Hungarian Medical Research Council (EKU/2018/12176-5).

**Protocol Version:** V1.0 10.07.2018.

**Start of the patient recruitment:** 1st March 2019

**Additional information and future plan:** Blood samples (serum and plasma) will be stored from all patients in order to study laboratory parameters later if required (e.g. the laboratory could not measure it), and in order to build up a biobank for later clinical studies to which all participants will give informed consent. The samples will be stored at -80°C.

1 The post-trial care will follow the routine treatment protocols. In case if patient suffer a harm during hospitalization all of the  
2 responsibility is taken by the hospital where the patient is treated.  
3  
4  
5

## 6 LIST OF ABBREVIATIONS

7 ABP – acute biliary pancreatitis

9 ASA – American Society of Anesthesiologists

11 CECT – contrast enhanced computed tomography

13 DCP – Data Cleaning Plan

15 DMP – Data Management Plan

17 ES – endoscopic shicterotomy

19 eCRF – electronic case report form

21 ESGE – European Society of Gastrointestinal Endoscopy

23 HPSG – Hungarian Pancreatic Study Group

25 IDMB – Independent Data Management Board

27 ITAB – International Translational Advisory Board

29 ITT – Intent to Treat

31 LC – Laparoscopic cholecystectomy

33 PPS – Per Protocol Set

35 SAS – Safety Analysis Set

37 SC – Steering Committee

## 41 References

- 44 1. Peery AF, Dellon ES, Lund J, Crockett SD, et al. Burden of gastrointestinal disease in the United States: 2012  
45 update. *Gastroenterology* 2012;143:1179–87. doi: 10.1053/j.gastro.2012.08.002
- 48 2. Dhiraj Y, Albert BL. The epidemiology of pancreatitis and pancreatic cancer *gastroenterology*. *Gastroenterology*  
49 2013;144(6):1252–1261. doi: 10.1053/j.gastro.2013.01.068
- 52 3. Schepers NJ, Bakker OJ, Besselink MG, et al. Early biliary decompression versus conservative treatment in acute biliary  
53 pancreatitis (APEC trial): study protocol for a randomized controlled trial. Schepers et al. *Trials* 2016;17:5. doi: 10.1186/s13063-  
55 015-1132-0
- 57 4. Uhl W, Müller CA, Krähenbühl L et al. Acute gallstone pancreatitis, Timing of laparoscopic cholecystectomy in mild and severe  
58 disease. *SurgEndosc* 1999;13:1070–1076

- 1 5. Schietroma M, Carlei F, Lezoche E, et al. Acute biliary pancreatitis: staging and management. *Hepato-*  
2 *gastroenterology* 2001;48(40):988–993
- 3
- 4 6. UK Working Party on Acute Pancreatitis. UK guidelines for the management of acute pancreatitis. *Gut* 2005;54(Suppl 3):iii1–  
5 iii9. doi: 10.1136/gut.2004.057026
- 6
- 7 7. Forsmark CE, Baillie J. AGA institute technical review on acute pancreatitis. *Gastroenterology* 2007;132:2022–2044. doi:  
8 10.1053/j.gastro.2007.03.065.
- 9
- 10 8. van Baal MC, Besselink MG, Bakker OJ, et al. for the Dutch Pancreatitis Study Group: Interval cholecystectomy after mild biliary  
11 pancreatitis is associated with a high risk of readmission for recurrent biliary events, especially recurrent biliary pancreatitis. *Annals*  
12 *of Surgery* 2012;255(5):860–866. doi: 10.1097/sla.0b013e3182507646
- 13
- 14 9. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. *Am J Gastroenterol* 2006;101:2379–2400. doi: 10.1111/j.1572-  
15 0241.2006.00856.x.
- 16
- 17 10. Uhl W, Warshaw A, Imrie C, et al. IAP Guidelines for the Surgical Management of Acute Pancreatitis. *Pancreatology*  
18 2002;2:565–573. doi: 10.1159/000067684
- 19
- 20 11. Nealon WH, Bawduniak J, Walser EM. Appropriate timing of cholecystectomy in patients who present with moderate to severe  
21 gallstone-associated acute pancreatitis with peripancreatic fluid collections. *Ann Surg* 2004;239:741–749. doi:10.1097/01.  
22 sla.0000128688.97556.94
- 23
- 24 12. da Costa DW, Bouwense SA, Schepers NJ, et al. Same-admission versus interval cholecystectomy for mild gallstone pancreatitis  
25 (PONCHO): a multicenter randomized controlled trial. *Lancet* 2015;386:1261–68. doi: 10.1016/s0140-6736(15)00274-3
- 26
- 27 13. Paul GL, Bettina WD, Markus ML. Clinical perspectives in pancreatology: Compliance with Acute Pancreatitis Guidelines in  
28 Germany. *Pancreatology* 2005;5:591–593. doi: 10.1159/000087501
- 29
- 30 14. Uomo G, Manes G, Laccetti M, et al. Endoscopic sphincterotomy and recurrence of acute pancreatitis in gallstone patients  
31 considered unfit for surgery. *Pancreas* 1997;14:28–31.
- 32
- 33 15. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern*  
34 *Med* 2013;158:200–7. doi: 10.7326/0003-4819-158-3-201302050-00583
- 35
- 36 16. Hritz I, Hegyi P. Early Achievable Severity (EASY) index for simple and accurate expedite risk stratification in acute  
37 pancreatitis. *J Gastrointest Liver Dis* 2015;24(2):177–82. doi: 10.15403/jgld.2014.1121.242.easy
- 38
- 39 17. Párniczky A, Mosztbacher D, Zsoldos F et al. Analysis of Pediatric Pancreatitis (APPLE Trial): Pre-study protocol of a  
40 multinational prospective clinical trial. *Digestion* 2016;93(2):105–10. doi: 10.1159/000441353
- 41
- 42 18. Zsoldos F, Párniczky A, Mosztbacher D, et al. Pain in the Early Phase of Pediatric Pancreatitis (PINEAPPLE Trial): Pre-study  
43 protocol of a multinational prospective clinical trial. *Digestion* 2016;93(2):121–6. doi: 10.1159/000441352
- 44
- 45 19. Dubravcsik Z, Madácsy L, Gyökeres T, et al. Preventive pancreatic stents in the management of acute biliary pancreatitis  
46 (PREPAST trial): pre-study protocol for a multicenter, prospective, randomized, interventional, controlled trial. *Pancreatology*  
47 2015;15(2):115–23. doi: 10.1016/j.pan.2015.02.007
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
20. Márta K, Szabó AN, Pécsi D, et al. High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial. *BMJ Open* 2017;7(9):e015874. doi: 10.1136/bmjopen-2017-015874
21. Dubravcsik Z, Farkas G, Hegyi P, et al. [Autoimmune pancreatitis. Evidence-based management guidelines prepared by the Hungarian Pancreatic Study Group ]. *Orvosi Hetilap* 2015;156(8):292–307. doi: 10.1556/OH.2015.30061
22. Hritz I, Czakó L, Dubravcsik Z, et al. [Acute pancreatitis. Evidence-based practice guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):244–61. doi: 10.1556/OH.2015.30059
23. Parniczky A, Czakó L, Dubravcsik Zs, et al. [Pediatric pancreatitis. Evidence-based management guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(8):308–25. doi: 10.1556/OH.2015.30062
24. Takacs T, Czakó L, Dubravcsik Z, et al. [Chronic pancreatitis. Evidence-based management guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):262–88. doi: 10.1556/OH.2015.30060
25. Bouwense SA, Besselink MG, van Brunschot S, et al. Pancreatitis of biliary origin, optimal timing of cholecystectomy (PONCHO trial): study protocol for a randomized controlled trial. Published online 26 Nov 2012. doi: 10.1186/1745-6215-13-225
26. Pier AT, Alberto M, Lars A, et al. Papillary cannulation and sphincterotomy techniques at ERCP: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Endoscopy* 2016 Jul;48(7):657-83. doi: 10.1055/s-0042-108641
27. Edmund AMN, Hans T, CK Kum, et al. EAES Clinical Practice Guidelines on Laparoscopic Cholecystectomy, Appendectomy, and Hernia Repair (1994). In: EAES guidelines for endoscopic surgery: Twelve years evidence-based surgery in Europe. E. Neugebauer, S. Sauerland, A.B. Fingerhut, B. Millat, G.F. Buess (Eds.). Springer Berlin Heidelberg, 2006:265-289
28. Testoni PA. Acute recurrent pancreatitis: Etiopathogenesis, diagnosis and treatment. *World J Gastroenterol* 2014;20(45):16891. doi: 10.3748/wjg.v20.i45.16891

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16 *Figure 1 Shows the flow chart of participants according to SPIRIT 2013 guideline [15]*

17 \* no pancreatic necrosis, no transient or persistent organ failure (>48 hours)) is present with any of the following 3 definitions:

18  
19 1) diagnosis of gallstones or sludge on imaging, 2) a dilated common bile duct on ultrasound (>8 mm in patients ≤75 years old or  
20 >10 mm in patients >75 years old) in the absence of gallstones or sludge in the gallbladder, 3) and alanine aminotransferase  
21 level >2 times higher than normal values with  $ALT > AST$   
22

23  
24  
25 \*\* American Society of Anesthesiologists (ASA) IV or V patients and ASA III >75 years old  
26  
27

28  
29 *Figure 2 Shows the evaluation of primary and secondary endpoints.*  
30  
31

32  
33 *Figure 3 Schedule of enrolment, interventions and assessments according to the SPIRIT 2013 statement [15].*

34 \*Diagnosis of acute biliary pancreatitis (any of the following 3 definitions): diagnosis of gallstones or sludge on imaging, a  
35 dilated common bile duct on ultrasound (>8 mm in patients ≤75 years old or >10 mm in patients >75 years old) in the absence of  
36 gallstones or sludge in the gallbladder; and alanine aminotransferase level >2 times higher than normal values with  $ALT > AST$ .  
37  
38 In the first 24 hours of admission, all patients will undergo either an ultrasonography or a contrast-enhanced computed  
39 tomography (CECT) to detect if the gallbladder contains gallstones or sludge and to determinate the diameter of the common bile  
40 duct. ABP is mild, when there is no pancreatic necrosis, or no transient or persistent organ failure (>48 hours).  
41  
42

43  
44  
45  
46 \*\*If it is necessary to perform endoscopic sphincterotomy during the current admission or ES in the medical history also  
47 acceptable.  
48

49  
50 \*\*\* Data will be collected in a personalized database, and follow-up will consist of questionnaires. The patient will be asked to  
51 note every biliary event during the follow-up period and will be contacted in person within the 90 days after discharge to collect  
52 information. After data collection, we can draw conclusions about the treatment strategy. Improperly completed datasheets and  
53 incorrect data upload will be avoided and controlled by the administrator. (Q5, Q7, Q8, Q=question)  
54  
55

56  
57  
58 \*\*\*\* The patient can be randomized by using a randomization module with sealed envelope. Patient data will be uploaded to the  
59 data base, which will be followed by the randomization. This randomization module will allocate the participants to the 2 different  
60 groups. This method makes it impossible for researchers to predict the allocation of the patients involved in the study. It is impossible




1 to conceal the distribution of the patients in this study because the patients need to be scheduled for either an early cholecystectomy  
2 or a delayed cholecystectomy.  
3

4 Allocation will be carried out based on predefined randomisation lists created separately for each recruiting centre. The allocation  
5 sequence will be prepared with a block size of 4 and with an allocation ratio 1:1 by the Independent Data Management Board  
6 (IDMB).  
7

8 \*\*\*\*\* The criteria are the following: (1) Anticipation on the part of the treating physician that the patient can be discharged  
9 within 1 or 2 days; (2) no need for analgesics; (3) declining C-reactive protein levels and <150 mg/l; (4) no evidence of local or  
10 systemic complications (for example, no fever); (5) oral feeding is tolerated for 24 hrs; and (6) ERCP/ES either during the index  
11 admission or in the medical history without complication. Before discharge or transfer to surgery department.  
12  
13  
14  
15  
16  
17  
18

19 Figure 4 The listed parameters were used to estimate results for the current sample size.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





25 Figure 1 Shows the flow chart of participants according to SPIRIT 2013 guideline [15]

26 \* no pancreatic necrosis, no transient or persistent organ failure (>48 hours) is present with any of the  
 27 following 3 definitions: 1) diagnosis of gallstones or sludge on imaging, 2) a dilated common bile duct on  
 28 ultrasound (>8 mm in patients ≤75 years old or >10 mm in patients >75 years old) in the absence of  
 29 gallstones or sludge in the gallbladder, 3) and alanine aminotransferase level >2 times higher than normal  
 values with ALT > AST

30 \*\* American Society of Anesthesiologists (ASA) IV or V patients and ASA III >75 years old

31  
32 105x59mm (300 x 300 DPI)

ENDPOINTS		
PRIMARY	SECONDARY	
Mortality	Biliary colic Difficulty of cholecystectomy	ICU admission Length of ICU stay
Recurrent biliary events (recurrent biliary pancreatitis, acute cholecystitis, uncomplicated biliary colic and cholangitis)	Conversion to open cholecystectomy Total length of hospital stay	Organ failure Biliary leakage
<p><b>Diagnosis of acute pancreatitis</b> at least two of the three following features are present<sup>[30]</sup></p> <ol style="list-style-type: none"> <li>Upper abdominal pain;</li> <li>Serum lipase or amylase levels above three times the upper level of normal;</li> <li>Characteristic findings of acute pancreatitis on cross-sectional abdominal imaging.</li> </ol>		
<p><b>Biliary pancreatitis</b> one of the following presents <sup>[31]</sup></p> <ol style="list-style-type: none"> <li>Gallstones and/or sludge diagnosed on imaging (transabdominal or endoscopic ultrasound or computed tomography);</li> <li>In the absence of gallstones and/or sludge, a dilated common bile duct on ultrasound (&gt;8 mm in patients ≤75 years old or &gt;10 mm in patients &gt;75 years old);</li> <li>The following laboratory abnormality: alanine aminotransferase (ALAT) level &gt;2 times higher than normal values, with ALAT &gt;aspartate aminotransferase.</li> </ol>	<p><b>Cholecystitis</b> 2007 Tokyo classification grade I to III <sup>[32,33]</sup></p> <p>A. Local signs of inflammation: <ol style="list-style-type: none"><li>Murphy's sign;</li><li>RUQ mass/pain/tenderness.</li></ol></p> <p>B. Systemic signs of inflammation: <ol style="list-style-type: none"><li>Fever;</li><li>Elevated C-reactive protein;</li><li>Elevated white blood cell count.</li></ol></p> <p>C. Imaging findings characteristic of acute cholecystitis.</p> <p style="text-align: center;"><b>Definite diagnosis</b></p> <p>1) One item in A and one item in B are positive; 2) C confirms the diagnosis when acute cholecystitis is suspected clinically.</p>	
<p><b>Cholangitis</b> All of the following features as previously defined <sup>[31]</sup></p> <ol style="list-style-type: none"> <li>Serum total bilirubin level &gt;40 μmol/l (&gt;2.3 mg/dl) and/or dilated common bile duct (&gt;6 mm) on transabdominal or endoscopic ultrasound or computed tomography;</li> <li>Temperature &gt;38.5°C.</li> </ol>	<p><b>Biliary colic</b> Rome criteria <sup>[33]</sup></p> <p>Upper abdominal pain (either right upper quadrant or epigastric pain) lasting at least 30 minutes, according to the</p>	

Figure 2 Shows the evaluation of primary and secondary endpoints.

198x154mm (300 x 300 DPI)

STUDY PERIOD							
DIVISION	Gastroenterology management				Department of Surgery		Control visit
SERVING	DOCTOR no.1 and no.2				DOCTOR no.3		DOCTOR no.4
	1	1	2	1			
OBJECT	MBP management and randomization				Cholecystectomy after discharge		Follow up
TIMEPOINT	- several days	0	+ several days		Within 6 days	Between day 45-60	Day 90±7 after discharge
<b>ENROLMENT:</b>							
Diagnosis of acute mild biliary pancreatitis*	X						
ES**		X					
Eligibility screen			X Q2-4				
TEST 1***				X Q5			
Sign of Informed consent form				X Q6			
Allocation****				X Q6			
Randomization****				X Q6			
Discharge***** to home or to surg.				X			
<b>INTERVENTIONS:</b>							
Group A Early cholecystectomy					X		
Group B Delayed cholecystectomy						X	
TEST 2***					X Q7	X Q7	
<b>ASSESSMENTS:</b>							
Follow up (with the help of an administrator)***							X Q8

Figure 3 Schedule of enrolment, interventions and assessments according to the SPIRIT 2013 statement [15].

\*Diagnosis of acute biliary pancreatitis (any of the following 3 definitions): diagnosis of gallstones or sludge on imaging, a dilated common bile duct on ultrasound (>8 mm in patients ≤75 years old or >10 mm in patients >75 years old) in the absence of gallstones or sludge in the gallbladder; and alanine aminotransferase level >2 times higher than normal values with ALT > AST. In the first 24 hours of admission, all patients will undergo either an ultrasonography or a contrast-enhanced computed tomography (CECT) to detect if the gallbladder contains gallstones or sludge and to determinate the diameter of the common bile duct. ABP is mild, when there is no pancreatic necrosis, or no transient or persistent organ failure (>48 hours).

\*\*If it is necessary to perform endoscopic sphincterotomy during the current admission or ES in the medical history also acceptable.

\*\*\* Data will be collected in a personalized database, and follow-up will consist of questionnaires. The patient will be asked to note every biliary event during the follow-up period and will be contacted in person within the 90 days after discharge to collect information. After data collection, we can draw conclusions about the treatment strategy. Improperly completed datasheets and incorrect data upload will be avoided and controlled by the administrator. (Q5, Q7, Q8, Q=question)

\*\*\*\* The patient can be randomized by using a randomization module with sealed envelope. Patient data will be uploaded to the data base, which will be followed by the randomization. This randomization module will allocate the participants to the 2 different groups. This method makes it impossible for researchers to predict the allocation of the patients involved in the study. It is impossible to conceal the distribution of the patients in this study because the patients need to be scheduled for either an early cholecystectomy or a delayed cholecystectomy.

Allocation will be carried out based on predefined randomisation lists created separately for each recruiting centre. The allocation sequence will be prepared with a block size of 4 and with an allocation ratio 1:1 by the Independent Data Management Board (IDMB).

\*\*\*\*\* The criteria are the following: (1) Anticipation on the part of the treating physician that the patient can be discharged within 1 or 2 days; (2) no need for analgesics; (3) declining C-reactive protein levels and <150 mg/l; (4) no evidence of local or systemic complications (for example, no fever); (5) oral feeding is tolerated for 24 hrs; and (6) ERCP/ES either during the index admission or in the medical history without complication. Before discharge or transfer to surgery department.

108x61mm (300 x 300 DPI)

Hypothesised proportion in each group	Significance level	Power	Acceptable max. difference for equivalency	Sample size needed for analysis (per group)	Sample size for screening (with 5% drop-out rate)
5%	95%	90%	14%	42	89

Figure 4 The listed parameters were used to estimate results for the current sample size.

271x39mm (300 x 300 DPI)

**E**ndoscopic sphincterotomy **M**y for delay **I**ng  
cho**L**ecystectomy in mild acute biliar **Y** pancreatitis

## QUESTIONNAIRE

### 1. Personal data

#### 1.1 Patient's data

Name: \_\_\_\_\_

Sex: Male / Female

Date of Birth: \_\_\_\_\_ Age: \_\_\_\_\_ Insurance number: \_\_\_\_\_

Phone number: \_\_\_\_\_

The patient's study number:

#### 1.2 Doctors' data

##### DOCTOR No. 1:

Name of the doctor **responsible for the treatment of ABP**: \_\_\_\_\_

The phone number of the doctor: \_\_\_\_\_

Institute: \_\_\_\_\_

##### DOCTOR No. 2:

Name of the doctor **responsible for the randomization**: \_\_\_\_\_

The phone number of the doctor: \_\_\_\_\_

Institute: \_\_\_\_\_

##### DOCTOR No. 3:

Name of the doctor **responsible for the operation**: \_\_\_\_\_

The phone number of the doctor: \_\_\_\_\_

Institute: \_\_\_\_\_

##### DOCTOR No. 4:

Name of the doctor **responsible for the 90 days' visit**: \_\_\_\_\_

The phone number of the doctor: \_\_\_\_\_

Institute: \_\_\_\_\_



**E**ndoscopic sphincterotomy for delay **I**ng  
cholecystectomy in mild acute biliary **Y** pancreatitis

**2. Inclusion criteria** /DOCTOR No. 2/

Patients older than 18 age	<b>YES</b>	<b>NO</b>
Diagnosis of acute pancreatitis (two of them have to be positive) - upper abdominal pain - serum lipase or amylase is three times higher of upper limit of normal - characteristic findings of acute pancreatitis on abdominal imaging	<b>YES</b>	<b>NO</b>
Presence of biliary pancreatitis (one of them has to be true) - diagnosis of gallstone or sludge on imaging - the absence of gallstone or sludge with a dilated common bile duct on ultrasound (>8 mm in patients ≤75 years of age or >10 mm in patients >75 years old) - alanine aminotransferase level >2 times higher than normal values	<b>YES</b>	<b>NO</b>
Mild acute biliary pancreatitis (all of them have to be true) /HAS TO BE DETERMINED AT DISCHARGE OF THE PATIENT/ - no peripancreatic fluid collections - no pancreatic necrosis - no persistent organ failure	<b>YES</b>	<b>NO</b>
ERCP/ES either during the index admission or in the medical history without complication	<b>YES</b>	<b>NO</b>
Written informed consent	<b>YES</b>	<b>NO</b>

**One „NO” is present = DO NOT INCLUDE!**

**3. Exclusion criteria** /DOCTOR No. 2/

American Society of Anesthesiologists (ASA) classification - III patients >75 years old - IV, V, VI. Groups	<b>YES</b>	<b>NO</b>
Acute or chronic cholecystitis during hospitalization	<b>YES</b>	<b>NO</b>
Previous cholecystectomy	<b>YES</b>	<b>NO</b>
Continuous alcohol abuse or chronic pancreatitis	<b>YES</b>	<b>NO</b>
Pregnancy	<b>YES</b>	<b>NO</b>

**One „YES” is present = EXCLUDE!**

**4. If all inclusions and no exclusion criteria are met, than the physician may indicate the patient to participate in the study. / DOCTOR No. 2/**

The treating physician (DOCTOR No. 2) anticipates that the patient can be discharged	<b>YES</b>	<b>NO</b>
No need for analgesics	<b>YES</b>	<b>NO</b>
Declining C-reactive protein levels and <150 mg/l	<b>YES</b>	<b>NO</b>
No evidence of local or systemic complications	<b>YES</b>	<b>NO</b>
The patient has resumed solid oral nutrient	<b>YES</b>	<b>NO</b>

**If all YES = RANDOMIZATION /see point 6/**

**E**ndoscopic sphincterotomy for delay **I**ng  
cho**L**ecystectomy in mild acute biliar **Y** pancreatitis  
**5. Medical History and characteristics of ABP / DOCTOR No. 1/**

Date of admission (diagnosis of AP):.....

Date of discharge: .....

### 5.1 Anamnesis

History of upper abdominal surgery: Yes / No  
If yes, interventions:.....  
.....  
History if biliary colics Yes / No  
History of cholecystitis Yes / No  
Fever Yes / No .....°C  
Diabetes Yes / No  
Antibiotic therapy during the ABP Yes / No

BMI Weight: \_\_\_\_ kg, Height: \_\_\_\_ cm, BMI: \_\_\_\_ kg/m<sup>2</sup>

ASA classification (ASA PHYSICAL STATUS CLASSIFICATION SYSTEM)

I. group(Normal healthy patient)	<b>YES</b>	<b>NO</b>
II. group(Patient with <b>mild systemic disease</b> with no functional limitations)	<b>YES</b>	<b>NO</b>
III. group(Patient with <b>moderate systemic disease with functional limitations</b> )	<b>YES</b>	<b>NO</b>

### 5.2. Laboratory measurements

At discharge after AP:

Amylase(U/l)		Hematocrit(%)	
Lipase(U/l)		Hemoglobin(g/l)	
Gamma GT(U/l)		Kreatinine(umol/l)	
White blood cell(G/l)		eGFR	
ASAT/GOT(U/l)		CRP(mg/l)	
INR(U/l)		Alkaline phosphatase(U/l)	



Endoscopic sphincterotomy for delay  
cholecystectomy in mild acute biliary pancreatitis

5.3. Pancreatic imaging /At discharge after AP/

5.3.1 Abdominal Computed Tomography: yes/no

Modified CTSI Score (0-10): .....

Please NOTE! Abdominal CT is compulsory when the patient is discharged

- CTSI:

**CTSI Score: (I)** Normal pancreas 0 point, intrinsic pancreatic abnormalities with or without inflammatory changes in peripancreatic fat 2 points, Pancreatic or peripancreatic fluid collection or peripancreatic fat necrosis 4 points **(II)** Necrosis absent 0 Points, < 30% necrosis 2 Points, > 30% necrosis 4 points **(III)** presence of extrapancreatic findings 2 points.

- Pancreas Size:

MAXIMUM OF: 10 points

- Normal
- Partially enlarged (body AP diameter is over 2 cm and/or head AP diameter is over 2,5 cm, none exceeds 3 cm)
- Definitely enlarged (any part over 3 cm AP diameter)

- Largest diameter of peripancreatic fat infiltration.....cm

- Peripancreatic fluid:

- none
- present
- Large pseudocyst(s)

- Size of peripancreatic fluid or pseudocyst: .....cm

- Necrotizing area (nonenhancement):

- Largest diameter of necrosis area .....cm
- Location of necrosis: .....
- Type: patchy / full width
- Estimated necrosis: 0%, < 30% , 30% - 60%, > 60%

- Wirsung dilatation: YES / NO (yes, diameter.....mm)

- Distant abdominal fluid:

- Small amount (hard to see, less than 2 cm in lesser pelvis, less than 1 cm around liver/spleen)





**E**ndoscopic sphincterotomy for delay **I**ng  
 cho **L**ecystectomy in mild acute biliar **Y** pancreatitis

- Moderate amount (easy to see, but without pelvic or abdominal distension)
- Large amount with abdominal/pelvic distension

**- Pleural effusion:**

- none
- one sided:..... (AP diameter .....cm)
- Both sides, L - ..... cm, R.....cm

**- Extrapancreatic findings:**

- Inflammation (Cholecystitis, Duodenitis, etc.) location: .....
- Cholecystolithiasis
- Choledocholithiasis
- Signs of bowel ischaemia
- Bowel distension, ileus
- Venous thrombosis
- Pseudoaneurysm
- Parenchymal organ involvement, define: .....
- none

Other Description:

.....  
 .....  
 .....

**5.4. Characteristics of AP**

Date of diagnosis (admission).....

Date of EST:.....

Date of discharge: .....



Endoscopic sphincterotomy for delaying  
cholecystectomy in mild acute biliary pancreatitis

**6. Randomization / DOCTOR No. 2/**

The patient will be randomized by an internet randomization module in the following 2 groups:

- Randomization:
- A.** Early cholecystectomy (within 6 days after discharge)
  - B.** Delayed cholecystectomy (between 45 and 60 days after discharge)

Please circle the relevant group after randomization:

A or B

Please inform the patient concerning the **1)** Date for imaging examination and blood measurements before the operation, **2)** Date for the operation, **3)** Date for the 90 days visit

**7. Operation /responsibility of DOCTOR No. 3/**

Date of operation: .....

Length of days between discharge and operation: .....

If the operation is not in the time period described in point 6 please provide the reason: .....

**E**ndoscopic sphincterotomy for delay **I**ng  
cho**L**ecystectomy in mild acute biliar **Y** pancreatitis

### 7.1 Anamnesis (between discharge after ABP and operation)

<b>Acute pancreatitis</b> - Upper abdominal pain - Serum lipase or amylase is three times higher of upper limit of normal - Characteristic findings of acute pancreatitis on cross-sectional abdominal imaging	<b>YES</b>	<b>NO</b>
<b>Biliary pancreatitis</b> - Diagnosis of gallstone or sludge on imaging - Dilated common bile duct on ultrasound (>8 mm in patients ≤75 years old or >10 mm in patients >75 years old - Alanine aminotransferase level >2 times higher than normal values	<b>YES</b>	<b>NO</b>
<b>Cholecystitis</b> A. Local signs of inflammation: 1) Murphy's sign; 2) RUQ mass/pain/tenderness. B. Systemic signs of inflammation: 1) Fever; 2) Elevated C-reactive protein; 3) Elevated white blood cell count. C. Imaging findings characteristic of acute cholecystitis <b>Final diagnosis</b> 1) One item in A and one item in B are positive; 2) C confirms the diagnosis when acute cholecystitis is suspected clinically	<b>YES</b>	<b>NO</b>
<b>Biliary colics</b> Upper abdominal pain (either right upper quadrant or epigastric pain) lasting at least 30 minutes, according to the Rome criteria	<b>YES</b>	<b>NO</b>
<b>Cholangitis</b> 1) Serum total bilirubin level >40 μmol/l (>2.3 mg/dl) and/or dilated common bile duct (>6 mm) on transabdominal or endoscopic ultrasound or computed tomography; 2) Temperature >38.5°C.	<b>YES</b>	<b>NO</b>
<b>Organ failure</b> 1) Respiratory: PaO <sub>2</sub> ≤60 mmHg (SaO <sub>2</sub> ≤ 90%) or need for mechanical ventilation; 2) Cardiovascular: systolic blood pressure <90 mmHg or need for catecholamine support; 3) Renal: creatinine level >177 μmol/l after rehydration or need for hemofiltration or hemodialysis (not including pre-existent renal failure).	<b>YES</b>	<b>NO</b>
Mortality	<b>YES</b>	<b>NO</b>

If any of the answers is **YES** please provide the dates: .....

Except mortality, all of the above mentioned diseases can occur multiple times.  
Please provide details for all events separately.

Other reasons for hospitalization: .....



**E**ndoscopic sphincterotomy for delay **I**ng  
cholelithiasis in mild acute biliary pancreatitis

**7.2 Laboratory measurements (no more than 24h before the operation)**

Amylase(U/l)		Hematocrit(%)	
Lipase(U/l)		Hemoglobin(g/l)	
Gamma GT(U/l)		Kreatinine(umol/l)	
White blood cell(G/l)		eGFR	
ASAT/GOT(U/l)		CRP(mg/l)	
INR(U/l)		Alcaline phosphatase(U/l)	

If the patient is in group A, and the operation is performed within 24h after the blood samples are taken during the discharge of the patients, NO ADDITIONAL BLOOD SAMPLE HAS TO BE TAKEN. Please copy the values from 5.2.

**7.3 Pancreatic imaging**

**7.3.1 Abdominal ultrasonography:**

- **Visualization:**
  - o Good, complete (head at least partially visualized, body and neck well visualized, tail: partially visualized)
  - o Partially, incomplete (only body or only head visualized)
  - o Poor, non-diagnostic
- **Size:**
  - o Normal
  - o Partially enlarged (body AP diameter is over 2 cm and/or head AP diameter is over 2,5 cm, none exceeds 3 cm)
  - o Definitely enlarged (any part over 3 cm AP diameter)
- **Peripancreatic fluid:**
  - o none
  - o present
  - o Large pseudocyst(s)
- Size of peripancreatic fluid or pseudocyst: .....cm
- **Pancreas homogeneity:**
  - o Homogenous
  - o Inhomogeneous, includes area(s) of low echogenicity
  - o Inhomogeneous, includes calcifications
- In case of circumscribed low echogenicity area, it's size.....cm
- **Wirsung dilatation:** YES / NO (yes, diameter.....mm)

Other Description:

.....

.....

.....

**E**ndoscopic sphincterotomy for delay **I**ng  
cho **L**ecystectomy in mild acute biliar **Y** pancreatitis

**7.3.2 Abdominal Computed Tomography:** yes/no  
Modified CTSI Score (0-10): .....

- **CTSI:**

**CTSI Score: (I)** Normal pancreas 0 point, intrinsic pancreatic abnormalities with or without inflammatory changes in peripancreatic fat 2 points, Pancreatic or peripancreatic fluid collection or peripancreatic fat necrosis 4 points **(II)** Necrosis absent 0 Points, < 30% necrosis 2 Points, > 30% necrosis 4 points **(III)** presence of extrapancreatic findings 2 points.

MAXIMUM OF: 10 points

- **Pancreas Size:**

- Normal
- Partially enlarged (body AP diameter is over 2 cm and/or head AP diameter is over 2,5 cm, none exceeds 3 cm)
- Definitely enlarged (any part over 3 cm AP diameter)

- Largest diameter of peripancreatic **fat infiltration**.....cm

- **Peripancreatic fluid:**

- none
- present
- Large pseudocyst(s)

- Size of peripancreatic fluid or pseudocyst: .....cm

- **Necrotizing area** (nonenhancement):

- Largest diameter of necrosis area .....cm
- Location of necrosis: .....
- Type: patchy / full width
- Estimated necrosis: 0%, < 30% , 30% - 60%, > 60%

- **Wirsung** dilatation: YES / NO (yes, diameter.....mm)

- Distant **abdominal fluid:**

- Small amount (hard to see, less than 2 cm in lesser pelvis, less than 1 cm around liver/spleen)



**E**ndoscopic sphincterotomy for delay **I**ng  
cho**L**ecystectomy in mild acute biliar **Y** pancreatitis

- Moderate amount (easy to see, but without pelvic or abdominal distension)
- Large amount with abdominal/pelvic distension

**- Pleural effusion:**

- none
- one sided:..... (AP diameter .....cm)
- Both sides, L - ..... cm, R.....cm

**- Extrapancreatic findings:**

- Inflammation (Cholecystitis, Duodenitis, etc.) location: .....
- Cholecystolithiasis
- Choledocholithiasis
- Signs of bowel ischaemia
- Bowel distension, ileus
- Venous thrombosis
- Pseudoaneurysm
- Parenchymal organ involvement, define: .....
- none

**Other Description:**

.....  
 .....  
 .....  
 .....

If the patient is in group A, and the operation is performed within 24h after the imaging is performed during the discharge of the patients, NO ADDITIONAL IMAGING EXAMINATION HAS TO BE ORDERED. Please copy the details from 5.3.

Endoscopic sphincterotomy for delay  
cholecystectomy in mild acute biliary pancreatitis

#### 7.4. Characteristics of the Operation

The difficulty of cholecystectomy (10 – hard, 5 – average difficulty):

1	2	3	4	5	6	7	8	9	10

Conversion to open cholecystectomy:

Yes / No

The length of the operation (min): \_\_\_\_\_

Days spent in hospital after cholecystectomy: \_\_\_\_\_

Intensive unit care:

Yes / No

Mortality:

Yes / No

Haemorrhage, reintervention needed:

Yes / No

No iatrogenic perforation of the gallbladder

Yes / No

Common bile duct (CBD) injuries

Yes / No

Bile leakage

Yes / No

Sub-hepatic abscess

Yes / No

#### 8. Visit 90 days after discharge / DOCTOR No. 4/

The visit has to be completed +/- 7 days (between 83 and 97 days after discharge)

Date of the visit: .....

Length of days between discharge and visit: .....

#### 8.1 Anamnesis (between the operation and visit)

<b>Acute pancreatitis</b> - Upper abdominal pain - Serum lipase or amylase is three times higher of upper limit of normal - Characteristic findings of acute pancreatitis on cross-sectional abdominal imaging	<b>YES</b>	<b>NO</b>
<b>Biliary pancreatitis</b> - Diagnosis of gallstone or sludge on imaging - Dilated common bile duct on ultrasound (>8 mm in patients ≤75 years old or >10 mm in patients >75 years old - Alanine aminotransferase level >2 times higher than normal values	<b>YES</b>	<b>NO</b>
<b>Cholecystitis</b> A. Local signs of inflammation: 1) Murphy's sign; 2) RUQ mass/pain/tenderness. B. Systemic signs of inflammation: 1) Fever; 2) Elevated C-reactive protein; 3) Elevated white blood cell count. C. Imaging findings characteristic of acute cholecystitis <b>Final diagnosis</b>	<b>YES</b>	<b>NO</b>



**E**ndoscopic sphincterotomy **M**y for delay **I**ng

1) cholelithiasis and/or one item in Biliary pancreatitis 2) C confirms the diagnosis when acute cholecystitis is suspected clinically		
<b>Biliary colics</b> Upper abdominal pain (either right upper quadrant or epigastric pain) lasting at least 30 minutes, according to the Rome criteria	<b>YES</b>	<b>NO</b>
<b>Cholangitis</b> 1) Serum total bilirubin level >40 µmol/l (>2.3 mg/dl) and/or dilated common bile duct (>6 mm) on transabdominal or endoscopic ultrasound or computed tomography; 2) Temperature >38.5°C.	<b>YES</b>	<b>NO</b>
<b>Organ failure</b> 1) Respiratory: PaO2 ≤60 mmHg (SaO2 ≤ 90%) or need for mechanical ventilation; 2) Cardiovascular: systolic blood pressure <90 mmHg or need for catecholamine support; 3) Renal: creatinine level >177 µmol/l after rehydration or need for hemofiltration or hemodialysis (not including pre-existent renal failure).	<b>YES</b>	<b>NO</b>
Mortality	<b>YES</b>	<b>NO</b>

If any of the answers **YES** please provide the dates: .....

Except mortality, all of the above mentioned diseases can occur multiple times. Please provide details for all events separately.

Other reason for hospitalization: .....

**SIGNATURES:**

**Doctor No.1**..... **Date:**.....  
**Doctor No.2**..... **Date:**.....  
**Doctor No.3**..... **Date:**.....  
**Doctor No.4**..... **Date:**.....





STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

## SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Description	Addressed on page number
<b>Administrative information</b>		
Title	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	Trial identifier and registry name. If not yet registered, name of intended registry	3
	All items from the World Health Organization Trial Registration Data Set	–
Protocol version	Date and version identifier	10
Funding	Sources and types of financial, material, and other support	10
Roles and responsibilities	Names, affiliations, and roles of protocol contributors	1, 10
	Name and contact information for the trial sponsor	5, 10
	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	5
	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	4,5, 8-9
<b>Introduction</b>		
Background and rationale	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
	Explanation for choice of comparators	4,8,9
Objectives	Specific objectives or hypotheses	5, 8
1		

1	Trial design	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5
2			
3			
4	<b>Methods: Participants, interventions, and outcomes</b>		
5			
6	Study setting	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5,8-9
7			
8	Eligibility criteria	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for studycentres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6
9			
10			
11	Interventions	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6-7-8
12			
13		Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	7
14			
15		Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	7
16			
17		Relevant concomitant care and interventions that are permitted or prohibited during the trial	–
18			
19	Outcomes	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	7
20			
21			
22			
23			
24	Participant timeline	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Fig.3
25			
26			
27	Sample size	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	8
28			
29			
30	Recruitment	Strategies for achieving adequate participant enrolment to reach target sample size	8
31			
32	<b>Methods: Assignment of interventions (for controlled trials)</b>		
33			
34	Allocation:		
35	Sequence generation	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	6
36			
37			
38			
39			
40			
41			
42			

1 Allocation concealment mechanism Mechanism of implementing the allocation sequence (eg, central telephone; sequentially 6  
2 numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until  
3 interventions are assigned  
4 Implementation Who will generate the allocation sequence, who will enrol participants, and who will assign 6  
5 participants to interventions  
6 Blinding (masking) Who will be blinded after assignment to interventions (eg, trial participants, care providers, 6  
7 outcome assessors, data analysts), and how  
8  
9  
10 If blinded, circumstances under which unblinding is permissible, and procedure for revealing a -  
11 participant's allocated intervention during the trial  
12  
13 **Methods: Data collection,**  
14 **management, and analysis**  
15  
16 Data collection methods Plans for assessment and collection of outcome, baseline, and other trial data, including any 8  
17 related processes to promote data quality (eg, duplicate measurements, training of assessors)  
18 and a description of study instruments (eg, questionnaires, laboratory tests) along with their  
19 reliability and validity, if known. Reference to where data collection forms can be found, if not in  
20 the protocol  
21  
22 Plans to promote participant retention and complete follow-up, including list of any outcome data 8  
23 to be collected for participants who discontinue or deviate from intervention protocols  
24  
25 Data management Plans for data entry, coding, security, and storage, including any related processes to promote 8-9  
26 data quality (eg, double data entry; range checks for data values). Reference to where details of  
27 data management procedures can be found, if not in the protocol  
28  
29 Statistical methods Statistical methods for analysing primary and secondary outcomes. Reference to where other 8  
30 details of the statistical analysis plan can be found, if not in the protocol  
31 Methods for any additional analyses (eg, subgroup and adjusted analyses) 9  
32 Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis),  
33 and any statistical methods to handle missing data (eg, multiple imputation) 9  
34

35 **Methods: Monitoring**

1	Data monitoring	Composition of data monitoring committee (DMC); summary of its role and reporting structure;	8-9
2		statement of whether it is independent from the sponsor and competing interests; and reference	
3		to where further details about its charter can be found, if not in the protocol. Alternatively, an	
4		explanation of why a DMC is not needed	
5			
6		Description of any interim analyses and stopping guidelines, including who will have access to	9
7		these interim results and make the final decision to terminate the trial	
8			
9			
10	Harms	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported	8-9
11		adverse events and other unintended effects of trial interventions or trial conduct	
12			
13			
14			
15	Auditing	Frequency and procedures for auditing trial conduct, if any, and whether the process will be	10
16		independent from investigators and the sponsor	
17			
18	<b>Ethics and dissemination</b>		
19	Research ethics approval	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	3,10
20			
21			
22	Protocol amendments	Plans for communicating important protocol modifications (eg, changes to eligibility criteria,	9
23		outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial	
24		registries, journals, regulators)	
25			
26			
27	Consent or assent	Who will obtain informed consent or assent from potential trial participants or authorised	6
28		surrogates, and how (see Item 32)	
29		Additional consent provisions for collection and use of participant data and biological specimens	10-11
30		in ancillary studies, if applicable	
31			
32			
33	Confidentiality	How personal information about potential and enrolled participants will be collected, shared, and	8
34		maintained in order to protect confidentiality before, during, and after the trial	
35			
36			
37	Declaration of interests	Financial and other competing interests for principal investigators for the overall trial and each	10
38		study site	
39			
40			
41			
42			

1	Access to data	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	8
2			
3			
4	Ancillary and post-trial care	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	10-11
5			
6			
7			
8	Dissemination policy	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	9
9			
10			
11			
12			
13		Authorship eligibility guidelines and any intended use of professional writers	9
14			
15			
16			
17		Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	9
18			
19			
20	<b>Appendices</b>		
21	Informed consent materials	Model consent form and other related documentation given to participants and authorised surrogates	Attached
22			
23			
24			
25			
26	Biological specimens	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	10-11
27			
28			
29			
30			
31			
32			

---

33 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 34 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 35 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.  
 36

# BMJ Open

## Endoscopic sphincterotomy for delaying cholecystectomy in mild acute biliary pancreatitis (EMILY study): protocol of a multicenter randomized clinical trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025551.R2
Article Type:	Protocol
Date Submitted by the Author:	20-Mar-2019
Complete List of Authors:	<p>Kucserik, Levente; Universitatea de Medicina si Farmacie din Targu Mures, Division of Surgery</p> <p>Márta, Katalin; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine; János Szentágothai Research Center, University of Pécs</p> <p>Vincze, Áron; Pecs Tudományegyetem Általános Orvostudományi Kar, Division of Gastroenterology, First Department of Internal Medicine; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine</p> <p>Lázár, György; University of Szeged, Department of Surgery</p> <p>Czakó, László; University of Szeged, First Department of Medicine</p> <p>Szentkereszty, Zsolt; University of Debrecen, Department for Surgery</p> <p>Papp, Maria; Debreceni Egyetem, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine</p> <p>Palatka, Károly; Debreceni Egyetem, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine</p> <p>Izbéki, Ferenc; Fejér County Saint George Teaching Hospital of University of Pécs, Division of Gastroenterology</p> <p>Altörjay, Áron; Fejér County Saint George Teaching Hospital of University of Pécs, Division of Surgery</p> <p>Török, Imola; Universitatea de Medicina si Farmacie din Targu Mures, Division of Gastroenterology</p> <p>Barbu, Sorin; Universitatea de Medicina si Farmacie din Cluj Napoca, Division of Gastroenterology</p> <p>Tantau, Marcel; Universitatea de Medicina si Farmacie din Cluj Napoca, Division of Gastroenterology</p> <p>Vereczkei, András; Pecs Tudományegyetem Általános Orvostudományi Kar, Department for Surgery</p> <p>Bogár, Lajos; Pecs Tudományegyetem Általános Orvostudományi Kar, Department of Anaesthesiology and Intensive Therapy</p> <p>Dénes, Márton; County Hospital Targu Mures</p> <p>Németh, Imola; Adware Research Developing and Consulting Ltd</p> <p>Szentesi, Andrea; Pecs Tudományegyetem, Institute for Translational Medicine; Szegedi Tudományegyetem, MTA-SZTE Translational Gastroenterology Research Group</p> <p>Zádori, Noémi; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine</p> <p>Antal, Judit; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine</p>

	Lerch, Markus; Universitätsmedizin Greifswald, Department of Medicine A Neoptolemos, John; University of Liverpool Department of Molecular and Clinical Cancer Medicine Sahin-Toth, Miklos; Boston University Petersen, Ole; Cardiff University, Medical Research Council Group Kelemen, Dezső; Pecs Tudományegyetem, Surgery Clinic Hegyí, Péter; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine; MTA-SZTE Translational Gastroenterology Research Group
<b>Primary Subject Heading</b>:	Gastroenterology and hepatology
Secondary Subject Heading:	Surgery
Keywords:	acute biliary pancreatitis, cholecystectomy, endoscopic sphincterotomy

SCHOLARONE™  
Manuscripts

**Endoscopic sphincterotomy for delayng choLecystectomy in mild acute biliarY pancreatitis (EMILY study): protocol of a multicenter randomized clinical trial**

Levente-Pál Kucserik MD<sup>1</sup>, Katalin Márta MD<sup>2,3</sup>, Áron Vincze MD PhD<sup>2,4</sup>, György Lázár MD PhD DSc<sup>5</sup>, László Czako MD PhD DSc<sup>6</sup>, Zsolt Szentkereszty MD PhD<sup>7</sup>, Mária Papp MD PhD<sup>8</sup>, Károly Palatka MD PhD<sup>8</sup>, Ferenc Izbéki MD PhD DSc<sup>9</sup>, Áron Altorjay MD PhD DSc<sup>10</sup>, Imola Török MD<sup>11</sup>, Sorin Barbu MD PhD<sup>12</sup>, Marcel Tantau MD PhD<sup>12</sup>, András Vereczkei MD PhD DSc<sup>13</sup>, Lajos Bogár MD PhD DSc<sup>14</sup>, Márton Dénes MD<sup>15</sup>, Imola Németh PhD<sup>16</sup>, Andrea Szentesi PhD<sup>2,21</sup>, Noémi Zádori MD<sup>2</sup>, Judit Antal PhD<sup>2</sup>, Markus M. Lerch MD PhD DSc<sup>17</sup>, John Neoptolemos MD PhD DSc<sup>18</sup>, Miklos Sahin-Tóth MD PhD DSc<sup>19</sup>, Ole H. Petersen MD PhD DSc<sup>20</sup>, Dezső Kelemen\* MD PhD<sup>13</sup>, Péter Hegyi\* MD PhD DSc<sup>2,21</sup>.

1 Division of Surgery, Universitatea de Medicina si Farmacie din Targu Mures, Targu Mures, RO

2 Institute for Translational Medicine, University of Pécs Medical School, Pécs, HU

3 János Szentágotthai Research Center, University of Pécs, Pécs, HU

4 Division of Gastroenterology, First Department of Internal Medicine, University of Pécs Medical School, Pécs, HU

5 Department of Surgery, University of Szeged, Szeged, HU

6 First Department of Medicine, University of Szeged, Szeged, HU

7 Department for Surgery, University of Debrecen, Debrecen, HU

8 Division of Gastroenterology, University of Debrecen, Debrecen, HU

9 Division of Gastroenterology, Fejér County Saint George Teaching Hospital of University of Pécs, Székesfehérvár, HU

10 Division of Surgery, Fejér County Saint George Teaching Hospital of University of Pécs, Székesfehérvár, HU

11 Division of Gastroenterology, Universitatea de Medicina si Farmacie din Targu Mures, Targu Mures, RO

12 4th Department of Surgery, University of Medicine & Pharmacy "Iuliu Hatieganu" Cluj, RO

13 Surgery Clinic, University of Pécs, Pécs, HU

14 Department of Anaesthesiology and Intensive Therapy, University of Pécs Medical School, Pécs, HU

15 County Hospital Targu Mures, Targu Mures, RO

16 Adware Research Developing and Consulting Ltd., Balatonfüred, HU

17 Department of Medicine A, University Medicine Greifswald, Germany

18 Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK

19 Center for Exocrine Disorders, Department of Molecular and Cell Biology, Boston, USA; University Henry M. Goldman School of Dental Medicine, Boston, Massachusetts, USA

20 Medical Research Council Group, Cardiff School of Biosciences, Cardiff University, Cardiff, CF10 3AX, Wales, UK

21 Hungarian Academy of Sciences - University of Szeged, Translational Multidisciplinary Research Group, Szeged, Hungary

\*: equally contributed

E-mail addresses of the authors:

LPK [k.levente.p@gmail.com](mailto:k.levente.p@gmail.com), KM [katalin.marta@aok.pte.hu](mailto:katalin.marta@aok.pte.hu), ÁV [vincze.aron@pte.hu](mailto:vincze.aron@pte.hu), GyL [lazar.gyorgy@med.u-szeged.hu](mailto:lazar.gyorgy@med.u-szeged.hu), LC [czako.laszlo@med.u-szeged.hu](mailto:czako.laszlo@med.u-szeged.hu), ZsSz [szentkerzs@freemail.hu](mailto:szentkerzs@freemail.hu), MP [papp.maria@med.unideb.hu](mailto:papp.maria@med.unideb.hu), KP [palatka@med.unideb.hu](mailto:palatka@med.unideb.hu), FI [fizbeki@gmail.com](mailto:fizbeki@gmail.com), ÁA [altorjay@mail.fmkorhaz.hu](mailto:altorjay@mail.fmkorhaz.hu), IT [torokimola@gmail.com](mailto:torokimola@gmail.com), SB [barbu@pancreasclub.ro](mailto:barbu@pancreasclub.ro), MT [matantau@gmail.com](mailto:matantau@gmail.com), AV [vereczkei.andras@pte.hu](mailto:vereczkei.andras@pte.hu), LB [bogar.lajos@pte.hu](mailto:bogar.lajos@pte.hu), MD [denesmatyi@yahoo.com](mailto:denesmatyi@yahoo.com), IN [imola.nemeth@adwareresearch.com](mailto:imola.nemeth@adwareresearch.com), ASz [szentesiai@gmail.com](mailto:szentesiai@gmail.com), NZ [znoemi@gmail.com](mailto:znoemi@gmail.com), JA [juditaltal2014@gmail.com](mailto:juditaltal2014@gmail.com), MML [lerch@uni-greifswald.de](mailto:lerch@uni-greifswald.de), JN [jneoptolemos1@gmail.com](mailto:jneoptolemos1@gmail.com), MST [miklos@bu.edu](mailto:miklos@bu.edu), OHP [PetersenOH@cardiff.ac.uk](mailto:PetersenOH@cardiff.ac.uk), DK [kelemende@gmail.com](mailto:kelemende@gmail.com), PH [p.hegyi@tm-centre.org](mailto:p.hegyi@tm-centre.org)



**Corresponding Investigator:**

Péter Hegyi MD, PhD, DSc

Phone: +(36-70) 375-1031

e-mail: [p.hegyi@tm-centre.org](mailto:p.hegyi@tm-centre.org)**Coordinating institution:**

University of Pecs – Medical School

Institute for Translational Medicine

12 Szigeti Street, PÉCS, H-7624, HUNGARY

FAX: +(36-72) 536-247

Phone: +(36-72) 536-246

web: [www.tm-centre.org](http://www.tm-centre.org)

For peer review only

**ABSTRACT**

**Introduction.** According to the literature, early cholecystectomy is necessary to avoid complications related to gallstones after an initial episode of acute biliary pancreatitis (ABP). A randomized, controlled multicenter trial (the PONCHO trial) revealed that in the case of gallstone-induced pancreatitis, early cholecystectomy was safe in patients with mild gallstone pancreatitis and reduced the risk of recurrent gallstone-related complications, as compared with interval cholecystectomy. We hypothesize that carrying out a sphincterotomy (ES) allows us to delay cholecystectomy, thus making it logistically easier to perform and potentially increasing the efficacy and safety of the procedure.

**Methods/Design.** EMILY is a prospective, randomized, controlled multicenter trial. All patients with mild ABP, who underwent ES during the index admission, or in the medical history will be informed to take part in EMILY study. The patients will be randomized into two groups: (1) early cholecystectomy (within 6 days after discharge) and (2) patients with delayed (interval) cholecystectomy (between 45 and 60 days after discharge). During a 12-month period, 93 patients will be enrolled from participating clinics. The primary endpoint is a composite endpoint of mortality and recurrent acute biliary events (that is, recurrent ABP, acute cholecystitis, uncomplicated biliary colic, and cholangitis). The secondary endpoints are organ failure, biliary leakage, technical difficulty of the cholecystectomy, surgical and other complications.

**Ethics and dissemination.** The trial has been registered at the ISRCTN (ref no. 10667869) and approved by the relevant organisation, the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (EKU/2018/12176-5).

**Keywords:** acute biliary pancreatitis, cholecystectomy, endoscopic sphincterotomy

## Strengths and limitation

**Strength 1:** The study is designed as a prospective, randomized-controlled trial to achieve conclusion on the highest evidence level to provide the first evidence concerning the possible benefits of ES on timing cholecystectomy, it is (i) multinational (ii) multicentric, (iii) internationally registered and (iv) the pre-study protocol is published.

**Strength 2:** Only high volume, expert centers can join to the study. They have to provide (i) laparoscopically trained surgeons with >100 laparoscopic procedures performed and (ii) if ERCP/ES is provided during the index admission, trained gastroenterologist with >50 ES completed within a year must be on duty.

**Strength 3:** The study enjoys continuous support from (i) an International Translational Advisory Board (ITAB) including top, well-established experts from different are of research field (ii) an Independent Data Management Board (IDMB).

**Strength 4:** The final conclusion can be achieved with low number of patients within a relatively short period.

**Limitation 1:** The study will provide evidence in a selected population (mild ABP who underwent ERCP+ES) and no evidence concerning the usefulness of ES in moderate and severe ABP.

## INTRODUCTION

Acute pancreatitis is one of the leading gastrointestinal causes of acute hospital admissions [1, 2]. In most cases, it is caused by gallstones, sludge or edema [3]. Gallstone-induced pancreatitis involves a pathophysiologic factor, namely a distal common channel of the biliary and pancreatic ducts, which can be found in 80% of acute biliary pancreatitis (ABP) [4]. Acute biliary pancreatitis is a clinical entity with high rates of morbidity (15–50%) and mortality (20–35%) [5]. After ABP, several complications may occur; recurrent acute pancreatitis, cholestasis and fistula affecting the hepatobiliary system or other biliary events, such as acute cholecystitis, obstruction of the common biliary duct, cholangitis or biliary colic [6, 7]. Interval cholecystectomy after mild ABP is associated with a high risk of readmission for recurrent biliary events, especially after recurrent ABP [8]. The international practice guidelines recommend that in case of cholangitis or choledocholithiasis an ERCP should be performed to clear the bile duct with endoscopic sphincterotomy (ES). In addition, cholecystectomy should also be performed to avoid complications related to recurrent biliary events [9, 10]. In patients with clinically severe pancreatitis, with local complications, such as pancreatic necrosis or organ failure, the intervention namely the laparoscopic cholecystectomy (LC) is delayed 6 months until complications are resolved [11]. In cases of mild ABP, cholecystectomy is recommended between days 7 and 21 [4]. The latest studies show that after discharge of patients with ABP, cholecystectomy could reduce the risk of a recurrent ABP and other gallstone-induced complications [12]. In this setting, surgeons still prefer delayed cholecystectomy for efficacy and safety and for logistical reasons [13]. Some publications draw attention to ERCP/ES, which could reduce mortality and the formation of severe biliary complications [3, 14]. The aim of the EMILY trial is to combine a surgical treatment and a gastroenterological procedure to investigate if ES with delayed cholecystectomy (within 45 to 60 days after discharge) compared with ES with early cholecystectomy (within 6 days after discharge) could reduce recurrent biliary events.

## METHODS

**Design:** EMILY is a prospective, randomized-controlled, multicenter trial. The patients are randomized to two groups: (1) Patients who undergo early cholecystectomy (within 6 days after discharge) and (2) patients who undergo delayed (interval) cholecystectomy (between 45 and 60 days after discharge). During a 12-month period, 93 patients will be enrolled from participating clinics. The primary endpoint is a composite endpoint of mortality and recurrent acute biliary events (which are recurrent ABP, acute cholecystitis, uncomplicated biliary colic and cholangitis). The secondary endpoints are: organ failure, biliary leakage, technical difficulty of cholecystectomy, and surgical and other complications.

This study was structured following the SPIRIT 2013 [15] guideline defining standard protocol items for clinical trials and got the relevant ethical approval EKU/2018/12176-5 (Scientific and Research Ethical Committee, Medical Research Council, Hungary).

**Trial organization, committees and boards:** The coordinator and designer of the EMILY study is the Centre for Translational Medicine at the University of Pécs Medical School (coordinating institution and sponsor, [www.tm-centre.org](http://www.tm-centre.org)) and the Hungarian Pancreatic Study Group (HPSG-coordinating society, [www.pancreas.hu](http://www.pancreas.hu)). The HPSG was established in 2011 to stimulate research in pancreatic diseases.

Until now, it has launched three international observational clinical studies in 2014 [16, 17, 18] (EASY, APPLE and PINEAPPLE) and two interventional studies (PREPAST [19] – 2014 and GOULASH [20] – 2017) and has published the relevant guidelines for pancreatic diseases to improve patient care in pancreatology [21, 22, 23, 24].

The following committees and boards will be involved: Steering Committee (SC): The committee will be led by PH (corresponding investigator, gastroenterologist and internal medicine specialist).

The members in Szeged (HU) will be: LC (gastroenterologist), GL (surgeon); Debrecen (HU): MP (gastroenterologist), KP (gastroenterologist), ZS (surgeon); Pécs (HU): ÁV (gastroenterologist), DK (surgeon); Székesfehérvár (HU): FI (gastroenterologist), ÁA (surgeon); Targu Mures (RO): IT (gastroenterologist), LPK (surgeon); Cluj Napoca (RO): BS (surgeon), TM (gastroenterologist). KM is a trial management specialist, whereas AS leads the multidisciplinary core facility which will assist the scientists to run the study successfully. The SC will make decisions concerning all relevant questions including drop outs during the study.

International Translational Advisory Board (ITAB): The board will consist of a gastroenterologist (MML), a surgeon and two basic scientists (JN, MST, OHP). The ITAB will continuously monitor the progress of the study and will advise the SC.

The study was designed by the SC and ITAB. It was funded by the University of Pécs, Medical School. The sponsor was not involved in the design of the study, and will have no access to database or the randomization code.

The study also contains an independent physician and safety manager as required by the ethical regulation.

**Study population:** All patients with mild ABP (according to the revised Atlanta classification [25]) will be informed of the possibility to take part in the EMILY trial. After the consent form is signed participants will be randomized to 2 groups if they meet all the inclusion and no exclusion criteria (*Figure 1*).

**Inclusion criteria:** The criteria for inclusion in the study: (1) patients older than 18 years of age; (2) diagnosis of acute pancreatitis (at least 2 of the following 3 symptoms: upper abdominal pain, serum lipase or amylase is three times higher than the upper limit of normal and characteristic findings for acute pancreatitis on imaging); (3) the presence of ABP (any of the following 3 definitions): diagnosis of gallstones or sludge on imaging, a dilated common bile duct on ultrasound (>8 mm in patients  $\leq 75$  years old or >10 mm in patients >75 years old) in the absence of gallstones or sludge in the gallbladder; and alanine aminotransferase level >2 times higher than normal values with ALT > AST; (4) mild ABP (meaning no pancreatic necrosis, no transient or persistent organ failure (>48 hours) is present; (5) ERCP/ES either during the index admission or in the medical history without complication (6) signed written informed consent (all included patient will sign the consent which contains the information about the trial and procedures) (*Figure 1*).

**Exclusion criteria:** A patient's bad physical status can be an exclusion criterion. American Society of Anesthesiologists (ASA) III patients >75 years old; ASA IV or V patients, will be excluded. Patients with continuous alcohol abuse, acute or chronic cholecystitis during hospitalization, chronic pancreatitis, pregnancy, previous cholecystectomy will also be excluded (*Figure 1*).

**Time of randomization:** 5 criteria are described by the PONCHO trial [26]. If these 5 criteria are met, the informed consent will be signed by the patient and a control abdominal CT will be carried out before discharge. These criteria are the following: (1) anticipation on the part of the treating physician that the patient can be discharged; (2) the patient has no abdominal pain and there is no need for analgesics; (3) declining C-reactive protein levels and <150 mg/l; (4) no evidence of local or systemic complications (for example, no fever); (5) oral feeding is tolerated for 24 hrs. The patient must be randomized on the day of the discharge.

**Randomization:** The method of randomization is the following: The patient can be randomized by the study coordinator using a randomization module with sealed envelope. Patient data will be uploaded with the help of the administrator to the data base, which will be followed by the randomization. This randomization module will allocate the participants to the 2 different groups. This method makes it impossible for researchers to predict the allocation of the patients involved in the study. It is impossible to conceal the distribution of the patients in this study because the patients need to be scheduled for either an early cholecystectomy or a delayed cholecystectomy (*Figure 1*).

Allocation will be carried out based on predefined randomisation lists created separately for each recruiting centre. The allocation sequence will be prepared with a block size of 4 and with an allocation ratio 1:1 by the Independent Data Management Board (IDMB).

**Blinding:** In prevention of patient's selection to group A and B trial participants, care providers and outcome assessors will be blinded until the allocation, as no access to randomization sequence. From assignment to intervention blinding cannot be provided

1 considering the study characteristics (exact date of cholecystectomy). The allocation sequence is unblinded only to data analysts  
2 who are completely independent form medical team (decision making) and data collection.  
3  
4  
5

## 6 **Endpoints**

7  
8 **Primary endpoint.** The primary endpoint is a composite endpoint, which is based on mortality and on recurrent biliary events  
9 (which are recurrent ABP, acute cholecystitis, uncomplicated biliary colic, and cholangitis). The observation period is three months.  
10 We decide based on criteria in *Figure 2* if a complication is present or not.  
11

12  
13 **Secondary endpoints.** We hypothesize that cholecystectomy for ABP between days 45-60 after discharge in patients with ES is as  
14 effective and safe as early cholecystectomy (within 6 day after discharge). In order to evaluate this, we will observe the following  
15 parameters: the number of biliary colic registered for the patient, difficulty of cholecystectomy (on a scale of 0-10, 0=easy,  
16 5=moderately difficult, 10=hard, rate of conversion to open cholecystectomy, total length of hospital stay, need for ICU admission  
17 and total length of ICU stay, organ failure and biliary leakage (*Figure 2*).  
18  
19  
20  
21  
22  
23

## 24 **Treatment protocol**

25  
26  
27 Randomization: Group A. Early cholecystectomy

28  
29 Group B. Delayed cholecystectomy

30  
31 We randomize patients into two groups after discharge (*Figure 3*):

32  
33 Group A: The patient is randomized to the early cholecystectomy group, and cholecystectomy will be performed within 6 days after  
34 discharge.  
35

36  
37 Group B: The patient is randomized to the delayed cholecystectomy group, and the cholecystectomy will be carried out between 45  
38 to 60 days.  
39

40  
41 Discontinuing or the modification of the allocated interventions for a trial participant is based on surgical causes like contraindicated  
42 opus, need for conversion to open cholecystectomy, or when the patient does not present to the hospital for cholecystectomy.  
43

44  
45 Switching over the two interventions is not possible considering the trial characteristics, however in case of acute cholecystitis acute  
46 cholecystectomy can be performed independently from this trial. The case must be presented to SC.  
47  
48  
49

50 **Surgical details and quality control:** If it will be the first ERCP/ES performed in the patient's medical history it will be performed  
51 according to the European Society of Gastrointestinal Endoscopy (ESGE) guidelines. [27] The laparoscopic cholecystectomy will  
52 follow the European Association Guidelines for Endoscopic Surgery [28]. The patients will be operated on by laparoscopically  
53 trained surgeons with >100 laparoscopic procedures performed and by a trained gastroenterologist with >50 ES completed within a  
54 year must be on duty if ERCP/ES is provided during the index admission. Centers which intend to randomize at least 15 patients  
55 and are able to perform an early cholecystectomy and ERCP/ES are eligible to participate in the study. In those centers which ES  
56  
57  
58  
59  
60

1 data will then be collected on the incidence of choledocholithiasis, percentage bile duct injury, duration, and perceived difficulty  
2 (on a scale of 0-10).  
3

4 **Diagnosing and treating ABP:** In the first 24 hours of admission, all patients will undergo either an ultrasonography or a contrast-  
5 enhanced computed tomography (CECT) to detect if the gallbladder contains gallstones or sludge and to determinate the diameter  
6 of the common bile duct. ERCP should be performed only in the case of cholangitis or choledocholithiasis, to clear the bile duct with  
7 endoscopic sphincterotomy (ES) as described in the IAP/APA guideline. When only the laboratory parameters suggest common  
8 bile duct obstruction or choledocholithiasis, MRCP/EUS should be carried out [10].  
9  
10  
11  
12  
13

14  
15 **Data collection and follow-up:** Data will be collected in a personalized database, and follow-up will consist of questionnaires  
16 (*Supplementary File*). The patient will be asked to note every biliary event during the follow-up period and will be contacted in  
17 person within 90 days after discharge to collect information. After data collection, we can draw conclusions about the treatment  
18 strategy. Improperly completed datasheets and incorrect data upload will be avoided and controlled by the administrator.  
19  
20  
21  
22

23 The personal information about enrolled participants will only be shared with IDMB as uploaded data for randomization, after data  
24 analysis only randomization code will be used for identification to protect confidentiality during, and after the trial. Only the  
25 principal investigator and the IDMB will have access to the final trial dataset. However only identification code is used, we can  
26 aside from duplicated patient's data as cholecystectomy can not be performed twice.  
27  
28  
29  
30  
31  
32

### 33 **Sample size estimation method**

34 **Primary endpoint:** a composite of gallstone-related complications or mortality occurring within 6 months after discharge.

35 **Hypothesis:** With regard to our hypothesis, based on a non-inferiority design, there is no difference between the two groups (5%)  
36 in mortality or readmission for gallstone-related complications within 3 months after discharge.  
37  
38  
39

40 **Starting point:** Sample size estimation was based on the results obtained by the PONCHO trial carried out on 264 patients, where  
41 a non-significant difference of 14% was obtained between the two study groups (3% in the same-admission cholecystectomy group  
42 compared to 17% in the interval admission group). Thus, using the hypothesized 5% for the occurrence of the primary endpoint in  
43 the same-admission cholecystectomy group and a max difference of 14% given by the results of the PONCHO trial a total sample  
44 size of 93 was obtained using a 10% drop-out rate. The sample size estimation results are listed in the table below (*Figure 4*).  
45  
46  
47  
48  
49  
50  
51

52 **Data management and statistical analyses:** Data will be handled by an independent Clinical Research Organizer. Electronic CRF  
53 (eCRF) will be used. The Investigator will ensure that the data in the eCRF are accurate, complete and legible. Detailed data flow  
54 will be described in a Data Management Plan (DMP). Data from completed eCRFs will be validated under the direction of the Data  
55 Manager according to a Data Cleaning Plan (DCP). Adverse events will be coded using MedDRA according to GCP, GLP, FDA  
56 21CFR PART11 and other relevant regulatory requirements.  
57  
58  
59  
60



1 Safety Analysis Set (SAS, all patients enrolled in the study), Per Protocol Set (PPS, all enrolled patients who finished the study  
2 conforming to the requirements of the study protocol) and Intention to Treat (ITT, all randomized participants who start on a  
3 treatment, excluding consent withdrawals) will be performed.  
4

5 Baseline patient and disease characteristics will be analyzed using descriptive analysis. Demographic and baseline characteristics  
6 will be summarized for the overall study population. Descriptive statistics for both the primary and secondary parameters will be  
7 analyzed similarly.  
8

9 Subgroup analyses will be performed concerning the imaging alterations (1: no gallstones or sludge on imaging, 2) sludge or 3)  
10 gallstone. Since we cannot exclude the possibility of fibrosis after earlier ES, we will perform a subgroup analysis during the interim  
11 analysis as well. If the results obtained from the interim analysis indicate that there could be significant difference between index  
12 admission and earlier ES, we will modify the trial protocol from the single-population (the same-admission endoscopic shterotomy  
13 or ES in the medical history) two-arm (two groups: 1. Early cholecystectomy; 2. Delayed cholecystectomy) set up to a two-  
14 population two-arm set up (four groups: 1. early or 2. delayed cholecystectomy with index admission ES, 3. early or 4. delayed  
15 cholecystectomy in patients having earlier ES). The required patients' number will be adjusted in both populations accordingly. In  
16 case of important protocol modifications IDMB will report to the SC. SC will discuss and if the adverse effect is confirmed it will  
17 be reported to the relevant institutional and national ethical committee <http://www.ett.hu/tukeb.htm>  
18

19 **Premature termination of the study:** In the interests of patient safety, an interim analysis will be conducted after 15 patients and  
20 after half of the presumed number of patients (45) have completed the study. IDMB will perform an independent assessment of the  
21 trial related documents and activities, with the aim of ensuring the respect of subjects' right, safety and well-being and to guarantee  
22 the plausibility of clinical data. Similarity of groups at baseline will be also checked. The study will also be stopped if the two  
23 groups' results differ significantly ( $p < 0.001$ ). The study will be discontinued if the difference between the planned number of  
24 patients and the actual number is higher than 60% within one year. IDMB will report to SC.  
25

26 **Centers:** The trial will be launched in four Hungarian (Szeged, Debrecen, Pécs and Székesfehérvár) and two Romanian centres  
27 (Targu Mures and Cluj Napoca), after which the study will be open to other centres. In all cases, the IDMB will conduct an audit of  
28 the center and will report to the SC. The SC maintains the right to decide whether a center meets the required quality to join the  
29 study.  
30

31 The full protocol will be available for public in an open access journal.

32 **Publication policy:** We would like to publish the results in one of the internationally highly recognized decent journals. Centers  
33 providing more than 25 patients can provide 4 authors to the authorship list: 2 surgeons and 2 gastroenterologists.  
34

35 **Patient and Public Involvement:** This pre-study protocol contains no results and data, therefore patients and or public were not  
36 involved.  
37



## DISCUSSION

In the case of early laparoscopic cholecystectomy, while dissection and logistics are more difficult [6, 7] compared with delayed (interval) cholecystectomy, it is still more effective. Delayed cholecystectomy in a mild form of ABP is preferred by many surgeons, but a number of complications can occur: recurrent ABP, acute cholecystitis, obstruction of ductus choledochus, and uncomplicated biliary colic [6, 7]. After ERCP/ES is performed, the common bile duct is cleared, the complications caused by gallstones or sludge are significantly reduced [29]. The EMILY study is designed to determine if ERCP/ES for mild ABP aids in delaying the cholecystectomy to day 45-60 after discharge among patients with ABP.

If an ES aids in delaying a cholecystectomy, then we can reduce early cholecystectomy-related complications and the surgeons can proceed with a safer, easier cholecystectomy using this method of treatment.

## ACKNOWLEDGEMENTS

**Funding:** Center costs (IT, biostatistics, trial organization, etc) are covered by the University of Pécs Medical School, Momentum Grant of the Hungarian Academy of Sciences (LP2014-10/2014); and Economic Development and Innovation Operative Programme Grant and Highly Cited Publication Grant of the National Research, Development and Innovation Office (GINOP-2.3.2-15-2016-00048 Stay Alive, KH-125678 and EFOP 3.6.2-16-2017-00006 Live Longer), and Translational Medicine Foundation.

Since no additional treatment is necessary for the study, the general healthcare costs are covered by the National Healthcare System (University of Pécs-Medical School).

This study was designed with help of the Centre for Translational Medicine at the University of Pécs. This center is committed to improve patient's life with research activities like registries, observational and interventional trial organizations (<https://tm-centre.org>).

There are no financial and other competing interests for principal investigators (LPK, DK), included patients or any member of the trial.

## AUTHORS' CONTRIBUTION

LPK, KM, DK, ÁV, LC, MP, FI, ÁA, MT and PH designed the study. As a member of the ITAB MML, JN, MST and OHP gave advices and will continuously monitor the progress of the study. LPK, KM, PH, ZsSz, KP drafted the manuscript, GyL, SB, AV, LB, MD, NZ, JA and ASz edited the manuscript. IN carried out the sample size calculation. ZsSz, KP, IT, NZ, JA, ASz edited the figures and tables. All authors read and approved the final manuscript.

During the study IT, ÁV, LC, MP and MT are going to manage the endoscopic treatments. DK, GyL, ZsSz, MD and SB are responsible for cholecystectomies. ITAB and SC members are listed ahead.

**Competing interests statement:** All authors declare no competing interests.

## ETHICS AND DISSEMINATION

**Trial registration:** The trial has been registered at the ISRCTN10667869.

**Ethical approval:** Scientific and Research Ethics Committee of the Hungarian Medical Research Council (EKU/2018/12176-5).

**Protocol Version:** V1.0 10.07.2018.

**Start of the patient recruitment:** 1st March 2019

**Additional information and future plan:** Blood samples (serum and plasma) will be stored from all patients in order to study laboratory parameters later if required (e.g. the laboratory could not measure it), and in order to build up a biobank for later clinical studies to which all participants will give informed consent. The samples will be stored at -80°C.

The post-trial care will follow the routine treatment protocols. In case if patient suffer a harm during hospitalization all of the responsibility is taken by the hospital where the patient is treated.

## LIST OF ABBREVIATIONS

ABP – acute biliary pancreatitis

ASA – American Society of Anesthesiologists

CECT – contrast enhanced computed tomography

DCP – Data Cleaning Plan

DMP – Data Management Plan

ES – endoscopic shicterotomy

eCRF – electronic case report form

ESGE – European Society of Gastrointestinal Endoscopy

HPSG – Hungarian Pancreatic Study Group

IDMB – Independent Data Management Board

ITAB – International Translational Advisory Board

ITT – Intent to Treat

LC – Laparoscopic cholecystectomy

PPS – Per Protocol Set

SAS – Safety Analysis Set

SC – Steering Committee

## References

1. Peery AF, Dellon ES, Lund J, Crockett SD, et al. Burden of gastrointestinal disease in the United States: 2012 update. *Gastroenterology* 2012;143:1179–87. doi: 10.1053/j.gastro.2012.08.002
2. Dhiraj Y, Albert BL. The epidemiology of pancreatitis and pancreatic cancer gastroenterology. *Gastroenterology* 2013;144(6):1252–1261. doi: 10.1053/j.gastro.2013.01.068
3. Schepers NJ, Bakker OJ, Besselink MG, et al. Early biliary decompression versus conservative treatment in acute biliary pancreatitis (APEC trial): study protocol for a randomized controlled trial. Schepers et al. *Trials* 2016;17:5. doi: 10.1186/s13063-015-1132-0
4. Uhl W, Müller CA, Krähenbühl L et al. Acute gallstone pancreatitis, Timing of laparoscopic cholecystectomy in mild and severe disease. *SurgEndosc* 1999;13:1070–1076
5. Schietroma M, Carlei F, Lezoche E, et al. Acute biliary pancreatitis: staging and management. *Hepato-gastroenterology* 2001;48(40):988–993
6. UK Working Party on Acute Pancreatitis. UK guidelines for the management of acute pancreatitis. *Gut* 2005;54(Suppl 3):iii1–iii9. doi: 10.1136/gut.2004.057026
7. Forsmark CE, Baillie J. AGA institute technical review on acute pancreatitis. *Gastroenterology* 2007;132:2022–2044. doi: 10.1053/j.gastro.2007.03.065.
8. van Baal MC, Besselink MG, Bakker OJ, et al. for the Dutch Pancreatitis Study Group: Interval cholecystectomy after mild biliary pancreatitis is associated with a high risk of readmission for recurrent biliary events, especially recurrent biliary pancreatitis. *Annals of Surgery* 2012;255(5):860–866. doi: 10.1097/sla.0b013e3182507646
9. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. *Am J Gastroenterol* 2006;101:2379–2400. doi: 10.1111/j.1572-0241.2006.00856.x.
10. Uhl W, Warshaw A, Imrie C, et al. IAP Guidelines for the Surgical Management of Acute Pancreatitis. *Pancreatology* 2002;2:565–573. doi: 10.1159/000067684
11. Nealon WH, Bawduniak J, Walser EM. Appropriate timing of cholecystectomy in patients who present with moderate to severe gallstone-associated acute pancreatitis with peripancreatic fluid collections. *Ann Surg* 2004;239:741–749. doi:10.1097/01.sla.0000128688.97556.94
12. da Costa DW, Bouwense SA, Schepers NJ, et al. Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicenter randomized controlled trial. *Lancet* 2015;386:1261–68. doi: 10.1016/s0140-6736(15)00274-3
13. Paul GL, Bettina WD, Markus ML. Clinical perspectives in pancreatology: Compliance with Acute Pancreatitis Guidelines in Germany. *Pancreatology* 2005;5:591–593. doi: 10.1159/000087501

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
14. Uomo G, Manes G, Laccetti M, et al. Endoscopic sphincterotomy and recurrence of acute pancreatitis in gallstone patients considered unfit for surgery. *Pancreas* 1997;14:28–31.
  15. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* 2013;158:200–7. doi: 10.7326/0003-4819-158-3-201302050-00583
  16. Hritz I, Hegyi P. Early Achievable Severity (EASY) index for simple and accurate expedite risk stratification in acute pancreatitis. *J Gastrointest Liver Dis* 2015;24(2):177–82. doi: 10.15403/jgld.2014.1121.242.easy
  17. Párniczky A, Mosztbacher D, Zsoldos F et al. Analysis of Pediatric Pancreatitis (APPLE Trial): Pre-study protocol of a multinational prospective clinical trial. *Digestion* 2016;93(2):105–10. doi: 10.1159/000441353
  18. Zsoldos F, Párniczky A, Mosztbacher D, et al. Pain in the Early Phase of Pediatric Pancreatitis (PINEAPPLE Trial): Pre-study protocol of a multinational prospective clinical trial. *Digestion* 2016;93(2):121–6. doi: 10.1159/000441352
  19. Dubravcsik Z, Madácsy L, Gyökeres T, et al. Preventive pancreatic stents in the management of acute biliary pancreatitis (PREPAST trial): pre-study protocol for a multicenter, prospective, randomized, interventional, controlled trial. *Pancreatology* 2015;15(2):115–23. doi: 10.1016/j.pan.2015.02.007
  20. Márta K, Szabó AN, Pécsi D, et al. High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial. *BMJ Open* 2017;7(9):e015874. doi: 10.1136/bmjopen-2017-015874
  21. Dubravcsik Z, Farkas G, Hegyi P, et al. [Autoimmune pancreatitis. Evidence-based management guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(8):292–307. doi: 10.1556/OH.2015.30061
  22. Hritz I, Czakó L, Dubravcsik Z, et al. [Acute pancreatitis. Evidence-based practice guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):244–61. doi: 10.1556/OH.2015.30059
  23. Párniczky A, Czakó L, Dubravcsik Zs, et al. [Pediatric pancreatitis. Evidence-based management guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(8):308–25. doi: 10.1556/OH.2015.30062
  24. Takacs T, Czakó L, Dubravcsik Z, et al. [Chronic pancreatitis. Evidence-based management guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):262–88. doi: 10.1556/OH.2015.30060
  25. Banks, P.A., et al., Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. *Gut*, 2013. 62(1): p. 102-11.
  26. Bouwense SA, Besselink MG, van Brunschot S, et al. Pancreatitis of biliary origin, optimal timing of cholecystectomy (PONCHO trial): study protocol for a randomized controlled trial. Published online 26 Nov 2012. doi: 10.1186/1745-6215-13-225
  27. Pier AT, Alberto M, Lars A, et al. Papillary cannulation and sphincterotomy techniques at ERCP: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Endoscopy* 2016 Jul;48(7):657-83. doi: 10.1055/s-0042-108641
  28. Edmund AMN, Hans T, CK Kum, et al. EAES Clinical Practice Guidelines on Laparoscopic Cholecystectomy, Appendectomy, and Hernia Repair (1994). In: EAES guidelines for endoscopic surgery: Twelve years evidence-based surgery in Europe. E. Neugebauer, S. Sauerland, A.B. Fingerhut, B. Millat, G.F. Buess (Eds.). Springer Berlin Heidelberg, 2006:265-289

29. Testoni PA. Acute recurrent pancreatitis: Etiopathogenesis, diagnosis and treatment. World J Gastroenterol 2014;20(45):16891.

doi: 10.3748/wjg.v20.i45.16891

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 *Figure 1 Shows the flow chart of participants according to SPIRIT 2013 guideline [15]*  
3

4 \* *no pancreatic necrosis, no transient or persistent organ failure (>48 hours) is present with any of the following 3 definitions:*

5  
6 *1) diagnosis of gallstones or sludge on imaging, 2) a dilated common bile duct on ultrasound (>8 mm in patients ≤75 years old or*  
7  
8 *>10 mm in patients >75 years old) in the absence of gallstones or sludge in the gallbladder, 3) and alanine aminotransferase*  
9  
10 *level >2 times higher than normal values with ALT > AST*

11 \*\* *American Society of Anesthesiologists (ASA) IV or V patients and ASA III >75 years old*  
12  
13

14  
15 *Figure 2 Shows the evaluation of primary and secondary endpoints.*  
16  
17

18  
19 *Figure 3 Schedule of enrolment, interventions and assessments according to the SPIRIT 2013 statement [15].*  
20

21 \**Diagnosis of acute biliary pancreatitis (any of the following 3 definitions): diagnosis of gallstones or sludge on imaging, a*  
22  
23 *dilated common bile duct on ultrasound (>8 mm in patients ≤75 years old or >10 mm in patients >75 years old) in the absence of*  
24  
25 *gallstones or sludge in the gallbladder; and alanine aminotransferase level >2 times higher than normal values with ALT > AST.*

26  
27 *In the first 24 hours of admission, all patients will undergo either an ultrasonography or a contrast-enhanced computed*  
28  
29 *tomography (CECT) to detect if the gallbladder contains gallstones or sludge and to determinate the diameter of the common bile*  
30  
31 *duct. ABP is mild, when there is no pancreatic necrosis, or no transient or persistent organ failure (>48 hours).*

32  
33 \*\**If it is necessary to perform endoscopic sphincterotomy during the current admission or ES in the medical history also*  
34  
35 *acceptable.*

36  
37 \*\*\* *Data will be collected in a personalized database, and follow-up will consist of questionnaires. The patient will be asked to*  
38  
39 *note every biliary event during the follow-up period and will be contacted in person within the 90 days after discharge to collect*  
40  
41 *information. After data collection, we can draw conclusions about the treatment strategy. Improperly completed datasheets and*  
42  
43 *incorrect data upload will be avoided and controlled by the administrator. (Q5, Q7, Q8, Q=question)*

44  
45 \*\*\*\* *The patient can be randomized by using a randomization module with sealed envelope. Patient data will be uploaded to the*  
46  
47 *data base, which will be followed by the randomization. This randomization module will allocate the participants to the 2 different*  
48  
49 *groups. This method makes it impossible for researchers to predict the allocation of the patients involved in the study. It is impossible*  
50  
51 *to conceal the distribution of the patients in this study because the patients need to be scheduled for either an early cholecystectomy*  
52  
53 *or a delayed cholecystectomy.*

54  
55 *Allocation will be carried out based on predefined randomisation lists created separately for each recruiting centre. The allocation*  
56  
57 *sequence will be prepared with a block size of 4 and with an allocation ratio 1:1 by the Independent Data Management Board*  
58  
59 *(IDMB).*

60  
61 \*\*\*\*\* *The criteria are the following: (1) Anticipation on the part of the treating physician that the patient can be discharged*  
62  
63 *within 1 or 2 days; (2) no need for analgesics; (3) declining C-reactive protein levels and <150 mg/l; (4) no evidence of local or*

1 *systemic complications (for example, no fever); (5) oral feeding is tolerated for 24 hrs; and (6) ERCP/ES either during the index*  
2 *admission or in the medical history without complication. Before discharge or transfer to surgery department.*  
3  
4  
5

6 *Figure 4 The listed parameters were used to estimate results for the current sample size.*  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




Figure 1 Shows the flow chart of participants according to SPIRIT 2013 guideline [15]  
 \* no pancreatic necrosis, no transient or persistent organ failure (>48 hours) is present with any of the following 3 definitions: 1) diagnosis of gallstones or sludge on imaging, 2) a dilated common bile duct on ultrasound (>8 mm in patients ≤75 years old or >10 mm in patients >75 years old) in the absence of gallstones or sludge in the gallbladder, 3) and alanine aminotransferase level >2 times higher than normal values with ALT > AST

\*\* American Society of Anesthesiologists (ASA) IV or V patients and ASA III >75 years old

105x59mm (300 x 300 DPI)



ENDPOINTS		
PRIMARY	SECONDARY	
Mortality	Biliary colic Difficulty of cholecystectomy	ICU admission Length of ICU stay
Recurrent biliary events (recurrent biliary pancreatitis, acute cholecystitis, uncomplicated biliary colic and cholangitis)	Conversion to open cholecystectomy	Organ failure
	Total length of hospital stay	Biliary leakage
<p><b>Diagnosis of acute pancreatitis</b> at least two of the three following features are present<sup>[30]</sup></p> <ol style="list-style-type: none"> <li>Upper abdominal pain;</li> <li>Serum lipase or amylase levels above three times the upper level of normal;</li> <li>Characteristic findings of acute pancreatitis on cross-sectional abdominal imaging.</li> </ol>		
<p><b>Biliary pancreatitis</b> one of the following presents<sup>[31]</sup></p> <ol style="list-style-type: none"> <li>Gallstones and/or sludge diagnosed on imaging (transabdominal or endoscopic ultrasound or computed tomography);</li> <li>In the absence of gallstones and/or sludge, a dilated common bile duct on ultrasound (&gt;8 mm in patients ≤75 years old or &gt;10 mm in patients &gt;75 years old);</li> <li>The following laboratory abnormality: alanine aminotransferase (ALAT) level &gt;2 times higher than normal values, with ALAT &gt;aspartate aminotransferase.</li> </ol>	<p><b>Cholecystitis</b> 2007 Tokyo classification grade I to III<sup>[32,33]</sup></p> <p>A. Local signs of inflammation:</p> <ol style="list-style-type: none"> <li>Murphy's sign;</li> <li>RUQ mass/pain/tenderness.</li> </ol> <p>B. Systemic signs of inflammation:</p> <ol style="list-style-type: none"> <li>Fever;</li> <li>Elevated C-reactive protein;</li> <li>Elevated white blood cell count.</li> </ol> <p>C. Imaging findings characteristic of acute cholecystitis.</p> <p style="text-align: center;"><b>Definite diagnosis</b></p> <ol style="list-style-type: none"> <li>One item in A and one item in B are positive;</li> <li>C confirms the diagnosis when acute cholecystitis is suspected clinically.</li> </ol>	
<p><b>Cholangitis</b> All of the following features as previously defined<sup>[31]</sup></p> <ol style="list-style-type: none"> <li>Serum total bilirubin level &gt;40 μmol/l (&gt;2.3 mg/dl) and/or dilated common bile duct (&gt;6 mm) on transabdominal or endoscopic ultrasound or computed tomography;</li> <li>Temperature &gt;38.5°C.</li> </ol>	<p><b>Biliary colic</b> Rome criteria<sup>[33]</sup></p> <p>Upper abdominal pain (either right upper quadrant or epigastric pain) lasting at least 30 minutes, according to the</p>	

Figure 2 Shows the evaluation of primary and secondary endpoints.

198x154mm (300 x 300 DPI)

DIVISION	STUDY PERIOD					
	Gastroenterology management			Department of Surgery		Control visit
	DOCTOR no.1 and no.2			DOCTOR no.3		DOCTOR no.4
SERVING	1	1	2	1		
OBJECT	MBP management and randomization			Cholecystectomy after discharge		Follow up
TIMEPOINT	- several days	0	+ several days	Within 6 days	Between day 45-60	Day 90±7 after discharge
ENROLMENT:						
Diagnosis of acute mild biliary pancreatitis*	X					
ES**		X				
Eligibility screen			X Q2-4			
TEST 1***				X Q5		
Sign of Informed consent form				X Q6		
Allocation****				X Q6		
Randomization****				X Q6		
Discharge***** to home or to surg.				X		
INTERVENTIONS:						
Group A Early cholecystectomy				X		
Group B Delayed cholecystectomy					X	
TEST 2***				X Q7	X Q7	
ASSESSMENTS:						
Follow up (with the help of an administrator)***						X Q8

Figure 3 Schedule of enrolment, interventions and assessments according to the SPIRIT 2013 statement [15].

\*Diagnosis of acute biliary pancreatitis (any of the following 3 definitions): diagnosis of gallstones or sludge on imaging, a dilated common bile duct on ultrasound (>8 mm in patients ≤75 years old or >10 mm in patients >75 years old) in the absence of gallstones or sludge in the gallbladder; and alanine aminotransferase level >2 times higher than normal values with ALT > AST. In the first 24 hours of admission, all patients will undergo either an ultrasonography or a contrast-enhanced computed tomography (CECT) to detect if the gallbladder contains gallstones or sludge and to determinate the diameter of the common bile duct. ABP is mild, when there is no pancreatic necrosis, or no transient or persistent organ failure (>48 hours).

\*\*If it is necessary to perform endoscopic sphincterotomy during the current admission or ES in the medical history also acceptable.

\*\*\* Data will be collected in a personalized database, and follow-up will consist of questionnaires. The patient will be asked to note every biliary event during the follow-up period and will be contacted in person within the 90 days after discharge to collect information. After data collection, we can draw conclusions about the treatment strategy. Improperly completed datasheets and incorrect data upload will be avoided and controlled by the administrator. (Q5, Q7, Q8, Q=question)

\*\*\*\* The patient can be randomized by using a randomization module with sealed envelope. Patient data will be uploaded to the data base, which will be followed by the randomization. This randomization module will allocate the participants to the 2 different groups. This method makes it impossible for researchers to predict the allocation of the patients involved in the study. It is impossible to conceal the distribution of the patients in this study because the patients need to be scheduled for either an early cholecystectomy or a delayed cholecystectomy.

Allocation will be carried out based on predefined randomisation lists created separately for each recruiting centre. The allocation sequence will be prepared with a block size of 4 and with an allocation ratio 1:1 by the Independent Data Management Board (IDMB).

\*\*\*\*\* The criteria are the following: (1) Anticipation on the part of the treating physician that the patient can be discharged within 1 or 2 days; (2) no need for analgesics; (3) declining C-reactive protein levels and <150 mg/l; (4) no evidence of local or systemic complications (for example, no fever); (5) oral feeding is tolerated for 24 hrs; and (6) ERCP/ES either during the index admission or in the medical history without complication. Before discharge or transfer to surgery department.

108x61mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Hypothesised proportion in each group	Significance level	Power	Acceptable max. difference for equivalency	Sample size needed for analysis (per group)	Sample size for screening (with 5% drop-out rate)
5%	95%	90%	14%	42	89

Figure 4 The listed parameters were used to estimate results for the current sample size.

271x39mm (300 x 300 DPI)

Endoscopic sphincterotomy for delay in  
cholecystectomy in mild acute biliary pancreatitis



## QUESTIONNAIRE

### 1. Personal data

#### 1.1 Patient's data

Name: \_\_\_\_\_

Sex: Male / Female

Date of Birth: \_\_\_\_\_ Age: \_\_\_\_\_ Insurance number: \_\_\_\_\_

Phone number: \_\_\_\_\_

The patient's study number:

#### 1.2 Doctors' data

##### DOCTOR No. 1:

Name of the doctor **responsible for the treatment of ABP**: \_\_\_\_\_

The phone number of the doctor: \_\_\_\_\_

Institute: \_\_\_\_\_

##### DOCTOR No. 2:

Name of the doctor **responsible for the randomization**: \_\_\_\_\_

The phone number of the doctor: \_\_\_\_\_

Institute: \_\_\_\_\_

##### DOCTOR No. 3:

Name of the doctor **responsible for the operation**: \_\_\_\_\_

The phone number of the doctor: \_\_\_\_\_

Institute: \_\_\_\_\_

##### DOCTOR No. 4:

Name of the doctor **responsible for the 90 days' visit**: \_\_\_\_\_

The phone number of the doctor: \_\_\_\_\_

Institute: \_\_\_\_\_

**E**ndoscopic sphincterotomy for delay **I**ng  
cholecystectomy in mild acute biliary **Y** pancreatitis

**2. Inclusion criteria** /DOCTOR No. 2/

Patients older than 18 age	<b>YES</b>	<b>NO</b>
Diagnosis of acute pancreatitis (two of them have to be positive) <ul style="list-style-type: none"> <li>- upper abdominal pain</li> <li>- serum lipase or amylase is three times higher of upper limit of normal</li> <li>- characteristic findings of acute pancreatitis on abdominal imaging</li> </ul>	<b>YES</b>	<b>NO</b>
Presence of biliary pancreatitis (one of them has to be true) <ul style="list-style-type: none"> <li>- diagnosis of gallstone or sludge on imaging</li> <li>- the absence of gallstone or sludge with a dilated common bile duct on ultrasound (&gt;8 mm in patients ≤75 years of age or &gt;10 mm in patients &gt;75 years old)</li> <li>- alanine aminotransferase level &gt;2 times higher than normal values</li> </ul>	<b>YES</b>	<b>NO</b>
Mild acute biliary pancreatitis (all of them have to be true) /HAS TO BE DETERMINED AT DISCHARGE OF THE PATIENT/ <ul style="list-style-type: none"> <li>- no peripancreatic fluid collections</li> <li>- no pancreatic necrosis</li> <li>- no persistent organ failure</li> </ul>	<b>YES</b>	<b>NO</b>
ERCP/ES either during the index admission or in the medical history without complication	<b>YES</b>	<b>NO</b>
Written informed consent	<b>YES</b>	<b>NO</b>
<b>One „NO” is present = DO NOT INCLUDE!</b>		

**3. Exclusion criteria** /DOCTOR No. 2/

American Society of Anesthesiologists (ASA) classification <ul style="list-style-type: none"> <li>- III patients &gt;75 years old</li> <li>- IV, V, VI. Groups</li> </ul>	<b>YES</b>	<b>NO</b>
Acute or chronic cholecystitis during hospitalization	<b>YES</b>	<b>NO</b>
Previous cholecystectomy	<b>YES</b>	<b>NO</b>
Continuous alcohol abuse or chronic pancreatitis	<b>YES</b>	<b>NO</b>
Pregnancy	<b>YES</b>	<b>NO</b>
<b>One „YES” is present = EXCLUDE!</b>		

**4. If all inclusions and no exclusion criteria are met, than the physician may indicate the patient to participate in the study.** / DOCTOR No. 2/

The treating physician (DOCTOR No. 2) anticipates that the patient can be discharged	<b>YES</b>	<b>NO</b>
No need for analgesics	<b>YES</b>	<b>NO</b>
Declining C-reactive protein levels and <150 mg/l	<b>YES</b>	<b>NO</b>
No evidence of local or systemic complications	<b>YES</b>	<b>NO</b>
The patient has resumed solid oral nutrient	<b>YES</b>	<b>NO</b>
<b>If all YES = RANDOMIZATION /see point 6/</b>		



Endoscopic sphincterotomy for delay  
 cholecystectomy in mild acute biliary pancreatitis  
**5. Medical History and characteristics of ABP / DOCTOR No. 1/**

Date of admission (diagnosis of AP):.....

Date of discharge: .....

**5.1 Anamnesis**

History of upper abdominal surgery: Yes / No  
 If yes, interventions:.....  
 .....  
 History if biliary colics Yes / No  
 History of cholecystitis Yes / No  
 Fever Yes / No .....°C  
 Diabetes Yes / No  
 Antibiotic therapy during the ABP Yes / No

BMI Weight: \_\_\_\_ kg, Height: \_\_\_\_ cm, BMI: \_\_\_\_ kg/m<sup>2</sup>

**ASA classification (ASA PHYSICAL STATUS CLASSIFICATION SYSTEM)**

I. group(Normal healthy patient)	<b>YES</b>	<b>NO</b>
II. group(Patient with <b>mild systemic disease</b> with no functional limitations)	<b>YES</b>	<b>NO</b>
III. group(Patient with <b>moderate systemic disease with functional limitations</b> )	<b>YES</b>	<b>NO</b>

**5.2. Laboratory measurements**

At discharge after AP:

Amylase(U/l)		Hematocrit(%)	
Lipase(U/l)		Hemoglobin(g/l)	
Gamma GT(U/l)		Kreatinine(umol/l)	
White blood cell(G/l)		eGFR	
ASAT/GOT(U/l)		CRP(mg/l)	
INR(U/l)		Alkaline phosphatase(U/l)	

Endoscopic sphincterotomy for delay  
cholecystectomy in mild acute biliary pancreatitis

### 5.3. Pancreatic imaging /At discharge after AP/

#### 5.3.1 Abdominal Computed Tomography: yes/no

Modified CTSI Score (0-10): .....

Please NOTE! Abdominal CT is compulsory when the patient is discharged

- **CTSI:**

**CTSI Score: (I)** Normal pancreas 0 point, intrinsic pancreatic abnormalities with or without inflammatory changes in peripancreatic fat 2 points, Pancreatic or peripancreatic fluid collection or peripancreatic fat necrosis 4 points **(II)** Necrosis absent 0 Points, < 30% necrosis 2 Points, > 30% necrosis 4 points **(III)** presence of extrapancreatic findings 2 points.

MAXIMUM OF: 10 points

- **Pancreas Size:**

- Normal
- Partially enlarged (body AP diameter is over 2 cm and/or head AP diameter is over 2,5 cm, none exceeds 3 cm)
- Definitely enlarged (any part over 3 cm AP diameter)

- Largest diameter of peripancreatic **fat infiltration**.....cm

- **Peripancreatic fluid:**

- none
- present
- Large pseudocyst(s)

- Size of peripancreatic fluid or pseudocyst: .....cm

- **Necrotizing area** (nonenhancement):

- Largest diameter of necrosis area .....cm
- Location of necrosis: .....
- Type: patchy / full width
- Estimated necrosis: 0%, < 30% , 30% - 60%, > 60%

- **Wirsung** dilatation: YES / NO (yes, diameter.....mm)

- Distant **abdominal fluid:**

- Small amount (hard to see, less than 2 cm in lesser pelvis, less than 1 cm around liver/spleen)



**E**ndoscopic sphincterotomy for delay  
**I**ng  
**cho**lecystectomy in mild acute biliar **Y** pancreatitis

- Moderate amount (easy to see, but without pelvic or abdominal distension)
- Large amount with abdominal/pelvic distension

**- Pleural effusion:**

- none
- one sided:..... (AP diameter .....cm)
- Both sides, L - ..... cm, R.....cm

**- Extrapancreatic findings:**

- Inflammation (Cholecystitis, Duodenitis, etc.) location: .....
- Cholecystolithiasis
- Choledocholithiasis
- Signs of bowel ischaemia
- Bowel distension, ileus
- Venous thrombosis
- Pseudoaneurysm
- Parenchymal organ involvement, define: .....
- none

Other Description:

.....  
 .....  
 .....

**5.4. Characteristics of AP**

Date of diagnosis (admission).....

Date of EST:.....

Date of discharge: .....





1 **E**ndoscopic sphincterotomy for delay **I**ng  
 2  
 3 cho**L**ecystectomy in mild acute biliar **Y** pancreatitis  
 4  
 5

6 **6. Randomization** / DOCTOR No. 2/  
 7

8 The patient will be randomized by an internet randomization module in the following 2  
 9 groups:  
 10

- 11 Randomization:           **A.** Early cholecystectomy (within 6 days after  
 12 discharge)  
 13                               **B.** Delayed cholecystectomy (between 45 and 60 days  
 14 after discharge)  
 15  
 16  
 17

18  
 19 Please circle the relevant group after randomization:  
 20  
 21

A or B

22  
 23  
 24 Please inform the patient concerning the **1)** Date for imaging examination and blood  
 25 measurements before the operation, **2)** Date for the operation, **3)** Date for the 90 days  
 26 visit  
 27  
 28  
 29

30  
 31 **7. Operation** /responsibility of DOCTOR No. 3/  
 32

33 Date of operation: .....

34 Length of days between discharge and operation: .....

35  
 36 If the operation is not in the time period described in point 6 please provide the  
 37 reason: .....  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60

**E**ndoscopic sphincterotomy for delay **I**ng  
cho**L**ecystectomy in mild acute biliar **Y** pancreatitis



**7.1 Anamnesis (between discharge after ABP and operation)**

<p><b>Acut pancreatitis</b>                      - Upper abdominal pain                      - Serum lipase or amylase is three times higher of upper limit of normal                      - Characteristic findings of acute pancreatitis on cross-sectional abdominal imaging</p>	<p><b>YES</b></p>	<p><b>NO</b></p>
<p><b>Biliary pancreatitis</b>                      - Diagnosis of gallstone or sludge on imaging                      - Dilated common bile duct on ultrasound (&gt;8 mm in patients ≤75 years old or &gt;10 mm in patients &gt;75 years old                      - Alanine aminotransferase level &gt;2 times higher than normal values</p>	<p><b>YES</b></p>	<p><b>NO</b></p>
<p><b>Cholecystitis</b>                      A. Local signs of inflammation:                      1) Murphy's sign;                      2) RUQ mass/pain/tenderness.                      B. Systemic signs of inflammation:                      1) Fever;                      2) Elevated C-reactive protein;                      3) Elevated white blood cell count.                      C. Imaging findings characteristic of acute cholecystitis  <b>Final diagnosis</b>                      1) One item in A and one item in B are positive;                      2) C confirms the diagnosis when acute cholecystitis is suspected clinically</p>	<p><b>YES</b></p>	<p><b>NO</b></p>
<p><b>Biliary colics</b>                      Upper abdominal pain (either right upper quadrant or epigastric pain) lasting at least 30 minutes, according to the Rome criteria</p>	<p><b>YES</b></p>	<p><b>NO</b></p>
<p><b>Cholangitis</b>                      1) Serum total bilirubin level &gt;40 µmol/l (&gt;2.3 mg/dl) and/or dilated common bile duct (&gt;6 mm) on transabdominal or endoscopic ultrasound or computed tomography;                      2) Temperature &gt;38.5°C.</p>	<p><b>YES</b></p>	<p><b>NO</b></p>
<p><b>Organ failure</b>                      1) Respiratory: PaO<sub>2</sub> ≤60 mmHg (SaO<sub>2</sub> ≤ 90%) or need for mechanical ventilation;                      2) Cardiovascular: systolic blood pressure &lt;90 mmHg or need for catecholamine support;                      3) Renal: creatinine level &gt;177 µmol/l after rehydration or need for hemofiltration or hemodialysis (not including pre-existent renal failure).</p>	<p><b>YES</b></p>	<p><b>NO</b></p>
<p>Mortality</p>	<p><b>YES</b></p>	<p><b>NO</b></p>

If any of the answers is **YES** please provide the dates: .....

Except mortality, all of the above mentioned diseases can occure multiple times.  
 Please provide details for all events separately.

Other reasons for hospitalization: .....

**E**ndoscopic sphincterotomy for delay **I**ng  
cholelithiasis in mild acute biliary pancreatitis

## 7.2 Laboratory measurements (no more than 24h before the operation)

Amylase(U/l)		Hematocrit(%)	
Lipase(U/l)		Hemoglobin(g/l)	
Gamma GT(U/l)		Kreatinine(umol/l)	
White blood cell(G/l)		eGFR	
ASAT/GOT(U/l)		CRP(mg/l)	
INR(U/l)		Alcaline phosphatase(U/l)	

If the patient is in group A, and the operation is performed within 24h after the blood samples are taken during the discharge of the patients, NO ADDITIONAL BLOOD SAMPLE HAS TO BE TAKEN. Please copy the values from 5.2.

## 7.3 Pancreatic imaging

### 7.3.1 Abdominal ultrasonography:

- **Visualization:**
  - Good, complete (head at least partially visualized, body and neck well visualized, tail: partially visualized)
  - Partially, incomplete (only body or only head visualized)
  - Poor, non-diagnostic
- **Size:**
  - Normal
  - Partially enlarged (body AP diameter is over 2 cm and/or head AP diameter is over 2,5 cm, none exceeds 3 cm)
  - Definitely enlarged (any part over 3 cm AP diameter)
- **Peripancreatic fluid:**
  - none
  - present
  - Large pseudocyst(s)
- Size of peripancreatic fluid or pseudocyst: .....cm
- **Pancreas homogeneity:**
  - Homogenous
  - Inhomogeneous, includes area(s) of low echogenicity
  - Inhomogeneous, includes calcifications
- In case of circumscribed low echogenicity area, it's size.....cm
- **Wirsung dilatation:** YES / NO (yes, diameter.....mm)

Other Description:

.....  
 .....  
 .....



Endoscopic sphincterotomy for delay in  
cholecystectomy in mild acute biliary pancreatitis

7.3.2 Abdominal Computed Tomography: yes/no  
Modified CTSI Score (0-10): .....

- **CTSI:**

**CTSI Score: (I)** Normal pancreas 0 point, intrinsic pancreatic abnormalities with or without inflammatory changes in peripancreatic fat 2 points, Pancreatic or peripancreatic fluid collection or peripancreatic fat necrosis 4 points **(II)** Necrosis absent 0 Points, < 30% necrosis 2 Points, > 30% necrosis 4 points **(III)** presence of extrapancreatic findings 2 points.  
MAXIMUM OF: 10 points

- **Pancreas Size:**
  - o Normal
  - o Partially enlarged (body AP diameter is over 2 cm and/or head AP diameter is over 2,5 cm, none exceeds 3 cm)
  - o Definitely enlarged (any part over 3 cm AP diameter)
- Largest diameter of peripancreatic **fat infiltration**.....cm
- **Peripancreatic fluid:**
  - o none
  - o present
  - o Large pseudocyst(s)
- Size of peripancreatic fluid or pseudocyst: .....cm
- **Necrotizing area** (nonenhancement):
  - o Largest diameter of necrosis area .....cm
  - o Location of necrosis: .....
  - o Type: patchy / full width
  - o Estimated necrosis: 0%, < 30% , 30% - 60%, > 60%
- **Wirsung** dilatation: YES / NO (yes, diameter.....mm)
- Distant **abdominal fluid:**
  - o Small amount (hard to see, less than 2 cm in lesser pelvis, less than 1 cm around liver/spleen)



**E**ndoscopic sphincterotomy for delay  
**I**ng  
**cho**lecystectomy in mild acute biliar **Y** pancreatitis

- Moderate amount (easy to see, but without pelvic or abdominal distension)
- Large amount with abdominal/pelvic distension

**- Pleural effusion:**

- none
- one sided:..... (AP diameter .....cm)
- Both sides, L - ..... cm, R.....cm

**- Extrapancreatic findings:**

- Inflammation (Cholecystitis, Duodenitis, etc.) location: .....
- Cholecystolithiasis
- Choledocholithiasis
- Signs of bowel ischaemia
- Bowel distension, ileus
- Venous thrombosis
- Pseudoaneurysm
- Parenchymal organ involvement, define: .....
- none

**Other Description:**

.....  
 .....  
 .....  
 .....

If the patient is in group A, and the operation is performed within 24h after the imaging is performed during the discharge of the patients, NO ADDITIONAL IMAGING EXAMINATION HAS TO BE ORDERED. Please copy the details from 5.3.



Endoscopic sphincterotomy for delay  
cholecystectomy in mild acute biliary pancreatitis

**7.4. Characteristics of the Operation**

The difficulty of cholecystectomy(10 – hard, 5 – average difficulty):

1	2	3	4	5	6	7	8	9	10

- Conversion to open cholecystectomy: Yes / No
- The length of the operation (min): \_\_\_\_\_
- Days spent in hospital after cholecystectomy: \_\_\_\_\_
- Intenziv unit care: Yes / No
- Mortality: Yes / No
- Haemorrhage, reintervention needed: Yes / No
- No iatrogenic perforation of the gallbladder Yes / No
- Common bile duct (CBD) injuries Yes / No
- Bile leakage Yes / No
- Sub-hepatic abscess Yes / No

**8. Visit 90 days after discharge / DOCTOR No. 4/**

The visit has to be completed +/- 7 days (between 83 and 97 days after discharge)

Date of the visit: .....

Length of days between discharge and visit: .....

**8.1 Anamnesis (between the operation and visit)**

<b>Acut pancreatitis</b> - Upper abdominal pain - Serum lipase or amylase is three times higher of upper limit of normal - Characteristic findings of acute pancreatitis on cross-sectional abdominal imaging	<b>YES</b>	<b>NO</b>
<b>Biliary pancreatitis</b> - Diagnosis of gallstone or sludge on imaging - Dilated common bile duct on ultrasound (>8 mm in patients ≤75 years old or >10 mm in patients >75 years old - Alanine aminotransferase level >2 times higher than normal values	<b>YES</b>	<b>NO</b>
<b>Cholecystitis</b> A. Local signs of inflammation: 1) Murphy’s sign; 2) RUQ mass/pain/tenderness. B. Systemic signs of inflammation: 1) Fever; 2) Elevated C-reactive protein; 3) Elevated white blood cell count. C. Imaging findings characteristic of acute cholecystitis	<b>YES</b>	<b>NO</b>
<b>Final diagnosis</b>		

## Endoscopic sphincterotomy for delay

1) cholelithiasis and/or one item in Biliary pancreatitis 2) C confirms the diagnosis when acute cholecystitis is suspected clinically		
<b>Biliary colics</b> Upper abdominal pain (either right upper quadrant or epigastric pain) lasting at least 30 minutes, according to the Rome criteria	<b>YES</b>	<b>NO</b>
<b>Cholangitis</b> 1) Serum total bilirubin level >40 µmol/l (>2.3 mg/dl) and/or dilated common bile duct (>6 mm) on transabdominal or endoscopic ultrasound or computed tomography; 2) Temperature >38.5°C.	<b>YES</b>	<b>NO</b>
<b>Organ failure</b> 1) Respiratory: PaO <sub>2</sub> ≤60 mmHg (SaO <sub>2</sub> ≤ 90%) or need for mechanical ventilation; 2) Cardiovascular: systolic blood pressure <90 mmHg or need for catecholamine support; 3) Renal: creatinine level >177 µmol/l after rehydration or need for hemofiltration or hemodialysis (not including pre-existent renal failure).	<b>YES</b>	<b>NO</b>
Mortality	<b>YES</b>	<b>NO</b>

If any of the answers **YES** please provide the dates: .....

Except mortality, all of the above mentioned diseases can occur multiple times.  
Please provide details for all events separately.

Other reason for hospitalization: .....

### SIGNATURES:

Doctor No.1.....

Date:.....

Doctor No.2.....

Date:.....

Doctor No.3.....

Date:.....

Doctor No.4.....

Date:.....



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Description	Addressed on page number
<b>Administrative information</b>		
Title	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	Trial identifier and registry name. If not yet registered, name of intended registry	3
	All items from the World Health Organization Trial Registration Data Set	–
Protocol version	Date and version identifier	10
Funding	Sources and types of financial, material, and other support	10
Roles and responsibilities	Names, affiliations, and roles of protocol contributors	1, 10
	Name and contact information for the trial sponsor	5, 10
	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	5
	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	4,5, 8-9
<b>Introduction</b>		
Background and rationale	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
	Explanation for choice of comparators	4,8,9
Objectives	Specific objectives or hypotheses	5, 8



1	Trial design	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5
2			
3			
4	<b>Methods: Participants, interventions, and outcomes</b>		
5			
6	Study setting	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5,8-9
7			
8	Eligibility criteria	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for studycentres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6
9			
10			
11	Interventions	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	6-7-8
12			
13		Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	7
14			
15		Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	7
16			
17			
18		Relevant concomitant care and interventions that are permitted or prohibited during the trial	–
19	Outcomes	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	7
20			
21			
22			
23			
24	Participant timeline	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Fig.3
25			
26			
27	Sample size	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	8
28			
29			
30	Recruitment	Strategies for achieving adequate participant enrolment to reach target sample size	8
31			
32	<b>Methods: Assignment of interventions (for controlled trials)</b>		
33			
34	Allocation:		
35	Sequence generation	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	6
36			
37			
38			
39			
40			
41			
42			

1	Allocation concealment mechanism	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	6
2			
3			
4	Implementation	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	6
5			
6	Blinding (masking)	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	6
7			
8			
9			
10		If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	–
11			
12			
13	<b>Methods: Data collection, management, and analysis</b>		
14			
15	<b>Data collection methods</b>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	8
16			
17			
18			
19			
20			
21			
22			
23		Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	8
24			
25	Data management	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	8-9
26			
27			
28	Statistical methods	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	8
29			
30		Methods for any additional analyses (eg, subgroup and adjusted analyses)	9
31			
32		Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	9
33			
34			

### Methods: Monitoring

1	Data monitoring	Composition of data monitoring committee (DMC); summary of its role and reporting structure;	8-9
2		statement of whether it is independent from the sponsor and competing interests; and reference	
3		to where further details about its charter can be found, if not in the protocol. Alternatively, an	
4		explanation of why a DMC is not needed	
5			
6		Description of any interim analyses and stopping guidelines, including who will have access to	9
7		these interim results and make the final decision to terminate the trial	
8			
9			
10	Harms	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported	8-9
11		adverse events and other unintended effects of trial interventions or trial conduct	
12			
13			
14			
15	Auditing	Frequency and procedures for auditing trial conduct, if any, and whether the process will be	10
16		independent from investigators and the sponsor	
17			
18	<b>Ethics and dissemination</b>		
19	Research ethics approval	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	3,10
20			
21			
22	Protocol amendments	Plans for communicating important protocol modifications (eg, changes to eligibility criteria,	9
23		outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial	
24		registries, journals, regulators)	
25			
26			
27	Consent or assent	Who will obtain informed consent or assent from potential trial participants or authorised	6
28		surrogates, and how (see Item 32)	
29		Additional consent provisions for collection and use of participant data and biological specimens	10-11
30		in ancillary studies, if applicable	
31			
32			
33	Confidentiality	How personal information about potential and enrolled participants will be collected, shared, and	8
34		maintained in order to protect confidentiality before, during, and after the trial	
35			
36			
37	Declaration of interests	Financial and other competing interests for principal investigators for the overall trial and each	10
38		study site	
39			
40			
41			
42			

1	Access to data	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	8
2			
3			
4	Ancillary and post-trial care	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	10-11
5			
6			
7			
8	Dissemination policy	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	9
9			
10			
11			
12			
13		Authorship eligibility guidelines and any intended use of professional writers	9
14			
15			
16			
17		Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	9
18			
19			
20	<b>Appendices</b>		
21	Informed consent materials	Model consent form and other related documentation given to participants and authorised surrogates	Attached
22			
23			
24			
25			
26	Biological specimens	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	10-11
27			
28			
29			
30			
31			
32			

33 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 34 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 35 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
 36  
 37  
 38  
 39  
 40  
 41